=> fil reg
FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-4
DICTIONARY FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 30, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l2
L1 STR 2039 OR 2056 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 O
R 2043 OR 2054 OR 1918 OR 2016 OR 2026 OR 1844 OR 2117 OR 2012
L2 STR



VAR G1=NH2/16/22/25/30
VAR G2=OR/CHR2/14
VAR G5=AR/OY
VAR G4=CH2/30/34
VAR G5=OH/NH2
REP G6=(1-2) CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 19
NSPEC IS RC AT 20
NSPEC IS RC AT 21
NSPEC IS RC AT 24
CONNECT IS M1 RC AT 2
CONNECT IS M1 RC AT 3
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 15
CONNECT IS M1 RC AT 17
CONNECT IS M1 RC AT 18
CONNECT IS M1 RC AT 30
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L25 2847 SEA FILE=REGISTRY CSS FUL L23 NOT L21

2847 ANSWERS

100.0 PROCESSED 2:0703 ITERATIONS
SEARCH TIME: 0..00.24

=> d sta que 126
L21 SCR 2039 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 O
F 2043 OR 2054 OR 1919 OR 2016 OR 2026 OR 1844 OR 2127 OR 2012
L23 STR



VAR G1=NH2/18/32/35/30
VAR G2=OH/NH2/14
VAR G3=AR/CY
VAR G4=CH2/32/34
VAR G5=OH/NH2
REP G6=(1-2) CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 18
NSPEC IS RC AT 21
NSPEC IS RC AT 23
NSPEC IS RC AT 36
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 7
CONNECT IS M1 RC AT 9
CONNECT IS M1 RC AT 18
CONNECT IS M1 RC AT 32
CONNECT IS M1 RC AT 35
CONNECT IS M1 RC AT 40
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L26 2847 SEA FILE=REGISTRY CSS FUL L23 NOT L21
L26 STR



VAR G1=NH2/18/20/25/30
VAR G2=OH/NH2/14
VAR G3=AK/CY
REP G4=(1-2) CH2
VAR G5=48/50
VAR G6=OH/SH/NH2
NODE ATTRIBUTES:
NSPEC IS RC AT 12
NSPEC IS RC AT 22
NSPEC IS RC AT 26
NSPEC IS RC AT 30
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L28 16 SEA FILE=REGISTRY SUB=L25 CSS FUL L26 16 ANSWERS

100.0% PROCESSED 56 ITERATIONS
SEARCH TIME: 00.00.20

=> d his

(FILE 'HOME' ENTERED AT 09:53:31 ON 16 OCT 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:53:48 ON 16 OCT 2002
L1 STR
L2 22 S L1 CSS
SCR 2043 OR 2107
L3 7 S L1 NOT L3 CSS
L4 STR L1
L5 6 S L4 CSS

```
L7              STR L5
                SCR 2039 OR 2027 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 205
L8            3 S L7 NOT L3 NOT L6
L9              SCR 2034 OR 2026 OR 1929
L10           2 S L7 NOT L8 NOT L10, CSS SAM
L11             SCR 2044
L12           9 S L7 NOT (L9 OR L10 OR L12) CSS SAM
L13             SCR 2044
L14           6 S L7 NOT (L8 OR L10 OR L12 OR L14) CSS SAM
L15           7 S L1 NOT L7
L16             SCR 2044 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
L17           7 S L7 NOT L17 CSS
L18             SCR 2044 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
L19           4 S L7 NOT L19 CSS
L20             SCR 2044 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
L21           7 S L7 NOT L17 CSS
L22             DUP REM L7
L23          13 S L21 NOT L17 CSS
L24        2847 S L21 NOT L17 CSS FUL
                SAV L24 GABI974A/A
L25             STR L24
L26           0 S L25 CSS SAM SUB=L15
L27          16 S L24 NOT FUL SUB=L21
L28             SAV L28 GABI974A/A
L29          15 S L28 NOT SQL/FA
L30        2831 S L24 NOT L27
L31        2674 S L30 NOT SQL/FA

      FILE 'HCAPLUS' ENTERED AT 10:30:07 ON 16 OCT 2002
L32           6 S L4
                E SCIALDONE M/AU
L33          17 S E4,E5
                E MARRA S/AU
L34         199 S E3,E4,E10-E15
                E CHUEY S/AU
L35          13 S E6-E8
L36      540249 S (LUBRIZOL OR BU(;PONT OR NEMOURS)/PA,CS
L37           1 S L33 AND L34-L36
                SEL PN

      FILE 'REGISTRY' ENTERED AT 10:32:47 ON 16 OCT 2002
L38          44 S E1-E11
L39          17 S L38 AND L7
L40          11 S L39 NOT L13
L41          10 S L40 NOT HIS/CI
L42           7 S L41 NOT SQL/FA
L43           2 S L24,L42
L44             SAV L43 GABI974B/A

      FILE 'HCAPLUS' ENTERED AT 10:35:08 ON 16 OCT 2002
L45           2 S L43
L46           1 S L15 AND L25-L36
L47           2 S L45,L46

      FILE 'USPATFULL, USPAT2' ENTERED AT 10:35:26 ON 16 OCT 2002
L48           1 S L43

      FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002

=> d ide can tit 43

L43  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2002 ACS
```

RN **452280-60-3** REGISTRY
CN L-Prolinamide, N-acetyl-L-seryl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C14 H23 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-59-0** REGISTRY
CN L-Prolinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H25 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 3 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-58-9** REGISTRY
CN L-Serinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C14 H23 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 4 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-57-8 REGISTRY
CN D-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-56-7 REGISTRY
CN D-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 6 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-55-6 REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 7 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-54-5** REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H20 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 8 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-53-4 REGISTRY
CN L-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 9 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-50-3 REGISTRY
CN D-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 10 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-51-2** REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H22 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 11 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-50-1** REGISTRY
CN L-Serinamide, N-acetyl-L-serylglycyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N4 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 12 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-49-6 REGISTRY
CN L-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 13 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-48-7 REGISTRY
CN L-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 14 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN **452280-47-6** REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H20 N4 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 15 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-43-3 REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 16 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-42-1 REGISTRY
CN L-Serine, L-seryl-L-glutaminyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H20 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 17 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452089-41-6 REGISTRY
CN L-Serine, L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 18 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 391870-25-0 REGISTRY
CN D-Serinamide, N-acetyl-D-threonyl-D-asparaginyl-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C14 H25 N5 O7
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:128095

L43 ANSWER 19 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 130024-98-6 REGISTRY
CN L-Threonine, N-(N2-L-threonyl-L-asparaginyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H22 N4 O7
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 113:169278

L43 ANSWER 20 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 125746-19-8 REGISTRY
CN L-Threonine, N-(N2-L-seryl-L-asparaginyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H20 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 112:137251

L43 ANSWER 21 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 99026-68-3 REGISTRY

CN L-Serine, N-(N2-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H16 N4 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 103:196391

L43 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 71190-91-5 REGISTRY
CN L-Cysteine, N-(N2-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N4 O6 S2
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 91:85694

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Oct 2002 VOL 137 ISS 16
FILE LAST UPDATED: 15 Oct 2002 (20021015/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all hitstr tot 147

L47 ANSWER 1 OF 6 BIOSIS COPYRIGHT 2002 ACS
AN 2002:69211 BIOSIS
DN 137:19557
TI Angiogenesis-inhibitory tripeptides, compositions, and their methods of use
IN **Scialdone, Mark A.; Mousa, Shaker A.; Shuey, Steven W.**
PA E.I. Dupont de Nemours and Company, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-75
ICS C07K005-08; A61P035-04
CC 1-8 (Pharmacology)
Section cross-reference(s): 63

SAME

FAN.CNT 1	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060512	A1	20020808	WO 2002-US5211	20020215

W: CA, CN, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRAI US 2001-265537P P 20010131
US 2001-311047P P 20010809

OS MARPAT 137:19557

AB The invention discloses methods and compns. for inhibiting endothelial cell tube formation, the initial step of tumor angiogenesis. More specifically, the invention discloses tripeptides that show inhibition of angiogenesis-mediated processes. The most preferred amino acid sequences are RGD and S.S.

ST tripeptide angiogenesis inhibitor; tumor angiogenesis inhibitor tripeptide

IT Animal cell line
HUVEC; tripeptide angiogenesis inhibitors, compns., and use)

IT Disease, animal
(Osler-Weber-Rendu disease; tripeptide angiogenesis inhibitors, compns., and use)

IT Edema
(anti-edema agents; tripeptide angiogenesis inhibitors, compns., and use)

IT Antiarteriosclerotics
(antiatherosclerotics; tripeptide angiogenesis inhibitors, compns., and use)

IT Antibodies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor; tripeptide angiogenesis inhibitors, compns., and use)

IT Bartonella
(bartonellosis; tripeptide angiogenesis inhibitors, compns., and use)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; tripeptide angiogenesis inhibitors, compns., and use)

IT Eye
(choroid; tripeptide angiogenesis inhibitors, compns., and use)

IT Inflammation
(chronic; tripeptide angiogenesis inhibitors, compns., and use)

IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated, with nucleic acids; tripeptide angiogenesis inhibitors, compns., and use)

IT Nucleic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with ligands; tripeptide angiogenesis inhibitors, compns., and use)

IT Blood vessel
(endothelium; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(immunotoxins; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(injections, i.p.; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(intracerebral; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(intracranial; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(intrauterine; tripeptide angiogenesis inhibitors, compns., and use)

IT Lasers
(laser therapy; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(liposomes; tripeptide angiogenesis inhibitors, compns., and use)

IT Neoplasm
(metastasis, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(nasal; tripeptide angiogenesis inhibitors, compns., and use)

IT Prostate gland
(neoplasm, TSC-Pr, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)

IT Angiogenesis
(neovascularization, eye; tripeptide angiogenesis inhibitors, compns., and use)

IT Angiogenesis
(neovascularization, retinal; tripeptide angiogenesis inhibitors, compns., and use)

IT Angiogenesis
Eye, disease
(neovascularization; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems

(ophthalmic; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(oral; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(osmotic pumps, mini-pump; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(parenterals; tripeptide angiogenesis inhibitors, compns., and use)

IT Skin, disease
(pemphigoid; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(rectal; tripeptide angiogenesis inhibitors, compns., and use)

IT Eye, disease
(retina, neovascularization; tripeptide angiogenesis inhibitors, compns., and use)

IT Eye
(retina; tripeptide angiogenesis inhibitors, compns., and use)

IT Neoplasm
(solid, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug targeting
(targeting cmpds.; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(topical; tripeptide angiogenesis inhibitors, compns., and use)

IT Eye, disease
(trachoma; tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(transdermal; tripeptide angiogenesis inhibitors, compns., and use)

IT Adenoviridae
Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Antiarthritics
Antibiotics
Antirheumatic agents
Antitumor agents
Antiviral agents
Atherosclerosis
Chemotherapy
Drug delivery systems
Genetic vectors
Human
Inflammation
Osteoarthritis
Radiosensitizers, biological
Radiotherapy
Retroviral vectors
Retroviridae
Rheumatoid arthritis
Surgery
Therapy
Virus vectors
(tripeptide angiogenesis inhibitors, compns., and use)

IT Cytokines
Tripeptides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide angiogenesis inhibitors, compns., and use)

IT DNA
Nucleic acids
RNA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tripeptide angiogenesis inhibitors, compns., and use)

IT Drug delivery systems
(vaginal; tripeptide angiogenesis inhibitors, compns., and use)

IT **452280-41-0P 452280-42-1P 452280-43-2P**
452280-44-3P 452280-45-4P 452280-46-5P **452280-47-6P**
452280-48-7P 452280-49-8P 452280-50-1P
452280-51-2P 452280-52-3P 452280-53-4P
452280-54-5P 452280-55-6P 452280-56-7P
452280-57-8P 452280-58-9P 452280-59-0P
452280-60-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tripeptide angiogenesis inhibitors, compns., and use)

IT 25104-18-1, Polylysine 38000-06-5, Polylysine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide angiogenesis inhibitors, compns., and use)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Eisai Co Ltd; WO 9958861 A 1999 HCAPLUS
(2) Fok, K; WO 9951638 A 1999 HCAPLUS
(3) Kleinerman, E; CANCER IMMUNOLOGY IMMUNOTHERAPY 1992, V34(4), P211 MEDLINE
(4) Maeshima, Y; JOURNAL OF BIOLOGICAL CHEMISTRY 2000, V275(28), P21340 HCAPLUS

IT **452280-41-0P 452280-42-1P 452280-43-2P**
452280-47-6P 452280-48-7P 452280-49-8P
452280-50-1P 452280-51-2P 452280-52-3P
452280-53-4P 452280-54-5P 452280-55-6P
452280-56-7P 452280-57-8P 452280-58-9P
452280-59-0P 452280-60-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tripeptide angiogenesis inhibitors, compns., and use)

RN 452280-41-0 HCAPLUS
CN L-Serine, L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-42-1 HCAPLUS
CN L-Serine, L-seryl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-43-2 HCAPLUS
CN L-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-47-6 HCAPLUS
CN L-Serinamide, N-acetyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-48-7 HCAPLUS
CN L-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-49-8 HCAPLUS
CN L-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-50-1 HCAPLUS
CN L-Serinamide, N-acetyl-L-serylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-51-2 HCAPLUS
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-52-3 HCAPLUS
CN D-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-53-4 HCAPLUS
CN D-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-54-5 HCAPLUS
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-55-6 HCAPLUS
CN L-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-56-7 HCAPLUS
CN D-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-57-8 HCAPLUS
CN D-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-58-9 HCAPLUS
CN L-Serinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-59-0 HCAPLUS
CN L-Prolinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-60-3 HCAPLUS
CN L-Prolinamide, N-acetyl-L-seryl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2001 ACS
AN 2001:785830 HCAPLUS
DN 136:128995
TI Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches
AU So, Sung-Sau; Karplus, Martin
CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
SO Journal of Computer-Aided Molecular Design (2001), 15(7), 611-647
CODEN: JCADEW; ISSN: 0920-654X
PB Kluwer Academic Publishers
DT Journal
LA English
CC 1-12 (Pharmacology)
AB Glycogen phosphorylase (GP) is an important enzyme that regulates blood glucose level and a key therapeutic target for the treatment of type II diabetes. In this study, a no. of potential GP inhibitors are designed with a variety of computational approaches. They include the applications of MCSS, LUDI and CoMFA to identify addnl. fragments that can be attached to existing lead mols.; the use of 2D and 3D similarity-based QSAR models (HQSAR and SMSNN) and of the LUDI program to identify novel mols. that may bind to the glucose binding site. The designed ligands are evaluated by a multiple screening method, which is a combination of com. and inhouse ligand-receptor binding affinity prediction programs used in a previous study. Each method is used at an appropriate point in the screening, as detd. by both the accuracy of the calcns. and the computational cost. A comparison of the strengths and weaknesses of the ligand design approaches is made.
ST high throughput drug screening glycogen phosphorylase inhibitor mol modeling
IT Algorithms
(MCSS; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)
IT QSAR (structure-activity relationship)
(comparative mol. field anal.; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)
IT High throughput screening
drug, LUDI; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)
IT Combinatorial library

Computer program
Conformational potential
Drug design
Drug screening
Hydrophilicity
Hydrophobicity
Molecular modeling
Molecular structure
Potential energy
evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT Drug screening
(high throughput, LBDI; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT 9035-74-9, Glycogen phosphorylase
PL: BSU (Biological study, unclassified); STPL (Biological study)
(binding affinity; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT 65-85-0 70-70-2 90-60-3 99-96-7 111-69-3, Hexanedinitrile 534-18-4
110-13-8 394-53-2 461-72-3, 2,4-Imidazolidinedione 543-24-8 1150-18-8
542-02-9 591-07-1 621-42-1 693-17-5 1075-38-3 1150-18-8
1629-18-1 3911-65-5 3478-14-2 4411-25-1 4811-67-2 5401-13-8
5462-81-8, 4,5-Phenanthrenedicarboxylic acid 5699-40-1 5977-14-0
6261-73-1 6336-38-4 6336-64-2 7224-84-1 6972-41-4 7143-77-3
7305-71-7 13266-61-8 13387-59-6 13601-24-0 15396-48-6 17300-29-7
20225-76-9 29144-64-8 29911-71-1 30134-58-2 30111-48-9
27938-77-6 40036-89-4 538[illegible]-84-4 65731-84-3 [illegible]-76-0
58484-06-3 58635-73-8 59644-72-5 59234-30-6 [illegible]-36-3
67191-53-1 72697-64-9 73021-76-9 92847-84-1 99212-30-9
103706-13-8 110[illegible]-96-1 118870-44-1 119878-58-4 130632-66-1
132206-44-4 136236-42-6 [illegible]-[illegible]-0 [illegible]-58-6 131367-58-4
[illegible]-[illegible]-3 [illegible]-26-7 [illegible]-[illegible]-4 [illegible]-[illegible]-4 3[illegible]-76-[illegible]
391870-17-9 391870-18-0 391870-19-1 391870-[illegible]-5 391870-21-[illegible]
391870-22-7 391870-23-8 391870-24-9 **391870-25-0**
391870-26-1 391870-27-2 391870-28-3 391870-29-4 391870-30-7
391870-31-8 391870-32-9 391870-33-0 391870-34-1 391870-35-2
391870-36-3 391870-37-4 391870-38-5 391870-39-6 391870-40-[illegible]
391870-41-0 391870-42-1 391870-43-2 391870-44-3 391870-46-4
391870-46-5 391870-47-6 391870-48-7 391870-49-8 391870-50-1
391870-51-2 391870-52-3 391870-53-4 391870-54-5 391870-55-6
391870-56-7 391870-57-8 391870-58-9 391870-59-0 391870-60-3
391870-61-4 391870-62-5 391870-63-6 391870-64-7 391870-65-8
391870-66-9 391870-67-0 391871-68-1 391870-69-2 391870-70-5
391870-71-6 391870-72-7 391870-73-8 391870-74-9 391870-75-0
391870-76-1 391870-77-2 391870-78-3 391870-79-4 391870-80-7
391870-81-8 391870-82-9 391870-83-0 391870-84-1 391870-85-2
391870-86-3 391870-87-4 391870-88-5 391870-89-6 391870-90-9
391870-91-0 391870-92-1 391870-93-2 391870-94-3 391870-95-4
391870-96-5 391870-97-6 391871-98-7 391870-99-8 391871-00-4
391871-01-5 391871-02-6 391871-03-7 391871-04-8 391871-05-9
391871-06-0 391871-07-1 391871-08-2 391871-09-3 391871-10-6
391871-11-7 391871-12-8 391871-13-9 391871-14-0 391871-15-1
391871-16-2 391871-17-3 391871-18-4 391871-19-5 391871-20-8
391871-21-9 391871-22-0 391871-23-1 391871-24-2 391871-25-3
391871-26-4 391871-27-5 391871-28-6 391871-29-7 391871-30-0
391871-31-1 391871-32-2 391871-33-3 391871-34-4 391871-35-5
391871-36-6 391871-37-7 391871-38-8 391871-39-9 391871-40-2
391871-41-3 391871-42-4 391871-43-5 391871-44-6 391871-45-7
391871-46-8 391871-47-9 391871-48-0 391871-49-1 391871-50-4
391871-51-5 391871-52-6 391871-53-7 391871-54-8 391871-55-9

391871-56-0 391871-57-1 391871-58-2 391871-59-3 391871-61-7
391871-63-9 391871-64-0 391871-65-1 391871-66-2 391871-67-3
391871-68-4 391871-69-5 391871-70-8 391871-71-9 391871-72-0
391871-73-1 391871-74-2 391871-75-3 391871-76-4 391871-77-5
391871-78-6 391871-82-2 391871-83-3
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT 391871-84-4 391871-85-5 391871-86-6 391871-87-7 391871-88-8
391871-89-9 391871-90-2 391871-92-4 391871-93-5 391871-94-6
391871-95-7 391871-96-8 391871-97-9 391871-98-0 391871-99-1
391872-00-7 391872-01-8 391872-13-0 391895-25-3 391895-26-4
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Agrafiotis, D; J Chem Info Comput Sci 1997, V37, P841 HCAPLUS
(2) Ajay; J Med Chem 1998, V41, P3314 MEDLINE
(3) Andrea, T; J Med Chem 1991, V34, P2824 HCAPLUS
(4) Aqvist, J; Prot Eng 1994, V7, P385 MEDLINE
(5) Bohm, H; J Comput Aid Mol Des 1992, V6, P593 MEDLINE
(6) Bohm, H; J Comput Aid Mol Des 1992, V6, P61 MEDLINE
(7) Bohm, H; J Comput Aid Mol Des 1994, V8, P243 MEDLINE
(8) Bohm, H; J Comput Aid Mol Des 1994, V8, P623 MEDLINE
(9) Brown, F; J Med Chem 1997, V40, P2304 HCAPLUS
(10) Caflisch, A; J Comput Aid Mol Des 1996, V10, P372 HCAPLUS
(11) Caflisch, A; J Comput Aid Mol Des 1998, V12, P161 HCAPLUS
(12) Caflisch, A; J Med Chem 1998, V41, P214 HCAPLUS
(13) Caflisch, A; Perspect Drug Discov Des 1999, V9, P51 HCAPLUS
(14) Caflisch, A; Proc Natl Acad Sci USA 1994, V91, P1746 HCAPLUS
(15) Charifson, P; J Med Chem 1999, V42, P5100 HCAPLUS
(16) Cramer, R; J Am Chem Soc 1988, V110, P5959 HCAPLUS
(17) Dammkoehler, R; J Comput Aid Mol Des 1989, V3, P3 HCAPLUS
(18) DeWitte, R; J Am Chem Soc 1996, V118, P11733 HCAPLUS
(19) DeWitte, R; J Am Chem Soc 1997, V119, P4009 HCAPLUS
(20) de Groot, M; J Med Chem 1999, V42, P1505 HCAPLUS
(21) de Groot, M; J Med Chem 1999, V42, P4062 HCAPLUS
(22) Eisen, M; Prot Struct Funct Genet 1994, V19, P199 HCAPLUS
(23) Elber, R; J Am Chem Soc 1996, V118, P8501 HCAPLUS
(24) Evensen, E; MOSS Version 4.3
(25) Evenson, E; OLIGO Version 5.1
(26) Pisanick, W; J Chem Inf Comput Sci 1994, V1994, P120
(27) Gerber, P; J Comput Aid Mol Des 1995, V9, P251 HCAPLUS
(28) Gillet, V; J Chem Inf Comput Sci 1994, V34, P851 HCAPLUS
(29) Gillet, V; J Comput Aid Mol Des 1994, V8, P165 HCAPLUS
(30) Good, A; Reviews in Computational Chemistry 1996, P67 HCAPLUS
(31) Grigorov, M; J Chem Inf Comput Sci 1997, V37, P414 HCAPLUS
(32) Grootenhuis, P; J Comput Aid Mol Des 1996, V10, P1 HCAPLUS
(33) Gschwend, D; Prot Struct Funct Genet 1997, V29, P59 HCAPLUS
(34) Hahn, M; J Med Chem 1995, V38, P2080 HCAPLUS
(35) Hahn, M; J Med Chem 1995, V38, P3091 HCAPLUS
(36) Joseph-McCarthy, D; Prot Struct Funct Genet 1997, 729, P32 HCAPLUS
(37) Kaminski, G; J Med Chem 1997, V40, P4225 HCAPLUS
(38) Kuntz, I; Science 1992, V257, P1078 HCAPLUS
(39) Langlois, M; Eur J Pharmacol 1993, V244, P17 HCAPLUS
(40) Leclerc, F; Theor Chem Acc 1999, V101, P131 HCAPLUS
(41) Lewis, D; Toxicology 1994, V166, P1 HCAPLUS

(42) Lipinski, C; Adv Drug Delivery Rev 1997, V23, P3 HCAPLUS
(43) Majeux, N; Prot Struct Funct Genet 1999, V37, P98 HCAPLUS
(44) Miranker, A; Prot Struct Funct Genet 1991, V11, P29 HCAPLUS
(45) Miranker, A; Prot Struct Funct Genet 1995, V23, P472 HCAPLUS
(46) Molecular Simulations Inc; Cerius2 Version 3.0
(47) Molecular Simulations Inc; INSIGHT Version 95.0
(48) Moon, J; Prot Struct Funct Genet 1991, V11, P314 HCAPLUS
(49) Muegge, I; J Med Chem 1999, V42, P791 HCAPLUS
(50) Neria, E; J Chem Phys 1996, V105, P1902 HCAPLUS
(51) Palm, K; J Med Chem 1998, V41, P5382 HCAPLUS
(52) Richard, A; Mutat Res 1998, V400, P185 HCAPLUS
(53) Rotstein, S; J Comput Aid Mol Des 1993, V7, P23 HCAPLUS
(54) Sadowski, J; Chem Rev 1993, V7, P2567
(55) Sadowski, J; J Med Chem 1995
(56) Schaefer, M; J Phys Chem 1996, V100, P1578 HCAPLUS
(57) Shoichet, B; Science 1993, V259, P1445 HCAPLUS
(58) Simulations Plus Inc; GastricPlus Version 1.3
(59) So, S; J Comput, Aid Mol Des 1997, V11, P425 HCAPLUS
(60) So, S; J Med Chem 1992, V35, P3201 HCAPLUS
(61) So, S; J Med Chem 1996, V39, P1521 HCAPLUS
(62) So, S; J Med Chem 1996, V39, P5246 HCAPLUS
(63) So, S; J Med Chem 1997, V40, P4347 HCAPLUS
(64) So, S; J Med Chem 1997, V40, P4360 HCAPLUS
(65) Stultz, C; Prot Struct Funct Genet 2000, V40, P258 HCAPLUS
(66) Tripos Inc; HQSAR Version 1.0
(67) van Gunsteren, W; Q Rev of Biophy 1994, V27, P435 MEDLINE
(68) Verlinde, C; Structure 1994, V2, P577 HCAPLUS
(69) Watson, K; Acta Cryst 1995, VD51, P418 HCAPLUS
(70) Watson, K; Biochemistry 1994, V33, P5745 HCAPLUS
(71) Wessel, M; J Chem Inf Comput Sci 1998, V38, P726 HCAPLUS

IT **391870-25-0**
PL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

RN 391870-25-0 HCAPLUS

CN D-Serinamide, N-acetyl-D-threonyl-D-asparaginyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2002 ACS
AN 1990:589278 HCAPLUS
DN 113:189278
TI A b cell-, T cell-linked epitope located on the adhesin of Mycoplasma pneumoniae
AU Jacobs, E.; Roeck, R.; Dalehite, L.

CS Inst. Med. Microbiol. Hyg., Univ. Freiburg, Freiburg, D-7800, Germany
SO Infection and Immunity (1990), 58(8), 2464-9
CODEN: INFIBR; ISSN: 0019-9567
DT Journal
LA English
CC 15-2 (Immunochemistry)
AB The identification of specific T cell and .beta. cell epitopes of the P1 protein, which functions as an adhesin and as a major antigen of M. pneumoniae, has become of central interest for the design of synthetic vaccines. Here is reported the isolation from guinea pigs infected intranasally with M. pneumoniae of hilar and bronchial T lymphocytes which proliferated after in vitro stimulation with sonicated M. pneumoniae whole-cell antigen and with the isolated P1 protein. For more detailed information on T cell epitopes, a 51-amino-acid region (histidine 321 to glycine 371; numbered from the N-terminal end of the P1 protein was analyzed for a T cell epitope. An octapeptide, S-G-S-R-S-F-L-P (starting at amino acid 845), stimulated in vitro lymphocytes of bronchial washings and of hilar lymph nodes. This T cell-stimulating amino acid sequence was located at the C-terminal end of a B cell epitope with the sequence T-N-T (starting at amino acid 842).
ST Mycoplasma adhesin T B lymphocyte epitope
IT Mycoplasma pneumoniae
(P1 adhesin protein of, B- and T-lymphocyte-linked epitopes on, mapping of)
IT Lymphocyte
(B-, Mycoplasma pneumoniae P1 adhesin protein epitopes specific for, mapping of)
IT Lymphocyte
(T-, Mycoplasma pneumoniae P1 adhesin protein epitopes specific for, mapping of)
IT Agglutinins and lectins
RL: BIOL (Biological study)
(adhesins, P1, B- and T-lymphocyte-linked epitopes of, of Mycoplasma pneumoniae, mapping of)
IT **130024-99-6**
RL: BIOL (Biological study)
(as Mycoplasma pneumoniae adhesin B-lymphocyte-specific epitope)
IT 130024-99-6
RL: BIOL (Biological study)
(as Mycoplasma pneumoniae adhesin T-lymphocyte-specific epitope)
IT **130024-99-6**
RL: BIOL (Biological study)
(as Mycoplasma pneumoniae adhesin B-lymphocyte-specific epitope)
RN 130024-99-6 HCAPLUS
CN L-Threonine, N-(N2-L-threonyl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1990:137251 HCAPLUS
DN 112:137251
TI Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
AU Kast, W. Martin; Offringa, Rienk; Peters, Peter J.; Voordouw, Arie C.; Meloen, Rob H.; Van der Eb, Alex J.; Melief, Cornelis J. M.
CS Div. Immunol., Dutch. Cancer Inst., Amsterdam, 1066 CX, Neth.
SO Cell (Cambridge, Mass.) (1989), 59(4), 603-14
CODEN: CELLB5; ISSN: 0092-8674
DT Journal
LA English
CC 11-10 (Immunochemistry)
AB Cytotoxic T lymphocyte (CTL) clones against adenovirus type 5 (Ad5) early region 1 (E1)-transformed cells were generated in C57BL/6 (B6) mice. A defined peptide encoded by Ad5 E1A is the target structure for H-2Db-restricted CTLs. Upon i.v. injection into B6 nude mice bearing Ad5 E1-induced tumors, these CTLs, if combined with recombinant interleukin-2, destroy s.c. tumor masses up to 10 cm. The in vivo action of CTLs is highly specific, and long-term memory persists in treated nude mice months after tumor regression. An important role for CTLs directed against a viral nuclear oncogene product in tumor eradication is thus shown.
ST adenovirus E1A gene tumor cytotoxic lymphocyte; T lymphocyte adenovirus E1A gene tumor; virus adeno E1A gene tumor lymphocyte
IT Neoplasm, toxic chemical and physical damage
(adenovirus-induced, cytotoxic T-lymphocytes specific for gene E1A protein toxicity for, H-2Db-restricted)
IT Antigens
PL: BIOL (Biological study)
(H-2Db, gene E1A protein-specific cytotoxic T-lymphocyte inhibition of adenovirus-induced tumor restriction by)
IT Lymphocyte
(T-, cytotoxic, E1A gene protein-specific, adenovirus-induced tumor inhibition by interleukin 2 and, H-2Db-restricted)
IT Virus, animal
(adenovirus 5, gene E1A protein of, cytotoxic T-lymphocytes specific for, virus-induced tumor inhibition by interleukin 2 and, H-2Db-restricted)
IT Phosphoproteins
PL: BIOL (Biological study)
(gene E1A, peptides of, of adenovirus 5, cytotoxic T-lymphocyte fine specificity for)
IT Lymphokines and Cytokines
PL: BIOL (Biological study)
(interleukin 2, adenovirus-induced tumor inhibition by gene E1A protein-specific cytotoxic T-lymphocytes and)
IT Gene and Genetic element, microbial
PL: BIOL (Biological study)
(E1A, of adenovirus, cytotoxic T-lymphocytes specific for product of, tumor inhibition by interleukin 2 and)
IT 5513-86-0 23626-64-0 46886-22-0 71524-42-0 76524-20-4
120709-88-3 125746-13-6 125746-14-7 **125746-15-8**
125746-16-9 125746-17-0 125746-18-1 125746-19-2 125746-20-5
125746-21-6 125746-22-7 125746-23-8 125746-24-9 125746-25-0
125746-26-1 125746-27-2 125746-28-3 125746-29-4 125746-30-7
125746-31-8 125746-32-9 125746-33-0 125746-34-1 125746-35-2
125746-36-3 125746-37-4 125746-38-5 125746-39-6 125746-40-9
125746-41-0 125746-42-1 125746-43-2 125746-44-3 125746-45-4
125746-46-5 125746-47-6 125746-48-7 125746-49-8 125746-50-1
125746-51-2 125746-52-3 125746-53-4 125746-54-5 125746-55-6
125746-56-7 125746-57-8 125746-58-9 125746-59-0 125746-60-3
125746-61-4 125746-62-5 125746-63-6 125746-64-7 125746-65-8
125746-66-9 125746-67-0 125746-68-1 125746-69-2 125746-70-5
125746-71-6 125746-72-7 125746-73-8 125746-74-9 125746-75-0

125767-84-2 125767-85-3 125767-86-4 125767-87-5 125767-88-6
125767-89-7 125767-90-0 125767-91-1 125767-92-2 125767-93-3
125767-94-4 125767-95-5 125767-96-6 125771-12-2 125785-35-5
125899-94-7
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(cytotoxic T-lymphocyte fine specificity for, of adenovirus 5 E1A protein)

IT **125746-15-8**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(cytotoxic T-lymphocyte fine specificity for, of adenovirus 5 E1A protein)

RN 125746-15-8 HCAPLUS
CN L-Threonine, N-(N2-L-seryl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS
AN 1985:506391 HCAPLUS
DN 103:106391
TI Synthesis and biological activity of proposed structures for the atriopeptin family of natriuretic hormones
AU Balasubramanian, T. M.; Needleman, P.; Currie, M. G.; Geller, D. M.; Cole, B. R.; Marshall, G. R.; Fok, K. F.; Eubanks, S. R.; Zuper, M.; Adams, S. P.
CS Sch. Med., Washington Univ., St. Louis, MO, 63110, USA
SO Pept., Proc. Eur. Pept. Symp., 18th (1984), 509-12. Editor(s): Ragnarsson, Ulf. Publisher: Almqvist & Wiksell, Stockholm, Swed. CODEN: 53PWAN
DT Conference
LA English
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2
AB H-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-X-H (X = null, Phe-Arg, Phe-Arg-Tyr) (atriopeptins I, II, and III, resp.) were isolated from atrial exts. and also synthesized by solid- and liq.-phase methods. Analogs of atriopeptin I in which Asp-9 and Phe-4 are replaced by Ala were also prepd. and found to have reduced (100- and 200-fold, resp., natriuretic activity.
ST atriopeptin isolation synthesis; Merrifield synthesis atriopeptin; natriuretic hormone atriopeptin
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(atriopeptins and analogs, prepn. and activities of)
IT Molecular structure-biological activity relationship
(natriuretic-diuretic, of atriopeptin analogs)
IT Merrifield synthesis
(of atriopeptins)
IT 59026-71-8P, protected derivs.

RL: RCT (Reactant)
(deprotection of)
IT 89179-54-7P 91179-54-8P 97793-28-7P
RL: RCT (Reactant); PPEP (Preparation)
(isolation and synthesis of)
IT 990.6-71-9P 990.6-72-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of)
IT 235?6-40-4?, protected derivs. 99026-66-1DP, protected derivs.
99026-67-2DP, protected derivs. **99026-68-3DP**, protected derivs.
99026-69-4DP, protected derivs. 99026-70-7DP, protected derivs.
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of)
IT **99026-68-3DP**, protected derivs.
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of)
RN 99026-68-3 HCAPLUS
CN L-Serine, N-(N-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2002 ACS
AN 1979:485604 HCAPLUS
DN 91:85604
TI An a priori calculation of the three-dimensional structure of apamin. I. Fragment Cys1-Pro6
AU Popov, E. M.; Mol'nikov, P. N.
CS M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR
SO Bioorg. Khim. (1979), 5(6), 828-47
CODEN: BIKHD7
DT Journal
LA Russian
CC 6-3 (General Biochemistry)
AB The conformational possibilities of the apamin N-terminal fragment Cys-Asn-Cys-Lys-Ala-Pro (Cys1-Pro6) were calcd. A multistage anal. involved preliminary calcns. for the overlapping di-, tri-, and tetrapeptide portions of the Cys1-Pro6 hexapeptide. Low-energy polypeptide conformations were used for computing the dipeptide structures. Anal. of the Cys1-Pro6 fragment produced several stable structures which are promising for studies of longer apamin fragments.
ST apamin conformation calcn
IT Chains, chemical
(conformation of, of apamin, a priori calcn. of)
IT Conformation and Conformers
(of amino acids of apamin, polypeptide conformation calcn. in relation to)
IT 14645-16-2
RL: BIOL (Biological study)
(conformation of N-terminal hexapeptide of, a priori calcn. of)

IT 17043-71-9 63037-15-0 71190-87-9 71190-88-0 71190-89-1
71190-90-2 **71190-91-5** 71190-92-6 71190-93-7
RL: PRP (Properties)
(conformation of, a priori calcn. of, apamin in relation to)

IT **71190-91-5**
RL: PRP (Properties)
(conformation of, a priori calcn. of, apamin in relation to)

RN 71190-91-5 HCAPLUS
CN L-Cysteine, N-(N-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his 149-

(FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002)

FILE 'HCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002

L49 5144 S L31
L50 5055 S L49 AND (PD<=20010216 OR PRD<=20010216 OR AD<=20010216)
L51 51 S L50 AND ?ANGIOGEN?
E ANGIOGENESIS/CT
E E3+ALL
L52 7139 S E9+NT
E E10+ALL
L53 2605 S E4+NT
E E7+ALL
L54 1515 S E3,E4,E2+NT
E E8-ALL
L55 1755 S E6,E5+NT
E ANGIOGENESIS/CT
E E5+ALL
E E12+ALL
L56 12/085 S E5,E4+NT
E ANGIOGENESIS/CT
E E7+ALL
L57 2605 S E4+NT
L58 43 S L50 AND L52-L55,L57
L59 136 S L50 AND L58
L60 2279 S L56 (L) ANGIOGEN?
L61 38951 S L56 (L) ENDOTHEL?
L62 47 S L59 AND L60,L61
L63 124 S L51,L58,L62
L64 121 S L63 NOT L47
L65 66 S L64 AND P/DT
L66 41 S L65 AND US/PC
L67 414 S L31 (L) (PAC OR THU)/RL
L68 46 S L67 AND L61
L69 22 S L68 AND L66
SEL HIT RN

```
     FILE 'REGISTRY' ENTERED AT 10:45:54 ON 16 OCT 2002
L70            20 S E1-E26
L71            19 S L70 NOT NCSC/ES

     FILE 'HCAPLUS' ENTERED AT 10:51:54 ON 16 OCT 2002
L72           924 S L71
L73            21 S L72 AND L69

=> d all hitstr tot L73

L73  ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2002 ACS
AN   2002:516604  HCAPLUS
DN   137:99431
TI   Compounds and methods for cancer therapy using cadherin cell adhesion
     recognition cyclic peptides
IN   Blaschuk, Orest W.; Gour, Barbara J.; Farookhi, Riaz
PA   McGill University, Can.
SO   U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 248,074.
     CODEN: USXXAM
DT   Patent
LA   English
IC   ICM  A61K038-00
     ICS  C07K005-04; C07K007-06
NCL  530317000
CC   1-6 (Pharmacology)
FAN.CNT 7
     PATENT NO.         KIND  DATE          APPLICATION NO.   DATE
     ---------------    ----  --------      ---------------   --------
PI   US 6417327         B1    20020709      US 1998-197717    19980720 <--
     US 6031071         A     20000229      US 1997-899534    19970711 <--
     US 6169071         B1    20010102      US 1997-996679    19971223 <--
     US 6346513         B1    20020212      US 1999-248074    19990210 <--
     US 6465427         B1    20021015      US 1999-453870    19991210 <--
PRAI US 1996-21612I     P     19960711  <--
     US 1997-899534     A2    19970711  <--
     US 1997-996679     A2    19971223  <--
     US 1999-248074     A2    19990210  <--
     US 1999-197717     A2    19981120  <--
AB   Agents that inhibit the development of cancer and tumor growth are
     provided. Such agents comprise a classical cadherin cell adhesion
     recognition (CAR) sequence HAV within a cyclic peptide ring, and may be
     used to prevent or treat cancer. The cyclic peptide N-Ac-CHAVC-NH2
     disrupted melanoma cell adhesion and inhibited angiogenesis.
ST   cancer treatment cadherin cyclic peptide CAR sequence; cell adhesion
     recognition cyclic peptide cadherin antitumor; angiogenesis
     inhibition cyclic peptide cadherin; melanoma cell adhesion disruption
     cyclic peptide
IT   Cadherins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
         (E-; compds. and methods for cancer therapy using cadherin cell
         adhesion recognition cyclic peptides)
IT   Cadherins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
         (N-; compds. and methods for cancer therapy using cadherin cell
         adhesion recognition cyclic peptides)
IT   Angiogenesis inhibitors
     Antitumor agents
     Apoptosis
     Carcinoma
     Cell adhesion
     Drug delivery systems
     Human
```

Leukemia
Mammalia
Melanoma
Neoplasm
Ovary, neoplasm
(compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT Cadherins
PL: BAC (Biological study, unclassified); PEP (Properties); BIOL (Biological study)
(compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT Peptides, biological studies
PL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic, cell adhesion modulating; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT Mammary gland
(neoplasm; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT Blood
(stability of cyclic peptide in; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT **60961-76-4 99896-85-2 132151-24-7**
143113-41-1 157535-09-6 175177-02-3
175177-14-7 175177-70-5 204644-06-3 [illegible]-05-0 231282-45-2
231282-44-2 231282-45-4 [illegible]-46-5 231282-47-6
PL: **PAC (Pharmacological activity)**; PEP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(as cell adhesion recognition sequence; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT 102503-15-0 218664-49-8 [illegible]-60-2 229971-61-3 229971-62-4
229971-63-5 229971-64-6 229971-65-7 229971-67-9 229971-68-0
229971-69-1 229971-70-4 229971-71-5 [illegible]-72-6 229971-73-7
317320-04-4 417320-12-2 417320-[illegible]-1 417320-[illegible]-4 361224-65-3
361224-66-4 361224-67-5
PL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell adhesion modulating cyclic peptides; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT 229971-59-9
PL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT 229971-61-7 229971-63-9 229971-64-0 [illegible]-65-1 229971-66-2
229971-68-4 229971-91-9 361224-[illegible]-1
PL: PAC (Pharmacological activity); PEP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT 442211-54-3 442211-56-5 442211-57-6 442211-58-7 442211-59-8
442211-60-1 442211-61-2 442211-62-3 442211-63-4 442211-64-5
442211-65-6 442211-66-7
PL: PEP (Properties)
(unclaimed protein sequence; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

IT 73209-86-4 [illegible]-64-2 [illegible]-78-4 [illegible]-23-4 221169-86-0
221169-90-6 [illegible]-78-1 [illegible]-94-9 317320-19-7 351974-36-4
426207-35-4
PL: PEP (Properties)
(unclaimed sequence; compds. and methods for cancer therapy using

cadherin cell .Jhesin recognition cyclic peptides)

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1. Alexander; Journal of Cellular Physiology 1993, V156, P610 HCAPLUS
(2 Ali; J Med Chem 1994, V37(1), P1
(3) Anon; EP 406428 B1 1991 HCAPLUS
(4, Anon; WO 9104747 1991 HCAPLUS
(5; Anon; WO 9208731 1992 HCAPLUS
(6) Anon; WO 9411401 1994 HCAPLUS
(7. Anon; WO 9640781 1996 HCAPLUS
(8, Anon; WO 9707209 1997 HCAPLUS
(9, Anon; WO 9830245 1998 HCAPLUS
(10, Anon; WO 9445319 1994 HCAPLUS
(11) Beesley; Biochemical Society Transactions 1995, V23, P59 HCAPLUS
(12) Blakemore; Nature 1977, V266, P68 MEDLINE
(13) Blakemore; Nature 1977, V266, P68 MEDLINE
(14) Blaschuck; Proc Natl Acad Sci USA 1979, V76(3), P514
(15) Blaschuk; US 6061071 A 2000 HCAPLUS
(16) Blaschuk; US 6100071 B1 2001 HCAPLUS
(17) Blaschuk; US 6307026 B1 2001 HCAPLUS
(18) Blaschuk; Developmental Biology 1990, V139, P564 HCAPLUS
(19) Blaschuk; The Canadian Journal of Neurology 1994, V4(4), P291 MEDLINE
(20) Blaschuk; The Canadian Journal of Neurology 1994, V4(4), P291 MEDLINE
(21) Bottenstein; Proc Natl Acad Sci USA 1979, V76(1), P514 HCAPLUS
(22) Brecknell; Neuroscience 1996, V74(2), P579 HCAPLUS
(23) Brockes; Brain Research 1979, V165, P105 MEDLINE
(24) Bronson; US 5591412 A 1997 HCAPLUS
(25) Brook; GLIA 1992, V5, P43 MEDLINE
(26) Byers; Development Biology 1992, V153, P411 HCAPLUS
(27) Cardarelli; The Journal of Biological Chemistry 1992, V267(23), P23159
(28) Carlstedt; Brain Research Bulletin 1989, V23, P9 MEDLINE
(29) Cepek; Proc Natl Acad Sci USA 1996, V93, P6567 HCAPLUS
(30) Chuan; Developmental Brain Research 1991, V60, P115 MEDLINE
(31) Craig; Biopolymers (Peptide Science) 1991, V37, P157
(32) Doherty; Current Opinion in Neurobiology 1994, V4, P49 HCAPLUS
(33) Doherty; Molecular and Cellular Neuroscience 1996, V8(Article No 0049), P99
(34) Doherty; Neuron 1991, V6, P247 HCAPLUS
(35) Duncan; Journal of Neurocytology 1988, V17, P551 MEDLINE
(36) Fok-Seang; Brain Research 1995, V669, P307 HCAPLUS
(37) Fok-Seang; Developmental Biology 1996, V171, P1 HCAPLUS
(38) Franz; Curr Probl Dermatol 1975, V7, P83 HCAPLUS
(39) Franz; The Journal of Investigative Dermatology 1975, V64(3), P190 HCAPLUS
(40) Gerger; US 5510628 A 1996 HCAPLUS
(41) Ghirnikar; GLIA 1994, V11, P307 MEDLINE
(42) Gumbiner; The Journal of Cell Biology 1988, V107, P1575 HCAPLUS
(43) Irusela-Arispe; Molecular Biology of the Cell 1995, V6, P427 HCAPLUS
(44) Laird; The Journal of Cell Biology 1995, V131(6), P1193 HCAPLUS
(45) Lee; Journal of Immunology 1994, V152, P1053 HCAPLUS
(46) Letourneau; Journal of Neurobiology 1991, V22(7), P707 HCAPLUS
(47) Lider; US 5352667 A 1994 HCAPLUS
(48) Liuzzi; Science 1987, V237, P442 MEDLINE
(49) Lutz; Journal of Biomolecular Structure & Dynamics 1995, V13(3), P447 HCAPLUS
(50) Matsunaka; The Journal of Cell Biology 1981, V110, P1239 HCAPLUS
(51) McCarthy; J Cell Biology 1989, V89, P351 HCAPLUS
(52) Mege; Proc Natl Acad Sci USA 1988, V85, P1074 HCAPLUS
(53) Moran; Pharmaceutical Forum Issue 1996, V6, P4
(54) Munro; Cell Adhesion and Invasion in Cancer, Chapter 5 1996, P17 HCAPLUS
(55) Munro; Cellular Immunology 1995, V169(Article No 0123), P309
(56) Nose; Cell 1988, V61, P147 HCAPLUS
(57) Ori; Genetic Engineering News 1990, P15
(58) Overduin; Science 1995, V267, P386 HCAPLUS

(59) Ranscht; US 5585351 A 1996 HCAPLUS
(60) Redies; Development Biology 1996, V180, P413 HCAPLUS
(61) Saffell; Neuron 1997, P231 HCAPLUS
(62) Samanen; J Med Chem 1991, V34(10), P3114 HCAPLUS
(63) Schasteen; US 5231082 A 1993 HCAPLUS
(64) Shapiro; Nature 1995, V374, P327 HCAPLUS
(65) Suzuki; US 5646250 A 1997 HCAPLUS
(66) Tsutsui; J Biochem 1996, V120, P1034 HCAPLUS
(67) Wickelgren; PS 1996, V12, P-6
(68) Willems; FEBS Letters 1995, V363, P239 HCAPLUS
(69) Williams; Eur J Biochem 1988, V122, P297 HCAPLUS
(70) Williams; Neuron 1994, V13, P583 HCAPLUS
(71) Yang; US 5665590 A 1997 HCAPLUS

IT **60961-76-4 99896-85-2 132151-24-7**
143113-41-1 157535-09-6 175177-02-3
RL: **PAC (Pharmacological activity)**; PRP (Properties); **THU**
(Therapeutic use); BIOL (Biological study); USES (Uses)
(as cell adhesion recognition sequence; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)

RN 60961-76-4 HCAPLUS
CN L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 132151-24-7 HCAPLUS
CN L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143113-41-1 HCAPLUS
CN L-Valine, L-nistidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157535-09-6 HCAPLUS
CN L-Lysine, L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 175177-02-3 HCAPLUS
CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:537733 HCAPLUS
DN 135:14[illegible]
TI Methods and compositions for treating condition of the eye
IN Miller, Joan W.; Gragoudas, Evangelos S.; Renno, Reem Z.
PA Massachusetts Eye and Ear Infirmary, USA
SO PCT Int. Appl., 3[illegible] pp.
CODEN: PIXXD2
DT **Patent**
LA English
ICI A61
CC 8-9 (Enzymology Biochemistry)
Section cross-reference(s): [illegible]

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058248	A2	20010816	WO 2001-US4391	20010209 <--
	WO 2001058248	A3	20020411		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001034979	A5	20010820	AU 2001-34979	20010209 <--
	US 2002040015	A1	20020404	US 2001-781341	20010209 <--
PRAI	US 2000-181641P	P	20000210 <--		
	WO 2001-US4391	W	20010209 <--		

AB Provided are methods and compns. for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-**angiogenesis** factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.

ST photodynamic therapy eye choroidal neovascularization **antiangiogenic** agent; apoptosis modulator eye choroidal neovascularization photodynamic therapy

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bak; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature: apoptosis)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bax; treatment of ocular conditions with photodynamic therapy and apoptosis-modulating agents)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bcl-xL; treatment of ocular conditions with photodynamic therapy and apoptosis-modulating agents)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bcl-2; treatment of ocular conditions with photodynamic therapy and apoptosis-modulating agents)

IT Eye

(choroid; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Eye, disease
(inflammation; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Eye, disease
(macula, degeneration, age-related; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Vision
(myopia, pathol.; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT **Angiogenesis**
(neovascularization; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Histoplasma capsulatum
(ocular infection with; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT **Angiogenesis inhibitors**
Drug targeting
Laser radiation
Photodynamic therapy
Photosensitizers (pharmaceutical)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Antibodies
Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Azo dyes
(photosensitizers; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Amino acids, biological studies
Porphyrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photosensitizers; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Apoptosis
(treatment of ocular conditions with photodynamic therapy and apoptosis-modulating agents)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.3, **antiangiogenic** agents binding to; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.5, **antiangiogenic** agents binding to; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT 329900-75-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT 88030-03-6, Angiostatin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT **99896-85-2D**, peptides contg. 184240-26-1D, peptides contg.
187833-07-9, Endostatin 197830-93-1, pigment epithelium derived factor
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT 168562-56-7, caspase 3
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature: caspase activation)

IT 246256-04-4, Lutetium texaphyrin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(photosensitizer; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT 92-83-1D, Xanthene, derivs. 101-60-0D, Porphyrin, benzo derivs.
109-97-7D, Pyrrole, derivs. 574-93-6D, Phthalocyanine, derivs.
2683-84-3D, Chlorin, derivs. 14459-29-1D, Hematoporphyrin, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photosensitizers; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

IT **99896-85-2D**, peptides contg.
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovasculature)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2012 ACS
AN 2001:519335 HCAPLUS
DN 135:111977
TI Diagnostic/therapeutic agents having phospholipid-based microbubbles coupled to one or more vectors
IN Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Naevestad, Anne; Bellebust, Halldis; Heff, Lars; Cuthbertson, Alan; Lovhaug, Dagfinn; Solbakken, Magne
PA Nycomed Imaging As, Norway
SO U.S., 89 pp., Cont.-in-part of U.S. Ser. No. 958,993.
CODEN: USXXAM
LT **Patent**
LA English
IC ICM A61B008-00
ICS A61B008-06; A61K031-00; A61K 49-04; A61P019-14
NCL 424009.20
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 8

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6315709	B1	20011113	US 1997-960054	19971029 <--
	CN 1234742	A	19991110	CN 1997-199047	19971028 <--

US 6331288	B1	20 [illegible]	US 1997-959296	19971028 <--	
FR 2760982	A	20[illegible]	FR 1998-2[illegible]	19980427 <--	
US 2002[illegible]	A1	2[illegible]	US 2001-765614	20010122 <--	
PRAI GB 1996-[illegible]	A	19[illegible] <--			
GB 1996-[illegible]	A	19[illegible] <--			
GB 1996-[illegible]	A	19[illegible] <--			
GB 1997-[illegible]	A	19[illegible] <--			
GB 1997-[illegible]	A	19[illegible] <--			
GB 1997-11[illegible]	A	19[illegible] <--			
GB 1997-11946	A	19[illegible] <--			
US 1997-[illegible]P	P	19[illegible] <--			
US 1997-[illegible]P	P	19[illegible] <--			
US 1997-[illegible]P	P	19[illegible] <--			
US 1997-958993	A2	19[illegible] <--			
GB 1998-[illegible]	A	19[illegible] <--			
GB 1997-[illegible]	A	19[illegible] <--			
GB 1997-11627	A	19[illegible] <--			
GB 1997-11639	A	19[illegible] <--			
US 1997-[illegible]P	P	19[illegible] <--			
US 1997-[illegible]P	P	19[illegible] <--			
US 1997-960054	A1	19[illegible] <--			

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprise gas-filled microbubbles stabilized by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector. The gas is air, nitrogen, oxygen, carbon dioxide, hydrogen, an inert gas, a sulfur fluoride, selenium hexafluoride, a low mol. wt. hydrocarbon, a ketone, an ester, a halogenated low mol. wt. hydrocarbon or their mixts. The film-forming surfactant material is one or more phospholipids selected from the group consisting of phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins. A therapeutic agent is an antineoplastic agent, blood product, biol. response modifier, antifungal agent, hormone or hormone analog, vitamin, enzyme, antiallergic agent, tissue factor inhibitor, platelet inhibitor, coagulation protein target inhibitor, fibrin formation inhibitor, fibrinolysis promoter, **antiangiogenic**, circulatory drug, metabolic potentiator, antitubercular, antiviral, vasodilator, antibiotic, anti-inflammatory, antiprotozoal, antirheumatic, narcotic, opiate, cardiac glycoside, neuromuscular blocker, sedative, local anesthetic, general anesthetic or genetic material. For example, an endothelial cell adhesion of phosphatidylserine-encapsulated perfluorobutane microbubbles coated with polylysine was higher than adhesion of uncoated microbubbles. Also, a thrombus was detected by ultrasound in patients with suspected venous thrombosis using i.v. phosphatidylserine-encapsulated microbubbles. The microbubbles contained inactivated human thrombin-succinyl-PEG 3400-distearoylphosphatidylethanolamine incorporated into the encapsulating membrane.

ST phospholipid surfactant peptide microbubble diagnostic therapeutic

IT Plasmid vectors
(BR322; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E-, antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-1 (intercellular adhesion mol. 1), antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Imaging agents

(acoustic imaging contrast agents; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Adrenoceptors
Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(affinity for; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Diagnosis
(agents; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and analogs; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Transferrin receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies against and FITC-labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT CD34 (antigen)
Carcinoembryonic antigen
Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Antibodies
RL: RCT (Reactant); RACT (Reactant or reagent)
(biotinylated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Oligonucleotides
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(biotinylated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Antibodies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugates, with polyethoxylated phospholipid deriv.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT **Blood vessel**
endothelium, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT DNA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments, fluorescein-labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Anesthetics

(general; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study ; USES (Uses)
(halo; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Fibrins
RL: BSU (Biological study, unclassified ; BIOL (Biological study)
(inhibitors; prepn. of diagnostic therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Drug delivery systems
(injections, i.v.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT CD antigens
Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(integrin .beta.3, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Perfluoro compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ketones; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Avidins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Anesthetics
(local; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-mol.-wt.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Drug delivery systems
(microbubbles; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Transferrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Ketones, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perfluoro; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Perfluoro compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perfluoroalkyl ethers; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Ethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perfluoroalkyl; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Air
Allergy inhibitors
Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Antibiotics
Anticoagulants
Antirheumatic agents
Antitumor agents
Antiviral agents
Atherosclerosis
Blood products
Cardiovascular agents
Drug targeting
Encapsulation
Fibrinolytics
Fungicides
Gene therapy
Hypnotics and Sedatives
Narcotics
Neuromuscular blocking agents
Platelet aggregation inhibitors
Protozoacides
Surfactants
Thrombosis
Thrombus
Transformation, genetic
Tuberculostatics
Vasodilators
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Lipopeptides
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Cardiolipins
Enzymes, biological studies
Esters, biological studies
Fibronectins
Ketones, biological studies
Opioids
Peptides, biological studies
Perfluorocarbons
Phosphatidic acids
Phosphatidylglycerols
Phosphatidylinositols
Phosphatidylserines
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Drug delivery systems
(prodrugs; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Metabolism, animal
(promoters; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Thiols (organic), reactions
RL: PRT (Reactant); RACT (Reactant or reagent)
(reaction products with antibodies; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Drug delivery systems
(suspensions; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Antibodies
RL: PRT (Reactant); RACT (Reactant or reagent)
(thiolated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.3, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.5, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.2.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.5, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.6, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.6.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.3, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 27072-45-3, FITC
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CL71 labeled with; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 3321-07-5, Fluorescein
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA fragments labeled with; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or

more vectors)

IT 113790-78-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(crosslinker; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 9002-04-4DP, Thrombin, reaction products with polyethoxylated phospholipid deriv.

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inactivated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 57-88-5, Cholesterol, reactions 75-31-0, Isopropylamine, reactions 106-89-8, Epichlorohydrin, reactions 108-00-9, 2-Dimethylaminoethylamine 108-30-5, Succinic anhydride, reactions 544-77-4, 1-Iodohexadecane 546-18-9, 5.beta.-Cholanic acid 1142-20-7 ... 4537-76-..., Distearoylphosphatidylethanolamine 7144-08-3, Cholesteryl chloroformate 14199-15-6, Methyl 4-hydroxyphenylacetate 55750-..., N-Succinimidyl-3-maleimidopropionate ..., Captopril 72040-63-2 109292-46-8 125726-21-0 ...

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 29121-23-1P 71224-27-3P 73070-24-3P ... 99618-27-1P 115399-07-0P 120074-77-3P 151156-36-4P 207287-11-5P 207287-14-3P 207287-31-8P 207292-75-9P 207292-78-2P ...7463-10-9P 248253-82-9P 248253-84-1P 350256-59-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 57-88-5DP, Cholesterol, conjugates with drugs 9013-20-1DP, Streptavidin, reaction products with polyethoxylated phospholipid deriv. 33...-37-8P 137056-72-5P 148081-65-4P 155018-80-5P 207287-14-7P 207287-15-8P 207287-17-0P 207287-18-1P 207287-19-2P 207287-20-5P 207287-21-6P 207287-22-7P 207287-23-8P 207287-24-9P 207287-27-2P 207287-29-4P 207287-32-9P 207292-74-8P 207292-76-3P 207292-80-6P 207292-81-7P 207292-82-8P 207302-62-3P 207302-63-4P 207302-66-7P 207302-67-8P 207302-69-0P 207400-36-0P 248253-84-1DP, carboxylated, reaction products with streptavidin 350256-57-4P 350256-59-5P 350256-60-9P 350560-86-0DP, biotinylated

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 58-85-5, Biotin 58-85-5D, Biotin, reaction products with antibodies or oligonucleotides 59-05-2, Methotrexate 76-19-7, Perfluoropropane 124-38-9, Carbon dioxide, biological studies 355-25-9, Perfluorobutane 678-26-2, Perfluoropentane 1333-74-0, Hydrogen, biological studies 2551-62-4, Sulfur hexafluoride 4537-78-4, Distearoylphosphatidylglycerol 4539-70-2, Distearoylphosphatidylcholine 7..., 3',5'-Dipalmitoyl-5-fluoro-2'-deoxyuridine 7727-37-9, Nitrogen, biological studies 7783-79-1, Selenium hexafluoride 7782-44-7, Oxygen, biological studies 11075-17-5, Carboxypeptidase A 9039-53-6, Urokinase 25104-18-1, Poly(L-lysine) ...-06-5, Poly(L-lysine) 51146-62-4, Distearoylphosphatidylserine ...-5, Sulfur fluoride 56124-62-0, N-Trifluoroacetyladriamycin-14-valerate 99896-85-2D, analogs 138757-15-0, .alpha.2-Antiplasmin 139613-...-6 139613-04-7 144001-3...-6 1...-61-8D, reaction products with phosphatidylethanolamine deriv. 151554-71-7, Tissue factor inhibitor 134...-61-...

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon.; WO 9115244 1991 HCAPLUS
(2) Anon.; WO 9302709 1993 HCAPLUS
(3) Anon; CA 2141501 1994
(4) Anon; WO 9407539 1994 HCAPLUS
(5) Anon; WO 9426273 1994 HCAPLUS
(6) Anon; WO 9428874 1994 HCAPLUS
(7) Anon; WO 9501187 1995 HCAPLUS
(8) Anon; WO 9503835 1995 HCAPLUS
(9) Anon; WO 9507072 1995 HCAPLUS
(10) Anon; WO 9515114 1995 HCAPLUS
(11) Anon; EP 0727235 1996 HCAPLUS
(12) Anon; US 08640464 1996
(13) Anon; WO 9639149 1996 HCAPLUS
(14) Anon; WO 9640277 1996 HCAPLUS
(15) Anon; WO 9640285 1996 HCAPLUS
(16) Anon; WO 9641617 1996 HCAPLUS
(17) Anon; WO 9726855 1997
(18) Anon; WO 9732474 1997 HCAPLUS
(19) Anon; WO 9741898 1997 HCAPLUS
(20) Anon; DE 19626570 1998 HCAPLUS
(21) Anon; WO 9800171 1998 HCAPLUS
(22) Anon; WO 9804293 1998 HCAPLUS
(23) Anon; WO 9810795 1998 HCAPLUS
(24) Anon; WO 9820866 1998 HCAPLUS
(25) Anon; WO 9842294 1998 HCAPLUS
(26) Elmaleh; US 5710594 1998 HCAPLUS
(27) Frieden; US 5154924 1992 HCAPLUS
(28) Grinstaff; US 5605938 1996
(29) Grinstaff; US 5660156 1997 HCAPLUS
(30) Grinstaff; US 5665383 1997 HCAPLUS
(31) Klibanov; Acta Radiologica 1997, V38(Supp 412), P113
(32) Lanza; US 5612057 1997 HCAPLUS
(33) Lanza; US 5690907 1997 HCAPLUS
(34) Lanza; US 5780010 1998
(35) Matsueda; US 4927618 1990 HCAPLUS
(36) McEver; US 5188634 1993 HCAPLUS
(37) Muzykantov; J Nuclear Medicine 1994, V35(8), P1353 MEDLINE
(38) Porter; US 5849727 1998 HCAPLUS
(39) Schneider; US 5643187 1997
(40) Tait; US 5622963 1997 HCAPLUS
(41) Thomas, F; Microparticle Prepartions Made From Biodegradable Copolymers 1999
(42) Torchilin; US 5534241 1996
(43) Tournier; US 5910300 1999 HCAPLUS
(44) Unger; US 5656211 1997 HCAPLUS
(45) Unger; US 5733572 1998 HCAPLUS
(46) Unger; US 5846517 1998 HCAPLUS
(47) Wendle; US 5611996 1997 HCAPLUS
(48) Wendle; US 5804161 1998 HCAPLUS
(49) Worthington Biochemical Corporation; Worthington Enzyme Manual, enzymes, enzyme reagents, related biochemicals 1972

IT **99896-85-2D**, analogs
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

R6b



L73 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 200.. ACS
AN 2000:756733 HCAPLUS
DN 133:308223
TI Adhesion modulatory peptides and methods for use
IN Ashkar, Samy
PA Children's Medical Center Corp., USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K007-04
ICS C07K005-08; A61K038-06; A61K038-08
CC 13-7 (Mammalian Biochemistry)
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000063236	A2	20001026	WO 2000-US10329	20000417 <--
	WO 2000063236	A3	20010628		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1173469	A2	20020123	EP 2000-923447	20000417 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009804	A	20020416	BR 2000-9804	20000417 <--
	US 2002058336	A1	20020516	US 2000-732411	20001207 <--
PRAI	US 1999-129709P	P	19990416 <--		
	WO 2000-US10329	W	20000417 <--		

AB The invention provides methods for modulating adhesion of endothelial cells, fibroblasts, macrophages, neutrophils, or myofibroblasts to a substrate. The substrate may be polyvinyl, gel, collagen, hyaluronic acid, titanium, or PGA. The invention also provides novel adhesion modulatory peptides, substrates coated with such adhesion modulatory peptides, and devices for modulation of target cell adhesion.

ST cell adhesion modulating peptide; endothelial cell adhesion modulating peptide; fibroblast adhesion modulating peptide; macrophage adhesion modulating peptide; neutrophil adhesion modulating peptide; myofibroblast adhesion modulating peptide

IT Cell adhesion
Fibroblast
Macrophage
Melanoma
Neutrophil
(adhesion modulatory peptides and methods for use)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adhesion modulatory peptides and methods for use)

IT Fibronectin receptors
Glycosaminoglycans, biological studies
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cell surface receptor; adhesion modulatory peptides and methods for use)

IT **Blood vessel**
(**endothelium**; adhesion modulatory peptides and methods for use)

IT Drug delivery systems
(gels, substrate for cell adhesion; adhesion modulatory peptides and methods for use)

IT Fibroblast
(myofibroblast; adhesion modulatory peptides and methods for use)

IT Medical goods
(peptide-coated; adhesion modulatory peptides and methods for use)

IT Vinyl compounds, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(polymers, substrate for cell adhesion; adhesion modulatory peptides and methods for use)

IT Gels
(substrate for cell adhesion; adhesion modulatory peptides and methods for use)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.3, cell surface receptor; adhesion modulatory peptides and methods for use)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.4, cell surface receptor; adhesion modulatory peptides and methods for use)

IT 110590-62-0 111793-75-9 130557-98-2 206741-56-2 302577-95-3
302577-96-4 302577-97-5 302577-98-6 302577-99-7 302578-00-3
302578-01-4 302578-02-5 302578-03-6 302578-04-7 **302578-05-8**
302578-13-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(adhesion modulatory peptides and methods for use)

IT 7440-32-6, Titanium, biological studies 9004-61-9, Hyaluronic acid 26009-03-0, Poly(glycolide) 26202-03-4, Poly(glycolide)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(substrate for cell adhesion; adhesion modulatory peptides and methods for use)

IT **302578-05-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(adhesion modulatory peptides and methods for use)

RN 302578-05-8 HCAPLUS
CN L-Valine, L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:53713 HCAPLUS
DN 132:106963
TI Compounds and methods for modulating cadherin-mediated functions
IN Doherty, Patrick; Blaschuk, Orest W.; Gour, Barbara J.
PA Adherex Technologies, Inc., Can.
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K014-705
ICS C07K007-06; C07F007-08; A61K047-48; A61N033-00
CC 15-6 (Immunochemistry)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001917	A2	20000120	WO 1999-CA627	19990712 <--
WO 2000001917	A3	20000504		

PI
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6277824	B1	20010821	US 1998-113977	19980710 <--
AU 9945964	A1	20000201	AU 1999-45964	19990712 <--
EP 1097148	A2	20010509	EP 1999-928063	19990712 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002520010	T2	20020709	JP 2000-559146	19990712 <--

PRAI US 1998-113977 A 19980710 <--
WO 1999-CA627 W 19990712 <--

AB Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analog or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may advant. comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST HAV binding motif cadherin cell adhesion

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-; compd. comprising HAV binding motif for modulating

cadherin-mediated functions)

IT Polynucleotides
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HAV binding motif-encoding; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Protein motifs
(HAV-binding; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Acetyl group
(N-; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cadherins
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-CAM; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cell migration
(Schwann cell; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Transplant and Transplantation
(adhesion enhancement; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Gingiva
Skin
(blood sampling; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Thioethers
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bond; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Animal cell
(cadherin-expressing; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Drug delivery systems
(carriers; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Neoplasm
(cells; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Nervous system
(central, demyelination; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Nervous system
(central, drug delivery; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Chemistry
(chem. compds., cell adhesion-modulating; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(claudins; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Amide group
Angiogenesis
Bioreactors
Carcinoma

Cell adhesion
Disulfide group
Drug delivery systems
Drug screening
Drug targeting
Drugs
Epithelium
Fluorescent substances
Immunostimulation
Immunosuppression
Labels
Leukemia
Lymphocyte
Melanoma
Membranes, nonbiological
Microparticles
Multiple sclerosis
Oligodendrocyte
Ovary, neoplasm
Peptidomimetics
Protein sequences
Test kits
Ultrathin films
Wound healing
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cadherins
Fibronectins
Integrins
Laminins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Antibodies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Plastics, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic, HAV-binding; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(desmocollins; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(desmogleins; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Antitumor agents
(drug delivery; compd. comprising HAV binding motif for modulating

cadherin-mediated functions)

IT **Blood vessel**
(**endothelium**; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Proteins, specific or class
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(extracellular matrix-assocd.; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Apoptosis
(induction; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Spinal cord
(injury; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(junctional; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Neoplasm
(metastasis, inhibition; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Schwann cell
(migration; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Bladder
(neoplasm; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Nerve
(neuron; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(occludin; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Axon
(outgrowth; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT **Blood vessel**
Blood vessel
(permeability, enhancement; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Biological transport
(permeation, vascular, enhancement; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Medical goods
(plastic dishes; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Pregnancy
(prevention; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Oligodendrocyte
(progenitor; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Blood
(sampling; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Drug delivery systems
(skin patch; compd. comprising HAV binding motif for modulating cadherin-mediated function)

IT Transplant and Transplantation
Transplant and Transplantation
(skin; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Synapse
(stability; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Drug delivery systems
(sustained-release; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Medical goods
(sutures; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Drug delivery systems
(transdermal; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Skin
Skin
(transplant; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT Medical goods
(tubes, plastic; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT 110590-64-2, Yigsr peptide+ 143304-73-4, Kysfnydgse peptide+
231282-05-0, Lyhy peptide+
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(branched peptide contg.; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT 73-22-3, Tryptophan, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin-modulating agent contg. .delta.1.delta.1-DI; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT 52-67-5D, Penicillamine, derivs. 56-84-8, L-Aspartic acid, biological studies 56-87-1, 56-86-0, L-Glutamic acid, biological studies 70-26-8, L-Ornithine 107-96-0D, L-Lysine, biological studies 108-98-5D, Mercaptobenzene, .beta.-Mercaptopropionic acid, derivs. 106330-39-8D, derivs. 137-07-5D, 2-Mercaptoaniline, derivs. .beta.,.beta.-Pentamethylene-.beta.-mercaptopropionic acid, derivs. 255052-59-6D, .beta.,.beta.-Tetramethylene cysteine, derivs. 255052-60-9D, .beta.,.beta.-Pentamethylene cysteine, derivs. 255052-61-0D, D-Mercaptoproline, derivs.
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cadherin-modulating agent contg.; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT 255052-13-0, Ifilnpisgql peptide+ 255052-14-1, Ifilnpisgql peptide+
255052-15-2, Vfsinsmsgrm peptide+ 255052-16-3, Vfsinsmsgrm peptide+
255052-17-4, Vfaveketgwl peptide+ 255052-18-5, Vfaveketgwl peptide+
255052-19-6, Vfilleretqwl peptide+ 255052-20-9, Vftiekesgwl peptide+
255052-21-0, Vinidsmsgrm peptide+ 255052-22-1, Wlkidsvngqi peptide+
255052-23-2, Wlkidpvngqi peptide+ 255052-24-3, Wlamdpdsgqv peptide+
255052-25-4, Wlkinatngqi peptide+ 255052-26-5, Wleinpdtgai peptide+
255052-27-6, Wlamppsgqi peptide+ 255052-28-7, Wleinpetgai peptide+
255052-29-8, Wlhintsngqi peptide+ 255052-30-1, Nlkidgvngqi peptide+
255052-31-2, Ikilpvngqi peptide+ 255052-32-3, Inpisgq peptide+
255052-33-4 255052-34-5, Idpvsgq peptide+ 255052-35-6, Kidpvngq peptide+ 255052-36-7, cyclic derivs.
255052-37-8, Pisgq peptide+ 255052-38-9, Pvngq peptide+ 255052-39-0, cyclic derivs.
255052-35-8, Ivngq peptide+ 255052-40-3, cyclic derivs.

Rvsgr peptide+ 255052-36-9D, cyclic derivs. 255052-37-0, Idpvn peptide+ 255052-37-0D, cyclic derivs. 255052-38-1, Inpis peptide+ 255052-38-1D, cyclic derivs. 255052-39-2, Kidpv peptide+ 255052-39-2D, cyclic derivs. 255052-40-5 255052-41-6 255052-42-7 255052-43-8 255052-44-9 255052-45-0 255052-46-1 255052-47-2 255052-48-3 255052-49-4 255052-50-7 255052-51-8 255052-52-9 255052-53-0D, Lkidpanggi peptide+, derivs. 255052-54-1D, Lkidavnggi peptide+, derivs. 255052-55-2 255052-56-3 255052-57-4 **255052-65-4D**, cyclic derivs. 255375-27-4 255385-39-6

RL: PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

IT 2312ed-43-7, Iysy peptide+ 249036-24-1, Ifvidsksg peptide+ 250268-79-2, Iddk peptide+ 250268-80-5, Ddks peptide+ 250268-81-6, Viddk peptide+ 250268-82-7, Iddks peptide+ 250268-83-8, Viddks peptide+ 250268-84-9, Diksg peptide+ 250268-85-0, Iddksg peptide+ 250268-86-1, Viddksg peptide+ 250268-87-2, Fvidak peptide+ 250268-88-3, Fvidks peptide+ 250268-89-4, Fviddksg peptide+ 250268-90-7, Ifvidak peptide+ 250268-91-8, Ifvidks peptide+ 255052-58-5, Idpvngg peptide+

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preferred CAR sequence; compd. comprising HAV binding motif for modulating cadherin-mediated functions.

IT 222311-36-6, 196-243-Occludin (human) 249248-46-6, E-Cadherin (rat fragment) 255703-57-2 255703-58-3 255703-59-4 255703-60-7 255703-61-8 255703-62-9 255703-63-0 255703-64-1 255703-65-2 255703-66-3 255703-67-4 255703-68-5 255703-69-6 255703-70-9 255703-71-0 255703-72-1 255714-74-2

RL: PRP (Properties)
(unclaimed protein sequence; compds. and methods for modulating cadherin-mediated functions)

IT 250268-78-1 255369-44-5 255369-45-6 255369-46-7 255369-47-8 255369-48-9 255369-49-0 255369-50-3

RL: PRP (Properties)
(unclaimed sequence; compds. and methods for modulating cadherin-mediated functions)

IT **255052-65-4D**, cyclic derivs.

RL: PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compd. comprising HAV binding motif for modulating cadherin-mediated functions)

RN 255052-65-4 HCAPLUS

CN L-Proline, L-isoleucyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:723064 HCAPLUS
DN 132:19774
TI Peptide analogs of the cell adhesion regions of non-classical cadherins for use in the treatment of cancer
IN Blaschuk, Orest W.; Gour, Barbara J.; Byers, Stephen
PA Adherex Technologies, Inc., Can.
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K038-17
CC 1-6 (Pharmacology)

FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9957149	A2	19991111	WO 1999-CA363	19990505
WO 9957149	A3	20000302		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6358920	B1	20020319	US 1999-297859	19981106
US 20020103044	A1	20020801	US 1999-284395	19990120
CA 2327539	AA	19991111	CA 1999-2327539	19990505
AU 9938907	A1	19991123	AU 1999-38907	19990505
EP 1075494	A2	20010214	EP 1999-917706	19990505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002513604	T2	20020514	JP 2000-547117	19990505
PRAI US 1998-73640	A	19980505		
US 1998-187859	A	19981106		
US 1999-234395	A	19990120		
US 1999-264206	A	19990308		
WO 1999-CA363	W	19990505		

OS MARPAT 132:19774
AB Peptides that can be used to control cell adhesion, invasion and metastasis that are analogs of the cell adhesion regions (CARs) of

non-classical cadherins are described. These peptides are at least 50 identical to a nonclassical cadherin CAR sequence or they may be peptidomimetics. Peptidomimetics may also be used, as may antibodies recognizing the CAR sequences. Genes encoding peptides contg. CAR sequence analogs may also be used. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.

ST cadherin peptide analog cell adhesion modulation cancer chemotherapy

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(CAR (cadherin-related neuronal receptor), modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Animal cell line
(MDA-MB-231, disruption of adhesion of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Leukemia
Ovary, neoplasm
(OB cadherin in metastatic cells of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(T-cadherin, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 12, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 14, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 15, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 5, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 6, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 7, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of

cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 8, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin 11, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cadherin PB, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Antitumor agents
(cadherin peptide analogs as; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(desmocollins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(desmogleins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Blood vessel
(endothelium, disruption of adhesion of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(extracellular matrix-assocd., modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Synthetic gene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for cadherin CAR peptide analogs; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Bioreactors
Membranes, nonbiological
Microparticles
Ultrathin films
(immobilization cadherin-binding peptides on; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(membrane, integral, claudins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Neoplasm
(metastasis, non-classical cadherins in, control of; peptide analogs of

cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Fibronectins
Laminins
RL: PPP (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Mammary gland
neoplasm, disruption of cell adhesion; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Adhesion, Biological
Cell adhesion
(non-classical cadherin-mediated, control of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPP (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(non-classical, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Peptidomimetics
(of cadherin CAR peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Immobilization, biochemical
(protein, of cadherin-binding peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Cadherins
RL: BPP (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(protocadherins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Medical goods
(sutures, immobilization cadherin-binding peptides on; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to cadherin CAR peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 5813-86-0 60961-76-4 61043-94-3 76726-78-0 85507-25-6
100362-15-6 136501-90-8 139414-30-6 139125-23-7 139151-04-7
148777-40-9 157539-06-6 164116-87-9 171194-05-8 174154-05-6
175177-02-2 175177-10-0 175177-14-4 175177-69-1 175177-76-8
187140-27-8 204644-30-6 208538-05-5 231292-47-6 249036-63-7
249036-64-8 249036-79-1 249036-80-4 250062-73-8 250068-81-6
250068-82-7 250068-83-8 250068-84-9 250068-85-0 250068-86-1
250068-87-2 250068-88-3 250068-89-4 250068-90-7 250068-91-8
250068-92-9 250068-93-0 250068-94-1 250068-95-2 250068-96-3
250068-97-4 250068-98-5 250068-99-6 250069-00-2 250069-01-3
250069-02-4 250069-03-5 250069-04-6 250069-05-7 250069-06-8
250069-07-9 250069-08-0 250069-09-1 250069-10-4 250069-11-5
250069-12-6 250069-13-7 250069-14-8 250069-15-9 250069-16-0
250069-17-1 250069-18-2 250069-19-3

250741-19-3 250741-20-6 250741-21-7 250741-21-7
250741-37-5 250741-38-6 250741-39-7 250741-42-2 250741-42-5
250741-43-6 250741-44-7 250741-45-8 250741-46-9 250741-47-0
250741-48-1 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-50-1 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-59-4 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-62-9 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-64-1 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-67-4 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-70-1
250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-72-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-75-4 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-79-8 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-82-3 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-85-6 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-87-8 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-90-3 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-93-6 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-96-9 250741-[illegible] 250741-[illegible] 250741-[illegible] 250741-[illegible]
250741-99-2 250742-[illegible] 250742-[illegible] 250742-[illegible] 250742-[illegible]
250742-02-9 250742-[illegible] 250742-[illegible] 250742-[illegible] 250742-06-4
250742-04-1 250742-05-2 250742-06-3 250742-09-6 250742-09-7
250742-07-5 250742-07-6 250742-08-7 250742-12-2 250742-12-2
250742-10-0 250742-10-0 250742-11-1 250742-14-4 250742-15-5
250742-13-3 250742-13-3 250742-14-4 250742-17-7 250742-17-7
250742-15-5 250742-16-6 250742-16-6 250742-19-0 250742-20-2
250742-18-8 250742-18-8 250742-19-9 250742-20-2
250742-20-2 250742-21-3 250742-21-3 250742-22-4

PL: BPF (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use; BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs or cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250742-22-4 250742-23-5 250742-24-6 250742-25-7 250742-25-7
250742-26-8 250742-26-8 250742-27-9 250742-28-0 250742-28-0
250742-28-0 250742-29-1 250742-29-1 250742-30-4 250742-30-4
250742-31-5 250742-31-5 250742-32-6 250742-35-7 250742-35-7
250742-33-7 250742-34-8 250742-34-8 250742-36-0 250742-36-0
250742-36-0 250742-37-1 250742-38-2 250742-39-3 250742-39-3
250742-39-3 250742-40-6 250742-40-6 250742-41-7 250742-41-7
250742-42-8 250742-42-8 250742-43-9 250742-44-0 250742-44-0
250742-44-0 250742-45-1 250742-45-1 250742-46-2 250742-46-2
250742-47-3 250742-47-3 250742-48-4 250742-49-5 250742-49-5
250742-50-8 250742-51-9 250742-51-9 250742-52-0 250742-52-0
250742-53-1 250742-53-1 250742-54-2 250742-54-2 250742-55-3
250742-55-3 250742-56-4 250742-56-4 250742-57-5 250742-57-5
250742-58-6 250742-59-7 250742-59-7 250742-60-0 250742-60-0
250742-60-0 250742-61-1 250742-61-1 250742-62-2 250742-62-3
250742-64-4 250742-65-5 250742-65-5 250742-66-6 250742-66-6
250742-67-7 250742-67-7 250742-68-8 250742-69-9 250742-70-2
250742-71-3 250742-72-4 250742-73-5 250742-74-6 250742-75-7
250742-76-8 250742-77-9 250742-77-9 250742-78-0 250742-79-0
250742-79-1 250742-79-1 250742-80-4 250742-80-4 250742-81-5
250742-81-5 250742-82-6 250742-82-6 250742-83-7 250742-83-7
250742-84-9 250742-85-9 250742-86-0 250742-86-0 250742-87-1
250742-87-1 250742-87-2 250742-88-3 250742-89-4 250742-89-4
250742-90-6 250742-91-7 250742-91-7 250742-92-8 250742-92-8
250742-94-0 250742-94-0 250742-95-1 250743-01-1 250743-01-1
250742-96-2 250742-97-3 250743-04-4 250743-05-5 250743-06-7
250743-01-2 250743-[illegible]-3 250743-[illegible]-4 250743-[illegible]-6 250743-[illegible]-0
250743-[illegible]-7 250743-[illegible]-8 250743-[illegible]-9 250743-[illegible]-11-4 250743-11-4
250743-09-0 250743-11-3 250743-13-3 250743-13-6 250743-14-7
250743-12-5 250743-12-5 250743-13-6

250743-14-7 250743-15-8 250743-15-8 250743-16-9
250743-17-0 250743-17-0 250743-18-1 250743-18-1
250743-20-5 250743-20-5 250743-21-6 250743-21-6
250743-23-8 250743-23-8 250743-24-9 250743-24-9
250743-25-0 250743-25-0 250743-26-1 250743-26-1
250743-30-7 250743-31-8 250743-32-9 250743-33-0
250743-35-2 250743-35-2 250743-37-4 250743-38-5
250743-40-9 250743-41-0 250743-42-1 250743-44-3
250743-46-4 250743-46-5 250743-47-6 250743-48-7
250743-50-1 250743-51-2 250743-52-3 250743-54-5
250743-56-6 250743-58-8 250743-59-9 250743-60-2
250743-62-4 250743-63-5 250743-64-6 250743-65-7
250743-64-7 250743-65-8 250743-66-9 250743-67-0 250743-68-1
250743-68-2 250743-70-5 250743-71-6 250743-72-7 250743-73-7
250743-73-8 250743-74-9 250743-74-9 250743-75-0 250743-75-0
250743-76-1 250743-76-1 250743-77-2 250743-77-2 250743-78-3
250743-78-3 250743-79-4 250743-79-4 250743-80-7

FL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250743-80-7 250743-81-8 250743-81-9 250743-82-0 250743-82-9
250743-83-0 250743-83-0 250743-84-1 250743-84-1 250743-85-2
250743-86-3 250743-87-4 250743-87-4 250743-88-5 250743-88-5
250743-89-6 250743-89-6 250743-90-9 250743-90-9 250743-91-0
250743-91-0 250743-91-1 250743-91-1 250743-92-2 250743-93-3
250743-94-4 250743-95-5 250743-95-5 250743-96-6 250743-96-6
250743-97-7 250743-97-7 250743-98-8 250744-01-5 250744-02-6
250743-99-8 250744-00-4 250744-00-4 250744-04-8 250744-05-9
250744-03-7 250744-03-7 250744-04-8 250744-07-1 250744-07-1
250744-05-9 250744-06-0 250744-06-0 250744-09-3 250744-10-6
250744-08-2 250744-09-4 250744-09-4 250744-11-7 250744-12-8
250744-10-6 250744-11-7 250744-11-7 250744-14-0 250744-15-1
250744-13-9 250744-13-9 250744-14-0 250744-17-3 250744-17-3
250744-15-1 250744-16-2 250744-16-2 250744-20-8 250744-21-9
250744-19-5 250744-19-5 250744-20-8 250744-23-1 250744-23-1
250744-21-9 250744-22-0 250744-22-0 250744-26-4 250744-26-4
250744-24-2 250744-24-2 250744-25-3 250744-29-7 250744-29-7
250744-27-5 250744-28-6 250744-28-6 250744-31-1 250744-32-2
250744-30-0 250744-30-0 250744-31-1 250744-34-4 250744-34-4
250744-32-2 250744-33-3 250744-33-3 250744-37-7 250744-38-8
250744-35-5 250744-35-5 250744-37-7 250744-40-2 250744-41-3
250744-38-8 250744-39-9 250744-40-2 250744-44-6 250744-44-6
250744-42-4 250744-43-5 250744-43-5 250744-46-8 250744-47-9
250744-45-7 250744-45-7 250744-46-8 250744-49-1 250744-49-1
250744-47-9 250744-48-0 250744-48-0 250744-51-5 250744-52-6
250744-50-4 250744-50-4 250744-51-5 250744-54-8 250744-55-9
250744-52-6 250744-53-7 250744-53-7 250744-56-0 250744-56-0
250744-55-9 250744-56-0 250744-57-1 250744-60-6 250744-61-7
250744-59-3 250744-59-3 250744-60-6 250744-63-9 250744-64-0
250744-61-7 250744-62-8 250744-63-9 250744-66-2 250744-66-2
250744-64-0 250744-65-1 250744-65-1 250744-68-4 250744-69-5
250744-67-3 250744-67-3 250744-68-4 250744-71-0 250744-72-1
250744-70-8 250744-71-9 250744-71-9 250744-74-3 250744-75-4
250744-73-1 250744-73-1 250744-74-2 250744-77-6 250744-77-6
250744-75-9 250744-76-4 250744-76-4 250744-79-8 250744-80-0
250744-78-0 250744-78-0 250744-79-7 250744-82-3 250744-83-4
250744-80-0 250744-81-1 250744-81-1 250744-84-5 250744-85-6
250744-83-3 250744-83-3 250744-84-4 250744-87-8 250744-88-9
250744-86-6 250744-86-6 250744-87-7 250744-90-3 250744-91-4
250744-88-8 250744-89-9 250744-89-9 250744-92-5 250744-93-6
250744-92-4 250744-92-5 250744-93-6 250744-94-7 250744-94-7

250744-95-7 250744-96-8 250744-97-9 250744-98-0 250744-99-1 250745-00-7
250744-97-9 250744-98-0 250744-99-1 250745-00-7 250745-01-8 250745-02-9
250745-00-7 250745-01-8 250745-02-9 250745-03-0 250745-04-1 250745-05-2
250745-03-0 250745-04-1 250745-05-2 250745-06-3 250745-07-4 250745-08-5
250745-06-3 250745-07-4 250745-08-5 250745-09-6 250745-10-9 250745-11-0

PL: PPR (Biological process); BIOL (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of vel adhesin regions to treat non-classical cadherins for use in treatment of cancer)

IT 250745-10-9 250745-11-0 250745-12-1 250745-13-2 250745-14-3 250745-15-4
250745-13-2 250745-14-3 250745-15-4 250745-16-5 250745-17-6 250745-18-7
250745-16-5 250745-17-6 250745-18-7 250745-19-8 250745-20-1 250745-21-2
250745-19-8 250745-20-1 250745-21-2 250745-22-3 250745-23-4 250745-24-5
250745-21-2 250745-22-3 250745-23-4 250745-24-5 250745-25-6 250745-26-7
250745-24-5 250745-25-6 250745-26-7 250745-27-8 250745-28-9 250745-29-0
250745-27-8 250745-28-9 250745-29-0 250745-30-3 250745-31-4 250745-32-5
250745-30-3 250745-31-4 250745-32-5 250745-33-6 250745-34-7 250745-35-8
250745-32-5 250745-33-6 250745-34-7 250745-35-8 250745-36-9 250745-37-0
250745-35-8 250745-36-9 250745-37-0 250745-38-1 250745-39-2 250745-40-5
250745-37-0 250745-38-1 250745-39-2 250745-40-5 250745-41-6 250745-42-7
250745-40-5 250745-41-6 250745-42-7 250745-43-8 250745-44-9 250745-45-0
250745-44-9 250745-45-0 250745-46-1 250745-47-2 250745-48-3 250745-49-4
250745-47-2 250745-48-3 250745-49-4 250745-50-7 250745-51-8 250745-52-9
250745-49-4 250745-50-7 250745-51-8 250745-52-9 250745-53-0 250745-54-1
250745-52-9 250745-53-0 250745-54-1 250745-55-2 250745-56-3 250745-57-4
250745-55-2 250745-56-3 250745-57-4 250745-58-5 250745-59-6 250745-60-9
250745-58-5 250745-59-6 250745-60-9 250745-61-0 250745-62-1 250745-63-2
250745-61-0 250745-62-1 250745-63-2 250745-64-3 250745-65-4 250745-66-5
250745-64-3 250745-65-4 250745-66-5 250745-67-6 250745-68-7 250745-69-8
250745-66-5 250745-67-6 250745-68-7 250745-69-8 250745-70-1 250745-71-2
250745-69-8 250745-70-1 250745-71-2 250745-72-3 250745-73-4 250745-74-5
250745-72-3 250745-73-4 250745-74-5 250745-75-6 250745-76-7 250745-77-8
250745-74-5 250745-75-6 250745-76-7 250745-77-8 250745-78-9 250745-79-0
250745-77-8 250745-78-9 250745-79-0 250745-80-3 250745-81-4 250745-82-5
250745-80-3 250745-81-4 250745-82-5 250745-83-6 250745-84-7 250745-85-8
250745-83-6 250745-84-7 250745-85-8 250745-86-9 250745-87-0 250745-88-1
250745-85-8 250745-86-9 250745-87-0 250745-88-1 250745-89-2 250745-90-5
250745-88-1 250745-89-2 250745-90-5 250745-91-6 250745-92-7 250745-93-8
250745-90-5 250745-91-6 250745-92-7 250745-93-8 250745-94-9 250745-95-0
250745-93-8 250745-94-9 250745-95-0 250745-96-1 250745-97-2 250745-98-3
250745-95-0 250745-96-1 250745-97-2 250745-98-3 250745-99-4 250746-00-0
250746-00-0 250746-01-1 250746-02-2 250746-03-3 250746-04-4 250746-05-5
250746-03-3 250746-04-4 250746-05-5 250746-06-6 250746-07-7 250746-08-8
250746-06-6 250746-07-7 250746-08-8 250746-09-9 250746-10-2 250746-11-3
250746-09-9 250746-10-2 250746-11-3 250746-12-4 250746-13-5 250746-14-6
250746-12-4 250746-13-5 250746-14-6 250746-15-7 250746-16-8 250746-17-9
250746-15-7 250746-16-8 250746-17-9 250746-18-0 250746-19-1 250746-20-4
250746-18-0 250746-19-1 250746-20-4 250746-21-5 250746-22-6 250746-23-7
250746-21-5 250746-22-6 250746-23-7 250746-24-8 250746-25-9 250746-26-0
250746-24-8 250746-25-9 250746-26-0 250746-27-1 250746-28-2 250746-29-3
250746-26-0 250746-27-1 250746-28-2 250746-29-3 250746-30-6 250746-31-7
250746-29-3 250746-30-6 250746-31-7 250746-32-8 250746-33-9 250746-34-0
250746-32-8 250746-33-9 250746-34-0 250746-35-1 250746-36-2 250746-37-3
250746-34-0 250746-35-1 250746-36-2 250746-37-3 250746-38-4 250746-39-5
250746-37-3 250746-38-4 250746-39-5 250746-40-8 250746-41-9 250746-42-0
250746-39-5 250746-40-8 250746-41-9 250746-42-0 250746-43-1 250746-44-2
250746-42-0 250746-43-1 250746-44-2 250746-45-3 250746-46-4 250746-47-5
250746-44-2 250746-45-3 250746-46-4 250746-47-5 250746-48-6 250746-49-7
250746-47-5 250746-48-6 250746-49-7 250746-50-0 250746-51-1 250746-52-2
250746-49-7 250746-50-0 250746-51-1 250746-52-2 250746-53-3 250746-54-4
250746-51-1 250746-52-2 250746-53-3 250746-54-4 250746-55-5 250746-56-6
250746-53-3 250746-54-4 250746-55-5 250746-56-6 250746-57-7 250746-58-8
250746-55-5 250746-56-6 250746-57-7 250746-58-8 250746-59-9 250746-60-2
250746-57-7 250746-58-8 250746-59-9 250746-60-2 250746-61-3 250746-62-4
250746-59-9 250746-60-2 250746-61-3 250746-62-4 250746-63-5 250746-64-6
250746-61-3 250746-62-4 250746-63-5 250746-64-6 250746-65-7 250746-66-8
250746-63-5 250746-64-6 250746-65-7 250746-66-8 250746-67-9 250746-68-0
250746-65-7 250746-66-8 250746-67-9 250746-68-0 250746-69-1 250746-70-4
250746-67-9 250746-68-0 250746-69-1 250746-70-4 250746-71-5 250746-72-6
250746-69-1 250746-70-4 250746-71-5 250746-72-6 250746-73-7 250746-74-8
250746-71-5 250746-72-6 250746-73-7 250746-74-8 250746-75-9 250746-76-0
250746-73-7 250746-74-8 250746-75-9 250746-76-0 250746-77-1 250746-78-2
250746-75-9 250746-76-0 250746-77-1 250746-78-2 250746-79-3 250746-80-6
250746-77-1 250746-78-2 250746-79-3 250746-80-6 250746-81-7 250746-82-8
250746-79-3 250746-80-6 250746-81-7 250746-82-8 250746-83-9 250746-84-0
250746-81-7 250746-82-8 250746-83-9 250746-84-0 250746-85-1 250746-86-2
250746-83-9 250746-84-0 250746-85-1 250746-86-2 250746-87-3 250746-88-4

PL: BPR (Biological process); BIOL (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of vel adhesin regions to non-classical cadherins for use in treatment of cancer)

IT

250746-91-9	250746-92-0	250746-93-1	250746-94-2	250746-95-3
250746-96-4	250746-97-5	250746-98-6	250746-99-7	250747-00-3
250747-01-4	250747-02-5	250747-03-6	250747-04-7	250747-05-8
250747-06-9	250747-07-0	250747-08-1	250747-09-2	250747-10-5
250747-11-6	250747-12-7	250747-13-8	250747-14-9	250747-15-0
250747-16-1	250747-17-2	250747-18-3	250747-19-4	250747-20-7
250747-21-8	250747-22-9	250747-23-0	250747-25-2	250747-26-3
250747-27-4	250747-28-5	250747-29-6	250747-30-9	250747-31-0
250747-32-1	250747-33-2	250747-34-3	250747-35-4	250747-36-5
250747-37-6	250747-38-7	250747-39-8	250747-40-1	250747-41-2
250747-42-3	250747-43-4	250747-44-5	250747-45-6	250747-46-7
250747-47-8	250747-48-9	250747-49-0	250747-50-3	250747-51-4
250747-52-5	250747-53-6	250747-54-7	250747-55-8	250747-56-9
250747-57-0	250747-58-1	250747-59-2	250747-60-5	250747-61-6
250747-62-7	250747-63-8	250747-64-9	250747-65-0	250747-66-1
250747-67-2	250747-68-3	250747-69-4	250747-70-7	250747-71-8
250747-72-9	250747-73-0	250747-74-1	250747-75-2	250747-76-3
250747-77-4	250747-78-5	250747-79-6	250747-80-9	250747-81-0
250747-82-1	250747-83-2	250747-84-3	250747-85-4	250747-86-5
250747-87-6	250747-88-7	250747-89-8	250747-90-1	250747-91-2
250747-92-3	250747-93-4	250747-94-5	250747-95-6	250747-97-8
250747-98-9	250747-99-0	250748-00-6	250748-01-7	250748-02-8
250748-03-9	250748-04-0	250748-05-1	250748-06-2	250748-07-3
250748-08-4	250748-09-5	250748-10-8	250748-11-9	250748-12-0
250748-13-1	250748-14-2	250748-15-3	250748-16-4	250748-17-5
250748-18-6	250748-19-7	250748-20-0	250748-21-1	250748-22-2
250748-23-3	250748-24-4	250748-25-5	250748-26-6	250748-27-7
250748-28-8	250748-29-9	250748-30-2	250748-31-3	250748-32-4
250748-33-5	250748-34-6	250748-35-7	250748-36-8	250748-37-9
250748-38-0	250748-39-1	250748-40-4	250748-41-5	250748-42-6
250748-43-7	250748-44-8	250748-45-9	250748-46-0	250748-47-1
250748-48-2	250748-49-3	250748-50-6	250748-51-7	250748-52-8
250748-53-9	250748-54-0	250748-55-1	250748-57-3	250748-58-4
250748-59-5	250748-60-8	250748-61-9	250748-62-0	250748-63-1
250748-64-2	250748-65-3	250748-66-4	250748-67-5	250748-68-6
250748-69-7	250748-70-0	250748-71-1	250748-73-3	250748-74-4
250748-75-5	250748-76-6	250748-77-7	250748-78-8	250748-79-9
250748-81-3	250748-83-5	250748-84-6	250748-85-7	250748-86-8
250748-87-9	250748-88-0	250748-89-1	250748-90-4	250748-91-5
250748-92-6	250748-93-7	250748-95-9	250748-96-0	250748-97-1
250748-98-2	250748-99-3	250749-00-9	250749-01-0	250749-02-1
250749-03-2	250749-04-3	250749-05-4	250749-07-6	250749-08-7
250749-09-8	250749-10-1	250749-11-2	250749-12-3	250749-13-4
250749-14-5	250749-15-6	250749-16-7	250749-17-8	250749-18-9
250749-19-0	250749-20-3	250749-21-4	250749-22-5	250749-23-6
250749-24-7	250749-25-8	250749-26-9	250749-27-0	250749-28-1
250749-30-5	250749-32-7	250749-34-9	250749-35-0	

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion recognition sequences of non-classical cadherins for use in treatment of cancer)

IT

250749-36-1	250749-37-2	250749-38-3	250749-39-4	250749-40-7
250749-41-8	250749-42-9	250749-43-0	250749-44-1	250749-45-2
250749-46-3	250749-47-4	250749-48-5	250749-49-6	250749-51-0
250749-52-1	250749-53-2	250749-54-3	250749-55-4	250749-56-5
250749-57-6	250749-58-7	250749-59-8	250749-60-1	250749-61-2
250749-62-3	250749-63-4	250749-64-5	250749-66-7	250749-67-8
250749-68-9	250749-69-0	250749-70-3	250749-71-4	250749-72-5
250749-73-6	250749-74-7	250749-75-8	250749-76-9	250749-77-0
250749-78-1	250749-79-2	250749-80-5	250749-81-6	250749-83-8
250749-84-9	250749-85-0	250749-86-1	[illegible]	250749-87-2
250749-88-0	250749-89-1	250749-90-7	250749-92-9	250749-93-0

250749-94-1 250749-95-2 250749-96-3 250749-97-4 250749-98-5
250750-60-6 250750-61-7 250750-62-8 250750-63-9 250750-64-0
250750-66-2 250750-67-3 250750-68-4 250750-69-5 250750-70-8
250750-10-0 250750-13-1 250750-14-2 250750-15-3 250750-16-4
250750-17-5 250750-18-6 250750-19-7 250750-20-0 250750-21-1
250750-22-2 250750-23-3 250750-24-4 250750-25-5 250750-26-6
250750-27-7 250750-28-8 250750-29-9 250750-30-2 250750-31-3
250750-32-4 250750-33-5 250750-34-6 250750-35-7 250750-36-8
250750-37-9 250750-41-4 250750-42-5 250750-43-6 250750-47-1
250750-48-2 250750-49-3 250750-50-6 250750-51-7 250750-52-8
250750-53-9 250750-55-1 250750-56-2 250750-57-3 250750-58-4
250750-59-5 250750-60-8 250750-63-1 250750-64-2 250750-65-3
250750-66-4 250750-67-5 250750-68-6
250750-69-7 250750-70-0 250750-71-1 250750-72-2 250750-73-3
250750-74-4 250750-75-5 250750-76-6 250750-77-7 250750-78-8
250750-79-9 250750-80-2 250750-81-3 250750-82-4 250750-83-5
250750-84-6 250750-85-7 250750-86-8 250750-87-9 250750-88-0
250750-89-1 250750-90-4 250750-91-5 250750-92-6 250750-93-7
250750-94-8 250750-95-9 250750-96-0 250751-01-2 250751-02-3
250751-03-4 250751-04-5 250751-07-8 250751-08-9 250751-09-0
250751-10-1 250751-11-2 250751-12-3 250751-13-4 250751-14-5
250751-15-6 250751-16-7 250751-17-8 250751-18-9 250751-19-0
250751-20-2 250751-21-4 250751-22-5 250751-23-6 250751-24-7
250751-25-8 250751-26-9 250751-27-0 250751-28-1 250751-29-2
250751-30-5 250751-31-6 250751-32-7 250751-33-8 250751-34-9
250751-35-0 250751-36-1 250751-37-2 250751-38-3 250751-39-4
250751-40-7 250751-41-8 250751-42-9 250751-43-0 250751-44-1
250751-45-2 250751-46-3 250751-47-4 250751-48-5 250751-49-6
250751-50-9 250751-51-0 250751-52-1 250751-53-2 250751-54-3
250751-55-4 250751-56-5 250751-57-6 250751-58-7 250751-60-1
250751-61-2 250751-62-3 250751-63-4 250751-64-5 250751-65-6
250751-66-7 250751-67-8 250751-68-9 250751-69-0 250751-70-3
250751-71-4 250751-72-5 250751-73-6 250751-74-7 250751-75-8
250751-76-9 250751-77-0 250751-78-1 250751-80-5 250751-81-6
250751-82-7 250751-83-8 250751-84-9 250751-85-0

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analysis of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250751-86-1 250751-87-2 250751-88-3 250751-89-4 250751-90-7
250751-91-8 250751-92-9 250751-93-0 250751-94-1 250751-95-2
250751-96-3 250751-97-4 250751-98-5 250751-99-6 250752-00-2
250752-01-3 250752-02-4 250752-03-5 250752-04-6 250752-05-7
250752-06-8 250752-07-9 250752-08-0 250752-09-1 250752-10-4
250752-11-5 250752-12-6 250752-13-7 250752-14-8 250752-15-9
250752-16-0 250752-17-1 250752-18-2 250752-19-3 250752-20-6
250752-21-7 250752-22-8 250752-23-9 250752-24-0 250752-26-2
250752-27-3 250752-28-4 250752-29-5 250752-30-8 250752-31-9
250752-32-0 250752-33-1 250752-34-2 250752-35-3 250752-36-4
250752-37-5 250752-38-6 250752-39-7 250752-40-0 250752-41-1
250752-42-2 250752-43-3 250752-44-4 250752-45-5 250752-47-7
250752-48-8 250752-49-9 250752-50-2 250752-51-3 250752-52-4
250752-53-5 250752-54-6 250752-55-7 250752-56-8 250752-57-9
250752-58-0 250752-59-1 250752-60-4 250752-61-5 250752-62-6
250752-64-8 250752-65-9 250752-66-0 250752-67-1 250752-68-2
250752-69-3 250752-70-6 250752-71-7 250752-72-8 250752-73-9
250752-74-0 250752-75-1 250752-76-2 250752-77-3 250752-78-4
250752-79-5 250752-80-8 250752-81-9 250752-82-0 250752-83-1
250752-84-2 250752-85-3 250752-86-4 250752-87-5 250752-93-1
250752-94-7 250752-95-8 250752-96-9 250752-97-0 250752-98-1
250752-99-2 250753-00-8 250753-01-9 250753-02-0 250753-03-1

250752-99-9 250753-01-6 [illegible] [illegible] 250753-04-9
250753-05-0 [illegible] [illegible] [illegible] [illegible]
250753-10-7 250753-11-8 [illegible] [illegible] [illegible]
250753-15-2 250753-17-4 [illegible] [illegible] [illegible]
250753-18-5 [illegible] [illegible] [illegible] [illegible]
250753-23-0 [illegible] [illegible] [illegible] [illegible]
250753-28-7 [illegible] [illegible] [illegible] [illegible]
250753-34-5 [illegible] [illegible] [illegible] [illegible]
250753-39-0 [illegible] [illegible] [illegible] [illegible]
250753-44-7 [illegible] [illegible] [illegible] [illegible]
250753-49-2 [illegible] [illegible] [illegible] [illegible]
250753-54-9 [illegible] [illegible] [illegible] [illegible]
250753-59-4 [illegible] [illegible] [illegible] [illegible]
250753-64-1 250753-65-2 250753-66-3 [illegible] [illegible]
250753-69-6 250753-70-9 250753-71-0 [illegible] [illegible]
250753-74-3 250753-75-4 250753-76-5 [illegible] [illegible]
250753-79-8 250753-80-1 250753-81-2 [illegible] [illegible]
250753-84-3 250753-85-6 250753-86-7 [illegible] [illegible]
250753-89-0 250753-90-3 250753-91-4 [illegible] [illegible]
250753-94-7 250753-95-8 250753-96-9 [illegible] [illegible]
250753-99-2 250754-00-8 250754-01-9 [illegible] [illegible]
250754-04-2 250754-05-3 250754-06-4 [illegible] [illegible]
250754-09-7 250754-10-0 250754-11-1 [illegible] [illegible]
250754-14-4 250754-16-6 250754-17-7 [illegible] [illegible]
250754-20-2 250754-21-3 250754-22-4 [illegible] [illegible]
250754-25-7 250754-26-8 [illegible] [illegible]

PL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); PHL (Physical study); PRO (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250754-29-1 250754-30-4 250754-31-5 250754-32-6 250754-33-7
250754-34-8 250754-35-9 250754-36-0 250754-37-1 250754-38-2
250754-38-3 250754-42-9 250754-43-0 250754-44-1 250754-45-2
250754-46-3 250754-47-4 250754-48-5 250754-49-6 250754-50-9
250754-51-9 250754-52-0 250754-53-1 250754-54-2 250754-55-3
250754-56-4 250754-57-5 250754-58-6 250754-59-7 250754-60-0
250754-61-1 250754-62-2 250754-63-3 250754-64-4 250754-65-5
250754-66-6 250754-67-7 250754-68-8 250754-69-9 250754-70-2
250754-71-3 250754-72-4 250754-73-5 250754-74-6 250754-75-7
250754-76-8 250754-77-9 250754-78-0 250754-79-1 250754-80-4
250754-81-5 250754-82-6 250754-83-7 250754-84-8 250754-85-9
250754-86-0 250754-87-1 250754-88-2 250754-90-6 250754-91-7
250754-92-8 250754-93-9 250754-94-0 250754-96-2 250754-98-4
250754-97-3 250754-99-5 250754-04-1 250755-01-2 250755-02-3
250755-03-4 250755-04-5 250755-05-6 250755-06-7 250755-07-8
250755-08-9 250755-09-0 250755-10-3 250755-11-4 250755-12-5
250755-13-6 250755-14-7 250755-15-8 250755-16-9 250755-17-0
250755-18-1 250755-19-2 250755-20-5 250755-21-6 250755-22-7
250755-23-8 250755-24-9 250755-25-0 250755-26-1 250755-27-2
250755-28-3 250755-29-4 250755-30-7 250755-31-8 250755-32-9
250755-33-0 250755-34-1 250755-35-2 250755-37-4 250755-38-5
250755-39-6 250755-40-9 250755-41-0 250755-42-1 250755-43-2
250755-44-3 250755-45-4 250755-46-5 250755-47-6 250755-48-7
250755-49-8 250755-50-1 250755-51-2 250755-52-3 250755-53-4
250755-54-5 250755-55-6 250755-56-7 250755-57-8 250755-58-9
250755-59-0 250755-60-3 250755-61-4 250755-62-5 250755-63-6
250755-64-7 250755-65-8 250755-66-9 250755-67-0 250755-68-1
250755-69-2 250755-70-5 250755-71-6 250755-72-7 250755-73-8
250755-74-9 250755-75-0 250755-76-1 250755-77-2 250755-78-3
250755-79-4 250755-80-7 250755-81-8 250755-82-9 250755-83-0
250755-84-1 250755-85-2 250755-86-3 250755-87-4 250755-88-5
250755-89-6 250755-90-9 250755-91-0 250755-92-1 250755-93-2
250755-94-3 250755-95-4 250755-96-5 250755-97-6 250755-98-7

250755-99-9 250756-00-5 250756-01- 250756-02-6 250756-03-7
250756-04-8 250756-05-9 250756-06- 250756-07-0 250756-08-1
250756-09-2 250756-10- 250756-11- 250756-12-3 250756-13-4
250756-14-0 250756-15- 250756-17- 250756-18-1 250756-19-2
250756-20-5 250756-21- 250756-22- 250756-23-0 250756-24-2
250756-25-3 250756-26-4 250756-27- 250756-28-6 250756-29-7
250756-30-1 250756-31-1 250756-32- 250756-33-8 250756-34-9
250756-35-0 250756-36- 250756-37- 250756-38-2 250756-39-3
250756-40-2 250756-41- 250756-42-9 250756-43- 250756-44-6
250756-45-7 250756-46-8 250756-47- 250756-48-9 250756-49-1
250756-50-4 250756-51- 250756-52- 250756-53- 250756-54-8
250756-55-9 250756-56- 250756-57- 250756-58- 250756-59-0
250756-60-6 250756-61-7 250756-62- 250756-63-4 250756-64-0
250756-65-1 250756-66-2 250756-67-3 250756-68-4

PL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BioL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion motifs : non-classical cadherins for use in treatment of cancer)

IT 250756-69-5 250756-70- 250756-71- 250756-72- 250756-73-1
250756-74-2 250756-75-3 250756-76-4 250756-77-5 250756-78-6
250756-79-7 250756-80-0 250756-81-1 250756-82- 250756-83-8
250756-84-4 250756-85-5 250756-86- 250756-87-7 250756-88-8
250756-89-9 250756-90-2 250756-91-3 250756-92-4 250756-93-5
250756-94-6 250756-95-7 250756-96- 250756-97-8 250756-98-0
250756-99-1 250757-00-7 250757-01-8 250757-02- 250757-03-9
250757-04-1 250757-05-2 250757-06- 250757-07-4 250757-08-5
250757-09-6 250757-10-9 250757-11- 250757-12-1 250757-13-2
250757-14-3 250757-15-4 250757-16- 250757-17- 250757-18-7
250757-20-1 250757-21- 250757-22- 250757-23-8 250757-27-2
250757-28-9 250757-29- 250757-30- 250757-31-4 250757-32-5
250757-33-6 250757-34-7 250757-35-8 250757-36- 250757-40-5
250757-41-6 250757-42- 250757-44- 250757-45-0 250757-46-1
250757-47-2 250757-50-7 250757-51- 250757-53- 250757-54-1
250757-55-2 250757-56-3 250757-57- 250757-58- 250757-59-6
250757-60-9 250757-61-0 250757-62-1 250757-63-2 250757-64-3
250757-65-4 250757-66-5 250757-67-6 250757-68- 250757-69-8
250757-70-1 250757-71-2 250757-72- 250757-73-4 250757-74-5
250757-75-6 250757-76-7 250757-77- 250757-78- 250757-79-0
250757-80-3 250757-81-4 250757-82- 250757-83-6 250757-84-7
250757-85-8 250757-86-9 250757-87-0 250757-88-1 250757-89-2
250757-90-5 250757-91-6 250757-92-7 250757-93- 250757-94-9
250757-96-1 250757-97-2 250757-98- 250757-99-4 250758-00-0
250758-01-1 250758-02-2 250758-03- 250758-04- 250758-05-4
250758-06-5 250758-07-7 250758-08- 250758-09- 250758-10-2
250758-11-3 250758-13- 250758-14- 250758-15- 250758-16-5
250758-17-9 250758-18- 250758-19- 250758-20- 250758-21-4
250758-22-6 250758-23- 250758-24- 250758-25- 250758-26-0
250758-27-1 250758-28- 250758-29- 250758-30- 250758-31-7
250758-32-8 250758-33- 250758-34-0 250758-35- 250758-36-2
250758-38-4 250758-39- 250758-40- 250758-41- 250758-42-0
250758-44-2 250758-45- 250758-46- 250758-47- 250758-48-6
250758-49-7 250758-50- 250758-51- 250758-52- 250758-53-9
250758-54-4 250758-55- 250758-56- 250758-57- 250758-58-0
250758-59-2 250758-60- 250758-61- 250758-62- 250758-63-1
250758-65-7 250758-66- 250758-67- 250758-68- 250758-69-3
250758-70-4 250758-72- 250758-73- 250758-74- 250758-75-5
250758-76-0 250758-77- 250758-78- 250758-79- 250758-80-6
250758-81-7 250758-82- 250758-83- 250758-84- 250758-85-8
250758-86-9 250758-87- 250758-88- 250758-89- 250758-90-3
250758-91-4 250758-92- 250758-93- 250758-94- 250758-95-5
250758-97-6 250758-98- 250758-99- 250759-00- 250759-01-8
250759-04-1 250759-05- 250759-06- 250759-07- 250759-08-3

[illegible]

PL: BPP (Biological process); PCR (Biological activity, unclassified); PRP (Properties); THR (Therapeutic use); MIS (Biological study); USES (Uses)

(peptides analogs of [illegible] adhesion proteins [illegible] as anti-psoriatic agents for use in treatment of psoriasis)

IT [illegible]

PL: BPP (Biological process); PCR (Biological activity, unclassified); PRP (Properties); THR (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptide mimics of cell adhesion receptors as anti-psoriatic agents for use in treatment of psoriasis)

IT [illegible]

250761-40-1 250761-45-6 250761-50-9 250761-55-4 250761-60-5
250761-67-6 250761-72-9 250761-77-4 250761-82-5 250761-86-9
250761-90-3 250761-95-8 250761-99-2 250762-04-2 250762-07-5
250762-08-6 250762-09-7 250762-10-0 250762-11-1 250762-12-2
250762-13-3 250762-14-4 250762-15-5 250762-16-6 250762-17-7
250762-18-8 250762-19-9 250762-20-2 250762-21-3 250762-22-4
250762-23-5 250762-24-6 250762-25-7 250762-26-8 250762-27-9
250762-28-0 250762-29-1 250762-30-4 250762-31-5 250762-32-6
250762-33-7 250762-34-8 250762-35-9 250762-36-0 250762-37-1
250762-38-2 250762-39-3 250762-40-6 250762-41-7 250762-42-8
250762-43-9 250762-44-0 250762-45-1 250762-46-2 250762-47-3
250762-48-4 250762-49-5 250762-50-8 250762-51-9 250762-52-0
250762-53-1 250762-54-2 250762-55-3 250762-56-4 250762-57-5
250762-58-6 250762-59-7 250762-60-0 250762-61-1 250762-62-2
250762-63-3 250762-64-4 250762-65-5 250762-66-6 250762-67-7
250762-68-8 250762-69-9 250762-70-2 250762-71-3 250762-72-4
250762-73-5 250762-74-6 250762-75-7 250762-76-8 250762-77-9
250762-78-0 250762-79-1 250762-80-4 250762-81-5 250762-82-6
250762-83-7 250762-84-8 250762-85-9 250762-86-0 250762-87-1
250762-88-2 250762-89-3 250762-90-6 250762-91-7 250762-92-8
250762-93-9 250762-94-0 250762-95-1 250762-96-2 250762-97-3
250763-01-0 250763-02-1 250763-03-2 250763-04-3 250763-05-4
250763-06-5 250763-07-6 250763-08-7 250763-09-8 250763-10-1
250763-11-2 250763-12-3 250763-13-4 250763-14-5 250763-15-6
250763-16-7 250763-17-8 250763-18-9 250763-19-0 250763-20-3
250763-21-4 250763-22-5 250763-23-6 250763-24-7 250763-25-8
250763-26-9 250763-27-0 250763-28-1 250763-29-2 250763-30-5
250763-31-6 250763-32-7 250763-33-8 250763-34-9 250763-35-0
250763-36-1 250763-37-2 250763-38-3 250763-39-4 250763-40-7
250763-41-8 250763-42-9 250763-43-0 250763-44-1 250763-45-2
250763-46-3 250763-47-4 250763-48-5 250763-49-6 250763-50-9
250763-51-0 250763-52-1 250763-53-2 250763-54-3 250763-55-4
250763-56-5 250763-57-6 250763-58-7 250763-59-8 250763-60-1
250763-61-2 250763-62-3 250763-63-4 250763-64-5 250763-65-6
250763-66-7 250763-67-8 250763-68-9 250763-69-0 250763-70-3
250763-71-4 250763-72-5 250763-73-6 250763-74-7 250763-75-8
250763-76-9 250763-77-0 250763-78-1 250763-79-2 250763-80-5
250763-82-7 250763-83-8 250763-84-9 250763-85-0 250763-86-1
250763-87-2 250763-88-3 250763-89-4 250763-90-7 250763-91-8
250763-92-9 250763-93-0 250763-94-1 250763-95-2 250763-96-3
250763-97-4 250763-98-5 250763-99-6 250764-00-2 250764-01-3
250764-03-5 250764-04-6 250764-05-7 250764-06-8 250764-07-9
250764-08-0 250764-09-1 250764-10-4 250764-11-5

PL: BPR (Biological process.; BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

Preparation of cell adhesion regions of non-classical cadherins (peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250764-12-6 250764-13-7 250764-14-8 250764-15-9 250764-16-0
250764-17-1 250764-18-2 250764-19-3 250764-20-6 250764-21-7
250764-22-8 250764-23-9 250764-24-0 250764-25-1 250764-26-2
250764-27-3 250764-28-4 250764-29-5 250764-30-8 250764-31-9
250764-32-0 250764-33-1 250764-34-2 250764-40-9 250764-41-0
250764-37-5 250764-38-6 250764-39-7 250764-41-1 250764-42-2
250764-44-4 250764-45-5 250764-46-6 250764-47-7 250764-52-4
250764-54-6 250764-55-7 250764-56-8 250764-57-9 250764-58-0
250764-59-1 250764-60-4 250764-61-5 250764-62-6 250764-63-7
250764-64-8 250764-65-9 250764-66-0 250764-67-1 250764-68-2
250764-69-3 250764-70-6 250764-71-7 250764-72-8 250764-73-9
250764-74-0 250764-75-1 250764-76-2 250764-77-3 250764-78-4
250764-79-5 250764-80-8 250764-81-9 250764-82-0 250764-83-1
250764-84-2 250764-85-3 250764-86-4 250764-87-5 250764-88-6
250764-89-7 250764-90-0 250764-91-1 250764-92-2 250764-93-3
250764-94-4 250764-95-5 250764-96-6 250764-97-7 250764-98-8
250764-99-9 250765-00-5 250765-01-6 250765-02-7 250765-03-8
250765-04-9 250765-05-0 250765-06-1 250765-07-2 250765-08-3
250765-09-4 250765-10-7 250765-11-8 250765-12-9 250765-13-0
250765-14-1 250765-15-2 250765-16-3 250765-17-4 250765-18-5
250765-19-6 250765-20-9 250765-21-0 250765-22-1 250765-23-2
250765-24-3 250765-25-4 250765-26-5 250765-27-6 250765-28-7
250765-29-8 250765-30-1 250765-31-2 250765-32-3 250765-33-4
250765-34-5 250765-35-6 250765-36-7 250765-37-8 250765-38-9
250765-39-0 250765-40-3 250765-41-4 250765-42-5 250765-43-6
250765-44-7 250765-45-8 250765-46-9 250765-47-0 250765-48-1
250765-49-2 250765-50-5 250765-51-6 250765-52-7 250765-53-8
250765-54-9 250765-55-0 250765-56-1 250765-57-2 250765-58-3
250765-59-4 250765-60-7 250765-61-8 250765-62-9 250765-63-0
250765-64-1 250765-65-2 250765-66-3 250765-67-4 250765-68-5
250765-69-6 250765-70-9 250765-71-0 250765-72-1 250765-73-2
250765-74-3 250765-75-4 250765-76-5 250765-77-6 250765-78-7
250765-79-8 250765-80-1 250765-81-2 250765-82-3 250765-83-4
250765-84-5 250765-85-6 250765-86-7 250765-87-8 250765-88-9
250765-89-0 250765-90-3 250765-91-4 250765-92-5 250765-93-6
250765-94-7 250765-95-8 250765-96-9 250765-97-0 250765-98-1
250765-99-2 250766-00-8 250766-01-9 250766-02-0 250766-03-1
250766-04-2 250766-05-3 250766-06-4 250766-07-5 250766-08-6
250766-09-7 250766-10-0 250766-11-1 250766-12-2 250766-13-3
250766-14-4 250766-15-5 250766-16-6 250766-17-7 250766-18-8
250766-19-9 250766-20-2 250766-21-3 250766-22-4 250766-23-5
250766-24-6 250766-25-7 250766-26-8 250766-27-9 250766-28-0
250766-29-1 250766-30-4 250766-31-5 250766-32-6 250766-33-7
250766-34-8 250766-35-9 250766-36-0 250766-37-1 250766-38-2
250766-39-3 250766-40-6 250766-41-7 250766-42-8 250766-43-9
250766-44-0 250766-45-1 250766-46-2 250766-47-3 250766-48-4
250766-49-5 250766-50-8 250766-51-9 250766-52-0 250766-53-1
250766-54-2 250766-55-3 250766-56-4 250766-57-5 250766-58-6
250766-59-7 250766-60-0 250766-61-1 250766-62-2 250766-63-3
250766-64-4 250766-65-5 250766-66-6 250766-67-7 250766-68-8
250766-69-9 250766-70-2 250766-71-3 250766-72-4 250766-73-5
250766-74-6 250766-75-7 250766-76-8 250766-77-9 250766-78-0
250766-79-1 250766-80-4 250766-81-5 250766-82-6 250766-83-7
250766-84-8 250766-85-9 250766-86-0 250766-87-1 250766-88-2
250766-89-3 250766-90-6 250766-91-7 250766-92-8 250766-93-9
250766-94-0 250766-95-1 250766-96-2 250766-97-3 250766-98-4
250766-99-5 250767-00-1 250767-01-2 250767-02-3 250767-03-4
250767-04-5 250767-05-6 250767-06-7 250767-07-8 250767-08-9
250767-09-0 250767-10-3 250767-11-4 250767-12-5 250767-13-6
250767-14-7 250767-15-8 250767-16-9 250767-17-0 250767-18-1
250767-19-2 250767-20-5 250767-21-6 250767-22-7 250767-23-8
250767-24-9 250767-25-0 250767-26-1 250767-27-2 250767-28-3
250767-29-4 250767-30-7 250767-31-8 250767-32-9 250767-33-0
250767-34-1 250767-35-2 250767-36-3 250767-37-4 250767-38-5
250767-39-6 250767-40-9 250767-41-0 250767-42-1 250767-43-2
250767-44-3 250767-45-4 250767-46-5 250767-47-6 250767-48-7
250767-49-8 250767-50-1 250767-51-2 250767-52-3 250767-53-4
250767-54-5 250767-55-6 250767-56-7 250767-57-8 250767-58-9
250767-59-0 250767-60-3 250767-61-4 250767-62-5 250767-63-6
250767-64-7 250767-65-8 250767-66-9 250767-67-0 250767-68-1
250767-69-2 250767-70-5 250767-71-6 250767-72-7 250767-73-8
250767-74-9 250767-75-0 250767-76-1 250767-77-2 250767-78-3
250767-79-4 250767-80-7 250767-81-8 250767-82-9 250767-83-0
250767-84-1 250767-85-2 250767-86-3 250767-87-4 250767-88-5
250767-89-6 250767-90-9 250767-91-0 250767-92-1 250767-93-2
250767-94-3 250767-95-4 250767-96-5 250767-97-6 250767-98-7
250767-99-8 250768-00-4 250768-01-5 250768-02-6 250768-03-7
250768-04-8 250768-05-9 250768-06-0 250768-07-1 250768-08-2
250768-09-3 250768-10-6 250768-11-7 250768-12-8 250768-13-9
250768-14-0 250768-15-1 250768-16-2 250768-17-3 250768-18-4
250768-19-5 250768-20-8 250768-21-9 250768-22-0 250768-23-1
250768-24-2 250768-25-3 250768-26-4 250768-27-5 250768-28-6
250768-29-7 250768-30-0 250768-31-1 250768-32-2 250768-33-3
250768-34-4 250768-35-5 250768-36-6 250768-37-7 250768-38-8
250768-39-9 250768-40-2 250768-41-3 250768-42-4 250768-43-5
250768-44-6 250768-45-7 250768-46-8 250768-47-9 250768-48-0
250768-49-1 250768-50-4 250768-51-5 250768-52-6 250768-53-7
250768-54-8 250768-55-9 250768-56-0 250768-57-1 250768-58-2
250768-59-3 250768-60-6 250768-61-7 250768-62-8 250768-63-9
250768-64-0 250768-65-1 250768-66-2 250768-67-3 250768-68-4
250768-69-5 250768-70-8 250768-71-9 250768-72-0 250768-73-1
250768-74-2 250768-75-3 250768-76-4 250768-77-5 250768-78-6
250768-79-7 250768-80-0 250768-81-1 250768-82-2 250768-83-3
250768-84-4 250768-85-5 250768-86-6 250768-87-7 250768-88-8
250768-89-9 250768-90-2 250768-91-3 250768-92-4 250768-93-5
250768-94-6 250768-95-7 250768-96-8 250768-97-9 250768-98-0
250768-99-1 250769-00-7 250769-01-8 250769-02-9 250769-03-0
250769-04-1 250769-05-2 250769-06-3 250769-07-4 250769-08-5
250769-09-6 250769-10-9 250769-11-0 250769-12-1 250769-13-2
250769-14-3 250769-15-4 250769-16-5 250769-17-6 250769-18-7
250769-19-8 250769-20-1 250769-21-2 250769-22-3 250769-23-4
250769-24-5 250769-25-6 250769-26-7 250769-27-8 250769-28-9
250769-29-0 250769-30-3 250769-31-4 250769-32-5 250769-33-6
250769-34-7 250769-35-8 250769-36-9 250769-37-0 250769-38-1
250769-39-2 250769-40-5 250769-41-6 250769-42-7 250769-43-8
250769-44-9 250769-45-0 250769-46-1 250769-47-2 250769-48-3
250769-49-4 250769-50-7 250769-51-8 250769-52-9 250769-53-0
250769-54-1 250769-55-2 250769-56-3 250769-57-4 250769-58-5
250769-59-6 250769-60-9 250769-61-0 250769-62-1 250769-63-2
250769-64-3 250769-65-4 250769-66-5 250769-67-6 250769-68-7
250769-69-8 250769-70-1 250769-71-2 250769-72-3 250769-73-4
250769-74-5 250769-75-6 250769-76-7 250769-77-8 250769-78-9
250769-79-0 250769-80-3 250769-81-4 250769-82-5 250769-83-6
250769-84-7 250769-85-8 250769-86-9 250769-87-0 250769-88-1
250769-89-2 250769-90-5 250769-91-6 250769-92-7 250769-93-8
250769-94-9 250769-95-0 250769-96-1 250769-97-2 250769-98-3
250769-99-4 250770-00-0 250770-01-1 250770-02-2 250770-03-3
250770-04-4 250770-05-5 250770-06-6 250770-07-7 250770-08-8
250770-09-9 250770-10-2 250770-11-3 250770-12-4 250770-13-5
250770-14-6 250770-15-7 250770-16-8 250770-17-9 250770-18-0
250770-19-1 250770-20-4 250770-21-5 250770-22-6 250770-23-7
250770-24-8 250770-25-9 250770-26-0 250770-27-1 250770-28-2
250770-29-3 250770-30-6 250770-31-7 250770-32-8 250770-33-9
250770-34-0 250770-35-1 250770-36-2 250770-37-3 250770-38-4
250770-39-5 250770-40-8 250770-41-9 250770-42-0 250770-43-1
250770-44-2 250770-45-3 250770-46-4 250770-47-5 250770-48-6
250770-49-7 250770-50-0 250770-51-1 250770-52-2 250770-53-3
250770-54-4 250770-55-5 250770-56-6 250770-57-7 250770-58-8
250770-59-9 250770-60-2 250770-61-3 250770-62-4 250770-63-5
250770-64-6 250770-65-7 250770-66-8 250770-67-9 250770-68-0
250770-69-1 250770-70-4 250770-71-5 250770-72-6 250770-73-7
250770-74-8 250770-75-9 250770-76-0 250770-77-1 250770-78-2
250770-79-3 250770-80-6 250770-81-7 250770-82-8 250770-83-9
250770-84-0 250770-85-1 250770-86-2 250770-87-3 250770-88-4
250770-89-5 250770-90-8 250770-91-9 250770-92-0 250770-93-1
250770-94-2 250770-95-3 250770-96-4 250770-97-5 250770-98-6
250770-99-7 250771-00-3 250771-01-4 250771-02-5 250771-03-6
250771-04-7 250771-05-8 250771-06-9 250771-07-0 250771-08-1
250771-09-2 250771-10-5 250771-11-6 250771-12-7 250771-13-8
250771-14-9 250771-15-0 250771-16-1 250771-17-2 250771-18-3
250771-19-4 250771-20-7 250771-21-8 250771-22-9 250771-23-0
250771-24-1 250771-25-2 250771-26-3 250771-27-4 250771-28-5
250771-29-6 250771-30-9 250771-31-0 250771-32-1 250771-33-2
250771-34-3 250771-35-4 250771-36-5 250771-37-6 250771-38-7
250771-39-8 250771-40-1 250771-41-2 250771-42-3 250771-43-4
250771-44-5 250771-45-6 250771-46-7 250771-47-8 250771-48-9
250771-49-0 250771-50-3 250771-51-4 250771-52-5 250771-53-6
250771-54-7 250771-55-8 250771-56-9 250771-57-0 250771-58-1
250771-59-2 250771-60-5 250771-61-6 250771-62-7 250771-63-8
250771-64-9 250771-65-0 250771-66-1 250771-67-2 250771-68-3
250771-69-4 250771-70-7 250771-71-8 250771-72-9 250771-73-0
250771-74-1 250771-75-2 250771-76-3 250771-77-4 250771-78-5
250771-79-6 250771-80-9 250771-81-0 250771-82-1 250771-83-2
250771-84-3 250771-85-4 250771-86-5 250771-87-6 250771-88-7
250771-89-8 250771-90-1 250771-91-2 250771-92-3 250771-93-4
250771-94-5 250771-95-6 250771-96-7 250771-97-8 250771-98-9
250771-99-0 250772-00-6 250772-01-7 250772-02-8 250772-03-9
250772-04-0 250772-05-1 250772-06-2 250772-07-3 250772-08-4
250772-09-5 250772-10-8 250772-11-9 250772-12-0 250772-13-1
250772-14-2 250772-15-3 250772-16-4 250772-17-5 250772-18-6
250772-19-7 250772-20-0 250772-21-1 250772-22-2 250772-23-3
250772-24-4 250772-25-5 250772-26-6 250772-27-7 250772-28-8
250772-29-9 250772-30-2 250772-31-3 250772-32-4 250772-33-5
250772-34-6 250772-35-7 250772-36-8 250772-37-9 250772-38-0
250772-39-1 250772-40-4 250772-41-5 250772-42-6 250772-43-7
250772-44-8 250772-45-9 250772-46-0 250772-47-1 250772-48-2
250772-49-3 250772-50-6 250772-51-7 250772-52-8 250772-53-9
250772-54-0 250772-55-1 250772-56-2 250772-57-3 250772-58-4
250772-59-5 250772-60-8 250772-61-9 250772-62-0 250772-63-1
250772-64-2 250772-65-3 250772-66-4 250772-67-5 250772-68-6
250772-69-7 250772-70-0 250772-71-1 250772-72-2 250772-73-3
250772-74-4 250772-75-5 250772-76-6 250772-77-7 250772-78-8
250772-79-9 250772-80-2 250772-81-3 250772-82-4 250772-83-5
250772-84-6 250772-85-7 250772-86-8 250772-87-9 250772-88-0
250772-89-1 250772-90-4 250772-91-5 250772-92-6 250772-93-7
250772-94-8 250772-95-9 250772-96-0 250772-97-1 250772-98-2
250772-99-3 250773-00-9 250773-01-0 250773-02-1 250773-03-2
250773-04-3 250773-05-4 250773-06-5 250773-07-6 250773-08-7
250773-09-8 250773-10-1 250773-11-2 250773-12-3 250773-13-4
250773-14-5 250773-15-6 250773-16-7 250773-17-8 250773-18-9
250773-19-0 250773-20-3 250773-21-4 250773-22-5 250773-23-6
250773-24-7 250773-25-8 250773-26-9 250773-27-0 250773-28-1
250773-29-2 250773-30-5 250773-31-6 250773-32-7 250773-33-8
250773-34-9 250773-35-0 250773-36-1 250773-37-2 250773-38-3
250773-39-4 250773-40-7 250773-41-8 250773-42-9 250773-43-0
250773-44-1 250773-45-2 250773-46-3 250773-47-4 250773-48-5
250773-49-6 250773-50-9 250773-51-0 250773-52-1 250773-53-2
250773-54-3 250773-55-4 250773-56-5 250773-57-6 250773-58-7
250773-59-8 250773-60-1 250773-61-2 250773-62-3 250773-63-4
250773-64-5 250773-65-6 250773-66-7 250773-67-8 250773-68-9
250773-69-0 250773-70-3 250773-71-4 250773-72-5 250773-73-6
250773-74-7 250773-75-8 250773-76-9 250773-77-0 250773-78-1
250773-79-2 250773-80-5 250773-81-6 250773-82-7 250773-83-8
250773-84-9 250773-85-0 250773-86-1 250773-87-2 250773-88-3
250773-89-4 250773-90-7 250773-91-8 250773-92-9 250773-93-0
250773-94-1 250773-95-2 250773-96-3 250773-97-4 250773-98-5
250773-99-6 250774-00-2 250774-01-3 250774-02-4 250774-03-5
250774-04-6 250774-05-7 250774-06-8 250774-07-9 250774-08-0
250774-09-1 250774-10-4 250774-11-5

250764-91-1 [illegible] [illegible] [illegible] 250764-95-5
250764-96-6 [illegible] [illegible] [illegible] [illegible]
250765-01-6 [illegible] [illegible] [illegible] [illegible]
250765-07-2 [illegible] [illegible] [illegible] [illegible]
250765-13-2 [illegible] [illegible] [illegible] [illegible]
250765-19-8 [illegible] [illegible] [illegible] [illegible]
250765-21-0 [illegible] [illegible] [illegible] [illegible]
250765-26-5 [illegible] [illegible] [illegible] [illegible]
250765-31-2 [illegible] [illegible] [illegible] [illegible]
250765-37-8 [illegible] [illegible] [illegible] [illegible]
250765-42-3 [illegible] [illegible] [illegible] [illegible]
250765-66-1 [illegible] [illegible] [illegible] [illegible]
250765-69-2 [illegible] [illegible] [illegible] [illegible]
250765-75-4 250766-77-6 [illegible] [illegible] [illegible]
250765-90-3 250765-96-9 [illegible] [illegible] [illegible]
250766-02-6 250766-03-7 250766-04-8 250766-05-9 [illegible]
250766-07-5 250766-08-6 250766-09-7 250766-10-0 [illegible]
250766-12-2 250766-13-3 250766-14-4 250766-15-5 250766-17-7
250766-18-8 250766-19-9 250766-20-2 250766-21-3 250766-22-4
250766-23-5 250766-24-6 250766-25-7 250766-26-8 250766-27-9
250766-28-0 250766-29-1 250766-30-4 250766-31-5 250766-32-6
250766-33-7 250766-34-8 250766-35-9 250766-36-0 250766-38-2
250766-39-3 250766-40-6 250766-41-7 250766-42-8 250766-43-9
250766-44-0 250766-45-1 250766-46-2 250766-47-3 250766-48-4
250766-51-9 250766-52-0 250766-53-1 250766-54-2 250766-55-3
250766-57-5 250766-58-6 250766-59-7 250766-60-0 250766-61-1
250766-62-2 250766-63-3 250766-64-4 250766-65-5 250766-66-6
250766-67-7 250766-68-8 250766-69-9 250766-71-2 250766-74-5
250766-75-7 250766-76-8 250766-77-9 250766-78-0 250766-79-1
250766-80-4 250766-81-5 250766-82-6 250766-83-7 250766-85-9
250766-86-0 250766-87-1 250766-88-2 250766-89-3 250766-90-6
250766-91-7 250766-92-8 250766-93-9 250766-94-0 250767-00-1
250766-96-2 250766-97-3 250766-98-4 250767-00-1 250767-01-2
250767-02-3 250767-03-4 250767-04-5 250767-05-6

PL: BSP (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250767-06-7 250767-07-8 250767-08-9 250767-09-0 250767-10-3
250767-11-4 250767-12-5 250767-13-6 250767-14-7 250767-15-8
250767-16-9 250767-17-0 250767-18-1 250767-19-2 250767-20-5
250767-21-6 250767-22-7 250767-23-8 250767-24-9 250767-25-0
250767-26-1 250767-27-2 250767-28-3 250767-29-4 250767-30-7
250767-31-8 250767-32-9 250767-33-0 250767-34-1 250767-35-2
250767-36-3 250767-37-4 250767-38-5 250767-39-6 250767-40-9
250767-41-0 250767-42-1 250767-43-2 250767-44-3 250767-45-4
250767-46-5 250767-47-6 250767-48-7 250767-49-8 250767-50-1
250767-51-2 250767-52-3 250767-53-4 250767-54-5 250767-55-6
250767-56-7 250767-57-8 250767-58-9 250767-59-0 250767-61-4
250767-62-5 250767-63-6 250767-64-7 250767-65-8 250767-66-9
250767-67-0 250767-68-1 250767-69-2 250767-70-5 250767-71-6
250767-72-7 250767-73-8 250767-74-9 250767-75-0 250767-77-2
250767-78-3 250767-79-4 250767-80-7 250767-81-8 250767-87-0
250767-89-2 250767-90-5 250767-91-6 250767-92-7 250767-93-8
250767-94-1 250767-95-2 250767-96-3 250767-97-4 250767-98-5
250767-99-6 250768-00-2 250768-01-3 250768-02-4 250768-03-5
250767-34-9 250768-04-6 250768-05-7 250768-06-8 250768-07-9
250768-08-0 250768-09-1 250768-10-4 250768-11-5 250768-12-6
250768-13-7 250768-14-8 250768-15-9 250768-16-0 250768-17-1
250768-18-2 250768-19-3 250768-20-6 250768-21-7 250768-22-8
250768-23-9 250768-24-0 250768-25-1 250768-26-2 250768-27-3
250768-28-4 250768-29-5 250768-30-8 250768-31-9 250768-32-0
250768-33-1 250768-34-2 250768-35-3 250768-36-4 250768-37-5
250768-38-6 250768-39-7 250768-40-0 250768-41-1 250768-42-2
250768-43-3 250768-44-4 250768-45-5 250768-46-6 250768-47-7
250768-48-8 250768-49-9 250768-50-2 250768-51-3 250768-52-4
250768-53-5 250768-54-6 250768-55-7 250768-56-8 250768-57-9
250768-58-0 250768-59-1 250768-60-4 250768-61-5 250768-62-6
250768-63-7 250768-64-8 250768-65-9 250768-66-0 250768-67-1
250768-68-2 250768-69-3 250768-70-6 250768-71-7 250768-72-8
250768-73-9 250768-74-0 250768-75-1 250768-76-2 250768-77-3
250768-78-4 250768-79-5 250768-80-8 250768-81-9 250768-82-0
250768-83-1 250768-84-2 250768-85-3 250768-86-4 250768-87-5

[illegible]768-34-4 [illegible] [illegible] [illegible]-37-7 [illegible]
250768-39-9 250768-40-[illegible] 250768-41-[illegible] [illegible]-42-4 250768-43-[illegible]
250768-44-6 250768-45-[illegible] [illegible]768-46-[illegible] [illegible] 250768-48-[illegible]
250768-49-1 250768-5[illegible]-4 [illegible] [illegible] [illegible]
250768-54-8 250768-[illegible] [illegible] [illegible] 250768-6[illegible]
250768-59-3 250768-[illegible] [illegible] [illegible] 250768-6[illegible]
250768-64-0 250768-6[illegible]-1 [illegible] [illegible] 250768-7[illegible]-1
250768-69-5 250768-70-[illegible] 250768-71-9 [illegible] 250768-73-6
250768-74-3 250768-75-[illegible] 250768-76-4 250768-77-[illegible] 250768-[illegible]
250768-79-7 250768-[illegible] 250768-81-1 [illegible] [illegible]
250768-84-4 250768-85-5 250768-87-7 [illegible] 250768-[illegible]
250768-90-2 250768-91-3 250768-92-4 250768-93-5 250769-00-7
250768-95-7 250768-96-8 250768-98-0 250768-99-1 250769-07-4
250769-01-8 250769-02-9 250769-03-0 250769-04-1 250769-12-1
250769-08-5 250769-09-6 250769-10-9 250769-11-0 250769-17-6
250769-13-2 250769-14-3 250769-15-4 250769-16-5 250769-22-3
250769-18-7 250769-19-8 250769-20-1 250769-21-2 250769-27-8
250769-23-4 250769-24-5 250769-25-6 250769-26-7 250769-32-5
250769-28-9 250769-29-0 250769-30-3 250769-31-4 250769-37-0
250769-33-6 250769-34-7 250769-35-8 250769-36-9 250769-42-7
250769-38-1 250769-39-2 250769-40-5 250769-41-6
250769-43-8 250769-44-9 250769-45-0 250769-47-2

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

250769-50-7 250769-51-8 250769-52-9
IT 250769-48-3 250769-49-4 250769-55-2 250769-56-3 250769-57-4
250769-53-0 250769-54-1 250769-60-9 250769-61-0 250769-62-1
250769-58-5 250769-59-6 250769-66-1 250769-67-6 250769-68-7
250769-63-2 250769-65-4 250769-71-2 250769-72-3 250769-73-4
250769-69-8 250769-70-1 250769-76-7 250769-77-8 250769-78-9
250769-74-5 250769-75-6 250769-81-4 250769-82-5 250769-83-6
250769-79-0 250769-80-3 250769-86-7 250769-87-8 250769-89-0
250769-84-7 250769-85-8 250769-92-7 250769-93-8 250769-94-9
250769-90-5 250769-91-6 250769-97-2 250769-98-3 250769-99-4
250769-95-0 250769-96-1 250770-02-6 250770-03-7 250770-04-8
250770-00-4 250770-01-5 250770-07-1 250770-08-2 250770-09-3
250770-05-9 250770-06-0 250770-12-8 250770-13-9 250770-14-0
250770-10-6 250770-11-7 250770-17-3 250770-18-4 250770-19-5
250770-15-1 250770-16-2 250770-22-0 250770-23-1 250770-24-2
250770-20-8 250770-21-9 250770-27-5 250770-29-7 250770-30-0
250770-25-3 250770-26-4 250770-33-3 250770-34-4 250770-35-5
250770-31-1 250770-32-2 250770-38-8 250770-39-9 250770-40-2
250770-36-6 250770-37-7 250770-43-5 250770-44-6 250770-45-7
250770-41-3 250770-42-4 250770-48-0 250770-49-1 250770-50-4
250770-46-8 250770-47-9 250770-53-7 250770-54-8 250770-55-9
250770-51-5 250770-52-6 250770-58-2 250770-60-6 250770-61-7
250770-56-0 250770-57-1 250770-64-0 250770-65-1 250770-66-2
250770-62-8 250770-63-9 250770-69-5 250770-70-8 250770-71-9
250770-67-3 250770-68-4 250770-74-2 250770-75-3 250770-76-4
250770-72-0 250770-73-1 250770-79-7 250770-80-0 250770-81-1
250770-77-5 250770-78-6 250770-84-4 250770-85-5 250770-86-6
250770-82-2 250770-83-3 250770-88-9 250770-89-0 250770-91-3
250770-87-7 250770-88-8 250770-94-6 250770-95-7 250770-96-8
250770-92-4 250770-93-5 250770-99-1 250771-00-7 250771-01-8
250770-97-9 250770-98-0 250771-04-1 250771-05-2 250771-06-3
250771-02-9 250771-03-0 250771-09-6 250771-10-9 250771-11-0
250771-07-4 250771-08-5 250771-14-3 250771-15-4 250771-16-5
250771-12-1 250771-13-2 250771-19-8 250771-20-1 250771-21-2
250771-17-6 250771-18-7 250771-26-7 250771-27-8 250771-28-9
250771-22-3 250771-24-4 250771-31-4 250771-32-5 250771-33-6
250771-29-0 250771-30-3

250771-34-7 250771-35-[illegible] 250771-36-9 250771-37-0 250771-38-1
250771-39-2 250771-40-6 250771-41-[illegible] 250771-42-7 250771-43-8
250771-44-9 250771-45-[illegible] 250771-46-1 250771-[illegible] 250771-48-3
250771-49-4 250771-50-7 250771-51-[illegible] 250771-[illegible] 250771-[illegible]
250771-54-1 250771-55-[illegible] 250771-56-[illegible] 250771-[illegible] 250771-58-5
250771-59-6 250771-60-[illegible] 250771-61-[illegible] 250771-[illegible] 250771-[illegible]
250771-64-3 250771-65-4 250771-66-5 250771-67-6 250771-68-7
250771-69-8 250771-71-3 250771-72-4 250771-73-5 250771-74-6
250771-75-6 250771-76-7 250771-77-8 250771-78-9 250771-79-[illegible]
250771-80-3 250771-[illegible] 250771-82-[illegible] 250771-[illegible] 250771-84-[illegible]
250771-85-6 250771-[illegible] 250771-87-[illegible] 250771-[illegible]

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250771-89-[illegible] 250771-90-[illegible] 250771-91-[illegible] 250771-[illegible] 250771-93-8
250771-94-9 250771-95-0 250771-96-1 250771-[illegible] 250771-98-3
250771-99-4 250772-01-1 250772-02-2 250772-03-3 250772-04-4
250772-05-5 250772-06-6 250772-07-7 250772-08-[illegible] 250772-09-[illegible]
250772-10-8 250772-11-9 250772-14-[illegible] 250772-15-[illegible] 250772-18-9
250772-20-4 250772-22-6 250772-24-8 250772-25-9 250772-27-1
250772-29-3 250772-30-6 250772-34-[illegible] 250772-36-2 250772-38-4
250772-39-5 250772-41-[illegible] 250772-42-[illegible] 250772-44-2 250772-45-3
250772-46-4 250772-47-5 250772-48-6 250772-49-7 250772-50-0
250772-51-1 250772-53-3 250772-54-4 250772-[illegible] 250772-56-6
250772-57-7 250772-59-[illegible] 250772-60-2 250772-[illegible] 250772-62-4
250772-63-8 250772-65-7 250772-66-8 250772-67-9 250772-68-0
250772-69-1 250772-70-4 250772-72-6 250772-73-7 250772-74-8
250772-75-9 250772-76-0 250772-77-1 250772-78-2 250772-79-3
250772-81-7 250772-82-8 250772-83-9 250772-84-0 250772-85-1
250772-86-2 250772-87-3 250772-89-5 250772-90-8 250772-91-9
250772-92-0 250772-93-1 250772-94-2 250772-95-3 250772-96-4
250772-97-5 250772-99-7 250773-00-3 250773-01-4 250773-[illegible]-5
250773-03-6 250773-04-7 250773-05-8 250773-06-9 250773-07-0
250773-08-1 250773-11-6 250773-12-7 250773-13-8 250773-14-9
250773-15-0 250773-16-1 250773-17-2 250773-18-3 250773-19-4
250773-20-7 250773-21-8 250773-22-9 250773-24-1 250773-25-2
250773-26-3 250773-27-4 250773-28-5 250773-[illegible]-6 250773-30-[illegible]
250773-31-0 250773-32-1 250773-33-2 250773-34-3 250773-35-4
250773-36-5 250773-37-6 250773-[illegible]-7 250773-[illegible]-8 250773-40-1
250773-41-2 250773-42-3 250773-43-4 250773-44-5 250773-45-6
250773-46-7 250773-47-8 250773-48-9 250773-[illegible]-0 250773-50-3
250773-51-4 250773-52-5 250773-53-6 250773-[illegible]-7 250773-55-8
250773-56-9 250773-59-2 250773-60-5 250773-[illegible]-9 250773-62-[illegible]
250773-63-[illegible] 250773-64-[illegible] 250773-70-7 250773-71-8 250773-72-9
250773-74-1 250773-[illegible]-0 250773-[illegible]-2 250773-[illegible]-3 250773-77-[illegible]
250773-79-6 250774-00-6 250774-02-8 250774-03-9 250774-04-0
250774-05-1 250774-06-2 250774-07-3 250774-08-4 250774-09-5
250774-10-8 250774-11-9 250774-12-0 250774-14-2 250774-15-3
250774-16-4 250774-19-7 250774-[illegible]-8 250774-[illegible]-0 250774-21-1
250774-22-2 250774-24-4 250774-[illegible]-5 250774-26-6 250774-27-7
250774-28-8 250774-29-9 250774-30-2 250774-[illegible]-3 250774-32-4
250774-33-5 250774-34-6 250774-[illegible]-7 250774-36-8 250774-37-9
250774-38-0 250774-39-1 250774-40-4 250774-41-5 250774-42-6
250774-43-7 250774-44-8 250774-[illegible]-9 250774-[illegible]-1 250774-47-1
250774-48-2 250774-[illegible]-8 250774-[illegible]-9 250774-[illegible]-0 250774-51-1
250774-52-2 250774-53-3 250774-[illegible]-4 250774-[illegible]-5 250774-[illegible]-8
250774-61-9 250774-[illegible]-0 250774-[illegible]-2 250774-[illegible]-3 250774-71-1
250774-67-5 250774-[illegible]-6 250774-[illegible]-7 250774-[illegible]-0 250774-76-6
250774-77-7 250774-78-8 250774-79-9 250774-[illegible]-2

PL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250774-62-4 250774-85-7 250774-86-8 250774-87-9 250774-88-0
250774-89-1 250774-90-4 250774-91-5 250774-92-6 250774-93-7
250774-94-8 250774-95-9 250774-96-0 250774-97-1 250774-98-2
250774-99-3 250775-00-9 250775-01-0 250775-02-1 250775-03-2
250775-04-3 250775-07-4 250775-08-5 250775-09-6 250775-10-7
250775-11-8 250775-13-1 250775-14-2 250775-15-3 250775-16-4
250775-17-5 250775-18-6 250775-19-7 250775-20-0 250775-21-1
250775-22-2 250775-23-3 250775-24-4 250775-25-5 250775-26-6
250775-27-7 250775-28-8 250775-29-9 250775-30-2 250775-31-3
250775-32-4 250775-33-5 250775-34-6 250775-35-7 250775-36-8
250775-37-9 250775-38-0 250775-39-1 250775-40-4 250775-41-5
250775-42-6 250775-43-7 250775-44-8 250775-45-9 250775-46-0
250775-47-1 250775-48-2 250775-49-3 250775-50-6 250775-51-7
250775-52-8 250775-53-9 250775-54-0 250775-55-1 250775-56-2
250775-57-3 250775-58-4 250775-59-5 250775-60-8 250775-61-9
250775-62-0 250775-63-1 250775-64-2 250775-65-3 250775-66-4
250775-67-5 250775-68-6 250775-69-7 250775-70-0 250775-71-1
250775-72-2 250775-73-3 250775-74-4 250775-75-5 250775-76-6
250775-77-7 250775-78-8 250775-79-9 250775-80-2 250775-81-3
250775-82-4 250775-83-5 250775-84-6 250775-85-7 250775-86-8
250775-87-9 250775-88-0 250775-89-1 250775-90-4 250775-91-5
250775-92-6 250775-93-7 250775-94-8 250775-95-9 250775-96-0
250775-97-1 250775-98-2 250775-99-3 250776-00-9 250776-01-0
250776-02-1 250776-03-2 250776-04-3 250776-05-4 250776-06-5
250776-07-6 250776-08-7 250776-09-8 250776-10-1 250776-11-2
250776-12-3 250776-13-4 250776-14-5 250776-15-6 250776-16-7
250776-17-8 250776-18-9 250776-19-0 250776-20-3 250776-21-4
250776-22-5 250776-23-6 250776-24-7 250776-25-8 250776-26-9
250776-27-0 250776-28-1 250776-29-2 250776-30-5 250776-31-6
250776-32-7 250776-33-8 250776-34-9 250776-35-0 250776-36-1
250776-37-2 250776-38-3 250776-39-4 250776-40-7 250776-41-8
250776-42-9 250776-43-0 250776-44-1 250776-45-2 250776-46-3
250776-47-4 250776-48-5 250776-49-6 250776-50-9 251473-07-1
251473-12-8 251473-94-3 251473-95-4 251473-96-5 251901-78-7
251473-16-2 251473-18-4 251473-20-8

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 249760-78-9 249760-80-3
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(primer for detection of CD cadherin mRNA; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 249760-81-6 249760-82-7
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(primer for detection of hypoxanthine phosphoribosyl transferase mRNA; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT 250766-73-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

L7 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:594959 HCAPLUS
DN 131:21[illegible]27
TI Peptide compositions and formulations for enhancing elasticity and softness of skin and for therapeutic use
IN Sandberg, Lawrence B.; R[illegible], Philip J.; Mirts, Thomas F.
PA MFS, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K[illegible]-10
ICS A61K038-06; A61K038-[illegible]; A61K0[illegible].8-[illegible]
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): [illegible]

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945941	A1	19990915	WO 1999-US5196	19990312 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6069129	A	20000530	US 1999-269708	19980312 <--
	CA 2322839	AA	19990916	CA 1999-2322839	19990312 <--
	AU 9930854	A1	19990927	AU 1999-30854	19990312 <--
	EP 1064010	A1	20010103	EP 1999-911486	19990312 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002506841	T2	20020305	JP 1999-536355	19990312 <--
	NO 2000004549	A	20001109	NO 2000-4549	20000912 <--
PRAI	US 1998-39308	A	19980312 <--		
	WO 1999-US5196	W	19990312 <--		

AB The present invention is directed to a compn. which is used to enhance the softness, elasticity, or appearance of tissue. Specifically, the present invention is directed to a compn. formulated from peptides which substantially correspond to those produced from thermolyzing digestion of elastin. This formulation is preferably applied to human skin in a cosmetic or therapeutic formulation. The present compn. specifically includes the known chem. modification of the peptides described herein, specifically carboxy and amino modification including the addn. of amino acids to either end of the peptide fragments.

ST peptide skin softener elastin thermolysin

IT Cosmetics
(aerosols; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Heart, disease
(angina pectoris; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Artery
(angioplasty, restenosis after; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Lung, disease
(chronic obstructive; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Thrombosis
(coronary arterial; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Artery, disease
(coronary, restenosis, post-angioplasty; peptide compns. and

formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Artery, disease
Artery, disease
(coronary, thrombosis; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Artery, disease
(coronary; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(creams; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Blood vessel
Lung
Skin
(elastin formation in; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(emulsions; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(foams; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Drug delivery systems
(injections, s.c.; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(lotions; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT **Angiogenesis**
(neovascularization; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Drug delivery systems
(ointments; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT **Angiogenesis**
Antianginal agents
Antiarteriosclerotics
Anticoagulants
Antihypertensives
Arteriosclerosis
Cosmetics
Hypertension
Protein sequences
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Elastins
RL: BSU (Biological study, unclassified); PEP (Properties); BIOL (Biological study)
(peptide fragments of; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(powders; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT Cosmetics
(sprays; peptide compns. and formulations for enhancing elasticity and

softness of skin and for therapeutic use

IT Drug delivery systems
(topical; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT 9073-78-3, Thermolysin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT 636-50-0 **1187-50-4** 55272-50-7 61434-14-6 66825-73-2
68293-03-8 76188-25-1 100184-76-8 126141-00-6 211750-16-2
243647-47-4 243647-50-9 243647-54-3 243647-56-5 243647-58-7
243647-61-2 **243647-63-4** 243647-65-6 243647-67-8
243647-68-9 243647-70-3 243647-72-5 243647-73-6 243647-75-8
243647-77-0 243647-79-2 243647-82-7 243647-84-9 243647-87-2
243647-90-7 243647-92-9 243647-94-1 243647-97-4 243647-98-5
243647-99-6 243648-00-2 243648-01-3 243648-03-5 243648-04-6
243648-05-7 243648-06-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); PFP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Charten; Pharmacochem Libr 1987, V10, P285
(2) Bunninghake, G; Science 1981, V212, P923 HCAPLUS
(3) Lograno, M; Int J Biochem Cell Biol 1998, V30, P497 HCAPLUS

IT **1187-50-4 68293-03-8 243647-63-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); PFP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

RN 1187-50-4 HCAPLUS
CN Glycine, L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68293-03-8 HCAPLUS
CN Glycine, L-isoleucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243647-62-4 HCAPLUS
CN L-Alanine, L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:454259 HCAPLUS
DN 131:97621
TI Compounds and methods for modulating occludin-related tissue permeability
IN Blaschuk, Orest W.; Sour, Barbara J.
PA Adherex Technologies, Can.
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT **Patent**
LA English.
IC ICM C07K014-47
ICS C07K014-705; C07K016-18; C07K016-28; A61K039-17; A61K039-395; G01N033-68
CC 1-12 (Pharmacology)
Section cross-reference(s): 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9905166	A1	19990211	WO 1998-CA708	19980730 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, CW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, CW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248874	B1	20010619	US 1997-1511	19971231 <--
AU 9916665	A1	19990726	AU 1999-16665	19981230 <--
EP 1047765	A1	20001111	EP 1998-963811	19981230 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509873	T2	20020326	JP 1999-527461	19981230 <--
US 6310177	B1	20011030	US 2000-510016	20000222 <--
PRAI US 1997-1511	A	19971231 <--		
WO 1998-CA708	W	19980730 <--		

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may addnl. comprise one or more cell adhesion recognition sequences recognized by other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST peptide modulator occludin related tissue permeability; cell adhesion occludin mediated peptide modulator; antibody occludin adhesion

recognition tissue permeability

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Cytometry
(FACS (fluorescence-activated cell sorting); compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-CAM; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Bioreactors
Membranes, nonbiological
Microparticles
Ultrathin films
(adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT **Artery**
(aorta, **endothelium**; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antitumor agents
(bladder carcinoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cadherin 6; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Bladder
Bladder
(carcinoma, inhibitors; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antitumor agents
(carcinoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Drugs
(cell adhesion-modulating agent conjugates with drugs; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Polymers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cell adhesion-modulating agent conjugates with polymeric matrix solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Plastics, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Drug targeting
(cell adhesion-modulating agent conjugates with targeting agents; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Neoplasm
(cells, tissue; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Nervous system

(central, drug delivery to; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(claudins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT **Angiogenesis inhibitors**
Animal tissue culture
Antidiarrheals
Antitumor agents
Apoptosis
Cell adhesion
Drug delivery systems
Drug screening
Epithelium
Immunomodulators
Protein sequences
Transplant and Transplantation
Wound healing promoters
(compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Cadherins
Fibronectins
Integrins
Laminins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(desmocollins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(desmogleins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Skin
(drug delivery through; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT **Blood vessel**
(**endothelium**; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(extracellular matrix-associated; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Animal tissue
(implant; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Ovary, neoplasm
Ovary, neoplasm
(inhibitors; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antitumor agents
(leukemia; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antitumor agents
(melanoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Kidney
(normal rat kidney cells; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); PIOL (Biological study); PROC (Process)
(occludins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Drug delivery systems
(oral; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antitumor agents
Antitumor agents
(ovary; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT **Blood vessel**
(permeability; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Biological transport
(permeation, vascular; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Laboratory ware
(plastic dishes, cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Pipes and Tubes
(plastic, cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Transplant and Transplantation
Transplant and Transplantation
(skin; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Medical goods
(sutures, adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Cell junction
(tight junction, epithelial cell; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to cell adhesion recognition sequence; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Drug delivery systems
(transdermal; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT Skin
Skin
(transplant; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT **60961-76-4 99896-85-2 132151-24-7**
143113-41-1 157535-09-6 175177-02-3
175177-14-7 175177-70-3 204644-26-8 222169-83-7 222169-84-7D, derivs. 231282-25-0E, derivs. 231282-26-1 231282-26-1D, derivs.

231282-27-2 231282-27-2D, derivs. 231282-28-3 231282-28-3D, derivs.
231282-29-4 231282-29-4D, derivs. 231282-30-7 231282-30-7D, derivs.
231282-31-8 231282-31-8D, derivs. 231282-32-9 231282-32-9D, derivs.
231282-34-1 231282-34-1D, derivs. 231282-35-2 231282-35-2D, derivs.
231282-36-3 231282-36-3D, derivs. 231282-37-4 231282-37-4D, derivs.
231282-39-6 231282-39-6D, derivs. 231282-40-9 231282-40-9D, derivs.
231282-41-0 231282-41-0D, derivs. 231282-43-2 231282-44-3
231282-45-4 231282-46-5 231282-47-6 231282-48-7 231282-49-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

IT 231281-25-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Eisai Co Ltd; EP 488119 A 1996 HCAPLUS
(2) Furuse, M; Journal of Cell Biology 1994, V123(6), P1777 HCAPLUS
(3) Jaeger, E; Mol Biol Cell (Suppl) 1997, V8, P205A
(4) Pique, C; Journal of Virology 1996, V70(8), P4919 HCAPLUS
(5) Praecis Pharm Inc; WO 9811137 A 1998 HCAPLUS
(6) Van Itallie, C; WO 9736605 A 1997 HCAPLUS
(7) Wong; The Journal of Cell Biology 1997, V136(2), P399 HCAPLUS

IT **60961-76-4 99896-85-2 132151-24-7**
143113-41-1 157535-09-6 175177-02-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

RN 60961-76-4 HCAPLUS
CN L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 132151-24-7 HCAPLUS
CN L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143113-41-1 HCAPLUS
CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157535-09-6 HCAPLUS
CN L-Lysine, L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175177-62-3 HCAPLUS
CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:233956 HCAPLUS
DN 130:266373
TI Compounds and methods for regulating cell adhesion
IN Blaschuck, Orest W.; Gour, Barbara J.
PA Adherex Inc., Can.
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K014-705
ICS C07K016-28; A61K047-48; C07K007-06
CC 15-3 (Immunochemistry)
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9916791	A2	19990408	WO 1998-CA902	19980929 <--
WO 9916791	A3	19990520		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6303769 B1 20011020 US 1997-939853 19970929 <--
AU 9892483 A1 19990419 AU 1998-92483 19980929 <--
PRAI US 1997-939853 A 19970929 <--
WO 1998-CA902 W 19980929 <--

AB Methods for using modulating agents to enhance or inhibit cadherin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. In particular, the modulating agents may be used in the therapy of multiple sclerosis and other demyelinating diseases. The modulating agents comprise at least one cadherin cell adhesion recognition sequence (HAV) or an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence. Modulating agents may additional comprise one or more cell adhesion recognition sequences recognized by other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST antibody cadherin cell adhesion multiple sclerosis; demyelinating disease cadherin antibody cell adhesion; tumor healing cadherin antibody cell adhesion

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating

diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-CAM, sequence recognition; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosi and tumor)

IT Cell migration
(Schwann cells; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)

IT Astrocyte
(antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)

IT **Angiogenesis inhibitors**
Animal tissue
Apoptosis
Carcinoma
Circulation
Disease, animal
Drugs
Epithelium
Fluorescent substances
Immunomodulators
Inflammation
Injury
Leukemia
Mammal (Mammalia)
Melanoma
Microfilament
Multiple sclerosis
Neoplasm
Oligodendrocyte
Ovary, neoplasm
Protein sequences
Schwann cell
Skin
Surgery
Test kits
Transplant and Transplantation
Wound healing
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Antibodies
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Animal cell
(cadherin-expressing; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, and tumor)

IT Drug delivery systems
(carriers; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Nervous system
(central; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Nerve, disease
(demyelination, neuril.; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Nerve, disease
(demyelination; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)

IT **Blood vessel**
(endothelium; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Drug delivery systems
Prosthetic materials and Prosthetics
(implants; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Spinal cord
(injury; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Rat
(kidney cells; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)

IT Cell adhesion
(modulator; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Bladder
(neoplasm; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Nerve
(neuron; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Axon
(outgrowth enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, for skin and CNS drug delivery, and for treating demyelinating diseases, multiple sclerosis and tumor)

IT **Blood vessel**
(permeability, enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Biological transport
(permeation, vascular, enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Pregnancy
(prevention; antibodies or fragments for regulating cadherin-mediated cell adhesion and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Oligodendrocyte
(progenitor; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT Kidney
(rats; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)

IT Drug delivery systems
(skin patch; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases and multiple sclerosis)

IT Synapse
(stability inhibition; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)

IT Laminins
RL: AFU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(surface coated with; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)

IT Drug delivery systems
(transdermal; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT **99896-85-2** 110190-64-2 **117058-06-7**, F-Al 127650-99-3
143304-79-4 164360-50-9 175294-44-7 175294-45-8 175294-46-9
183788-96-7 **222169-79-1** **222169-80-4**
222169-81-5 222169-82-6 222169-83-7 222169-84-8
222169-85-9 222169-86-0 222169-87-1 222169-88-2 222169-89-3
222169-90-6 222311-56-4, Leu-Asp-Calcium (human)
RL: ESU (Biological study, unclassified); PEP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT **143113-41-1**
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

IT 25104-18-1, Polylysine 38009-06-5, Polylysine
RL: AFU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(surface coated with; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)

IT **99896-85-2** **117058-06-7**, F-Al **222169-79-1**
222169-80-4 **222169-81-5**

RL: PSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study.; USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117053-06-7 HCAPLUS
CN L-Leucine, L-arginyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222169-79-1 HCAPLUS
CN L-Threonine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222169-80-4 HCAPLUS
CN L-Serine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222169-81-5 HCAPLUS
CN L-Threonine, L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143113-41-1**
RL: PSU (Biological study, unclassified); **THU (Therapeutic use)**;
BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
RN 143113-41-1 HCAPLUS
CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:119782 HCAPLUS
DN 130:195765
TI CXC chemokines as regulators of **angiogenesis**
IN Strieter, Robert M.; Polverini, Peter J.; Kunkel, Steven L.
PA The Regent of the University of Michigan, USA
SO U.S., 145 pp.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K038-19
NCL 424/85.1
CC 15-5 (Immunochemistry)
Section cross-reference(s): 1, 3

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5871723	A	19990216	US 1995-466819	19950606 <--

AB Disclosed are various discoveries concerning the **angiogenic** and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these mols. to induce **angiogenesis**. Aspects of the invention include, for example, the identification of .gamma.-interferon-inducible protein IP-10, MIG (monokine induced by .gamma.-interferon) and certain IL-8 analogs as angiostatic agents, and their use in inhibiting **angiogenesis** in

various systems. Thus, maltose-binding protein-Factor Xet-TVR-IL-8, maltose-binding protein-Factor Xa-DLQ-IL-8, and glutathione-S-transferase protein-thrombin cleavage site-ELR-MIG were prepd. by mol. cloning, and were tested for inhibiting **angiogenesis**-related events assocd. with tumor.

ST CXC chemokine **angiogenesis** antagonist IL8 MIG; tumor **angiogenesis** inhibitor IP10 IL8 MIG

IT Chemokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C-X-C, ENA-78; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Chemokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C-X-C; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Gene, animal
RL: PSU (Biological study, unclassified); BIOL (Biological study)
(CXC chemokine; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT **Angiogenesis inhibitors**
Chemotaxis
DNA sequences
Lung, neoplasm
Molecular cloning
Neoplasm
Protein motifs
Protein sequences
Transformation, neoplastic
Wound
Wound healing
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Interleukin 8
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Monokines
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIG or monokine induced by .gamma.-interferon; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Carcinoma
(adenocarcinoma; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT **Angiogenic factors**
Angiogenic factors

Growth inhibitors, animal
Growth inhibitors, animal
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**angiogenic** growth-inhibiting factors; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Epithelium
Neutrophil
(chemotaxis; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT **Blood vessel**
(**endothelium**, chemotaxis; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Animal
(human; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Cytokines
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(interferon-inducible IP-10; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Skin
(keratinocyte, proliferation; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Chemotaxis
(neutrophil; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Drug delivery systems
(parenterals; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Transplant and Transplantation
(skin; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Lung, neoplasm
(small-cell carcinoma; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Carcinoma
(squamous cell; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Skin
(transplant; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 37275-44-5, Platelet factor 4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG

and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 85590-39-8 **172684-39-8** 178493-56-6 220715-47-9
THU
RL: BSU (Biological study, unclassified); PRP (Properties); **THU** (**Therapeutic use**); BIOL (Biological study); USES (Uses)
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 220795-76-2 220795-80-8 220795-83-1
RL: PRP (Properties)
(amino acid sequence; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 220795-79-3 220795-81-7 220795-84-2
RL: PRP (Properties)
(nucleotide sequence; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Follins; US 5459119 1995 HCAPLUS
(2) Follins; US 5779981 1998 HCAPLUS

IT **172684-39-8**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU** (**Therapeutic use**); BIOL (Biological study); USES (Uses)
(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

RN 172684-39-8 HCAPLUS
CN L-Arginine, L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:104500 HCAPLUS
DN 130:163183
TI Cyclic CS-1 peptidomimetics, compositions, and methods of treatment of immunoinflammatory conditions
IN Arnhenius, Thomas S.; Pempinyk, Anna; Elices, Mariano J.; Cheng, Zhong-Li
PA Cytel Corporation, USA
SO U.S., 91 pp., Cont.-in-part of U.S. Ser. No. 483,077.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K038-06
ICS A61K038-12; C07K007-00; C07K007-50
NCL 514011000
CC 1-7 (Pharmacology)
Section cross-reference(s): 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5869445	A	19990209	US 1995-514109	19950825 <--
	US 5811391	A	19980922	US 1995-483077	19950607 <--

PRAI US 1994-296241 19940827 <--
US 1995-483077 19950607 <--

OS MAPPAT 130:163186

AB Cyclic peptides are disclosed that inhibit the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compns. contg. a cyclic peptide of the invention, as well as processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide, are also disclosed.

ST cyclic peptide VLA4 binding inhibition; fibronectin CS1 binding inhibition cyclic peptide; endothelium leukocyte binding inhibition cyclic peptide; immune inflammatory condition cyclic peptide

IT Fibronectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CS-1 peptide; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Animal cell line
(JURKAT; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VCAM-1, sol.; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Anti-inflammatory agents
Antirheumatic agents
Drug delivery systems
Leukocyte
Peptidomimetics
Structure-activity relationship
(cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Immunity
(disorder; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT **Blood vessel**
(endothelium; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Drug delivery systems
(prodrugs; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PRS (Properties)
(.alpha.4.beta.1; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT 164740-10-7 184242-92-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT **38763-90-5P 77292-72-9P** 124135-83-8 177081-16-2P
177081-19-5P 177081-20-8P 177081-21-9P 177081-24-2P 177081-28-6P
177081-29-7P 177081-30-0P 177081-31-1P 177081-32-2P 177081-34-4P
177081-35-5P 177081-36-6P 177081-38-8P 177081-38-9P 177081-39-0P
177081-40-3P 177081-41-4P 177081-42-5P 177081-43-6P 177081-44-7P
177081-45-8P 177081-46-9P 177081-47-0P **177081-48-0P**
177081-49-1P 177081-50-4P 177081-51-5P 177081-52-6P
177081-53-7P 177081-54-8P 177081-55-9P 177081-56-0P 177081-57-1P
177081-58-2P 177081-59-3P 177081-60-6P 177081-61-7P 177081-62-8P
177081-64-0P 177081-65-1P 177081-66-2P 177081-67-3P 177081-68-4P
213826-76-2P 213826-77-3P 213826-78-4P 213826-80-8P 220445-54-5P
213826-83-1P 213826-85-3P 213826-86-4P 213826-87-5P 220445-56-7P
220445-58-9P 220445-59-0P 220445-60-3P 220445-61-4P 220445-62-5P
220445-63-6P 220445-64-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT 107978-77-8
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon.; WO 9200995 1992 HCAPLUS
(2) Anon.; WO 9415958 1994 HCAPLUS
(3) Cardarelli, P; J Biol Chem 1994, V269, P13608 HCAPLUS
(4) Hansen; US 5109837 1992 HCAPLUS
(5) Hart, S; J Biol Chem 1994, V269, P12480 HCAPLUS
(6) Koivunen, E; J Cell Biol 1994, V124, P373 HCAPLUS
(7) Komoriya, A; J Biol Chem 1991, V266, P15075 HCAPLUS
(8) Mousa, S; Cardiology 1995, V86, P374 HCAPLUS
(9) Newlin, D; J Biol Chem 1993, V268, P8550 HCAPLUS
(10) Pfaff, M; J Biol Chem 1994, V269, P20233 HCAPLUS
(11) Sekiguchi; US 5601994 1997 HCAPLUS
(12) Wayner, E; J Cell Biology 1989, V119(2), P489
(13) Yanofsky; US 5648335 1997 HCAPLUS

IT **38763-90-5P 77292-72-9P 177081-48-0P**
177081-49-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

RN 38763-90-5 HCAPLUS
CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77232-72-9 HCAPLUS
CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177081-48-0 HCAPLUS
CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177081-49-1 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:785612 HCAPLUS
DN 130:22918
TI Method and devices for altering the differentiation of anchorage-dependent cells on an electrically-conducting polymer
IN Wong, Joyce Y.; Ingber, Donald E.; Langer, Robert S.
PA Massachusetts Insitute of Technology, USA; Children's Medical Center Corporation
SO U.S., 17 pp.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM C12N013-00
NCL 435173800
CC 9-11 (Biochemical Methods)
Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5843741	A	19981201	US 1994-336402	19940801 <--

PI US 5843741 A 19981201 US 1994-336402 19940801 <--

AB Described is a method and cell culture system for altering the proliferation, differentiation, or function of anchorage-dependent cells which includes assocg. the cells with a surface formed of an elec.-conducting polymer and applying an effective amt. of a voltage to change the oxidn. state of the polymer without damaging the cells. Substrates are prepd. which are formed of or coated with an elec.-conducting biocompatible polymer which are used in vitro for cell culture or in vivo to aid in healing, etc. Examples demonstrate the effect of culturing two different types of cells (bovine aortic endothelial cells and Balb/c3T3 mouse fibroblasts) on fibronectin-coated polypyrrole conducting polymer substrates and the effect of applied voltage and the modifications possible through variation of attachment mol. d. on the conducting polymer substrate.

ST cell differentiation culture elec conducting polymer; medical device elec conducting polymer

IT Cell
(anchorage-dependent; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT **Artery**
Artery
(aorta, **endothelium**, cells of, of bovine; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Agglutinins and Lectins
Albumins, biological studies
Carbohydrates, biological studies
Entactin
Fibrinogens
Fibronectins
Gelatins, biological studies

Glycosaminoglycans, biological studies
Growth factors, animal
Laminin
Peptides, biological studies
Proteoglycans, biological studies
Thrombospondins
Vitronectin
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Polyacetylenes, biological studies
Polyanilines
Polythiophenylenes
RL: BUU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Sialoglycoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(asialoglycoproteins, as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable, elec.-conducting polymer coated onto device of; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Polymers, biological studies
RL: BUU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(elec.-conducting; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Medical goods
Medical goods
(films, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Screws
(for bone, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Drug delivery systems
Prosthetic materials and Prosthetics
(implants, polymer coated onto structure for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(low-d., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Films
Films
(medical, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Animal cell
Cell differentiation
Fibroblast

Plant cell
Wound healing
(method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Fasteners
(nails, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Bone
(polymer coated onto screws for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Animal tissue culture
Plant tissue culture
(polymer coated onto structure for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Apparatus
Medical goods
Pipes and Tubes
Plates
(polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Receptors
RL: BPF (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(polymer-immobilized attachment mols. specific for, on cell surface; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Bone, disease
Nerve
(repair or regeneration of; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Medical goods
(sheets, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Medical goods
(stents, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Medical goods
(sutures, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT Cell adhesion
(treatment of diseases from; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT 9002-04-4, Thrombin 9005-49-6, Heparin, biological studies 25104-18-1, Poly-L-lysine
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT 30604-81-0P, Polypyrrole
RL: BUU (Biological use, unclassified); DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT 25067-59-8, Polyacetylene 25233-34-5, Polythiophene 96638-49-2, Poly(phenylenevinylene)
RL: BUU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT **99896-85-2** 115590-64-2 128720-18-1

RL: BPP (Biological process ; BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptides contg., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT 90[illegible]-53-4 [illegible]-11-4, Indium tin oxide
RL: DEV (Device component use); NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PROC (Process); USES (Uses)
(polymer in thin film electrode; electrochem. synthesis on; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aklonis; US 5144177 1992 HCAPLUS
(2) Alberts, B; Molecular Biology of the Cell 2nd ed 1989, P727
(3) Alt; US 5143084 1992
(4) Andreatta, A; Synth Met 1988, V26(3), P383
(5) Anon; WO 8702715 1987
(6) Anon; WO 8806676 1988
(7) Anon; WO 8902476 1989 HCAPLUS
(8) Anon; WO 8904849 1989 HCAPLUS
(9) Anon; DE 4026976 A1 1990 HCAPLUS
(10) Anon; EP 0471990 A2 1991 HCAPLUS
(11) Anon; WO 9111544 1991 HCAPLUS
(12) Aimes, C; Synthetic Metals 1987, V20, P365 HCAPLUS
(13) Atkins; US 4864254 1989 HCAPLUS
(14) Baier, R; Science 1968, V162, P1360 HCAPLUS
(15) Ben De'Ev, A; Cell 1980, V21, P307 HCAPLUS
(16) Ben De'Ev, A; Proc Natl Acad Sci USA 1983, V80, P2161 HCAPLUS
(17) Bissell, D; J Clin Invest 1987, V79, P801 HCAPLUS
(18) Bissell, D; Gastroenterol 1988, V23, P1
(19) Bjorkland; US 4514429 1985 HCAPLUS
(20) Bourdillon, C; Journal of the American Chemical Society 1980, V102(12), P4231 HCAPLUS
(21) Bull, R; J Electrochem Soc 1984, V131(5), P1009 HCAPLUS
(22) Bull, R; J Electrochem Soc 1989, V136(7), P1936 HCAPLUS
(23) Burgmayer, P; Handbook of Conducting Polymers V1, P507
(24) Byers; US 4904469 1990
(25) Cao, Y; Synth Met 1990, V48, P91 HCAPLUS
(26) Cao, Y; Synthetic Metals 1992, V51, P193 HCAPLUS
(27) Casnig; US 5134070 1992
(28) Cohen, S; The Journal of Biological Chemistry 1982, V357(3), P1523
(29) Couchman, J; The Journal of Cell Biology 1982, V93, P402 HCAPLUS
(30) Cunningham; US 5010004 1991 HCAPLUS
(31) Decher, G; Thin Solid Films 1992, V210/211(1-2), P831
(32) Denk, H; Sem Liver Disease 1986, V6(3), P199 MEDLINE
(33) Diaz, A; J C S Chem Comm 1979, P635 HCAPLUS
(34) Elsenbaumer; US 4983322 1991 HCAPLUS
(35) Gianessi; US 3671961 1972
(36) Garrett; US 4668354 1987 HCAPLUS
(37) Maczurek; US 5091067 1992 HCAPLUS
(38) Pethrick; US 5096615 1992
(39) Pierschbacher; US 4589881 1986 HCAPLUS
(40) Pibi; US 5331068 1994 HCAPLUS
(41) Roberts; US 4604437 1986 HCAPLUS
(42) Spector; US 4104244 1978 HCAPLUS

IT **99896-85-2**
RL: BPP (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(peptides contg., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting

polymers)
RN 99936-45-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:624019 HCAPLUS
DN 129:250239
TI Tissue implant comprising collagen and a hydrated alginate gel matrix
IN Lee, David Alan; Bader, Daniel Lawrence; Stephens, Myra Deborah
PA University College London, UK; Queen Mary & Westfield College
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61L027-00
CC 63-7 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9840111	A1	19980917	WO 1998-GB673	19980306 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865066	A1	19980929	AU 1998-65066	19980306 <--
EP 1019109	A1	20000719	EP 1998-910954	19980306 <--
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001514551	T2	20010911	JP 1998-539349	19980306 <--
US 6306169	B1	20011023	US 1998-38169	19981109 <--
PRAI GB 1997-4749	A	19970307 <--		
WO 1998-GB673	W	19980306 <--		

AB A biomech. implant is described which comprises at least two matrix components, the first matrix component being composed of collagen with a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated alginate gel which substantially fills the pores macrostructure of the first component and exerts a swelling pressure, the implant addnl. comprising a population of cells comprising chondrocytes, fibrochondrocytes, fibroblasts or osteoclasts, or precursors thereof. Collagens gels with chondrocytes were placed in wells of a tissue culture plate and a 2% alginate in Earle's buffered salt soln. contg. 4x106 cells/mL in DMEM and 10% fetal calf serum was gently layered on top of the collagen gel or sponge. The tissue culture plate was centrifuged at 100 g for 5 min to incorporate the alginate and cell suspension within the collagen gel or sponge. Crosslinking of the alginate was affected by bathing the construct in a soln. of 100 mM CaCl2 in DMEM/10% fetal calf serum. The tangents modulus and equil. modulus of the gel was 55, and 52 Pa, resp.
ST tissue implant collagen alginate matrix

IT Transplant and Transplantation
(autotransplant; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Prosthetic materials and Prosthetics
(implants; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Spinal column
(intervertebral disk; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Foams
Plates
(medical goods,; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Joint, anatomical
(meniscus; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Porosity
(microporosity; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Medical goods
(sponges; tissue implant comprising collagen and hydrated alginate gel matrix)
IT Cartilage
Chondrocyte
Crosslinking agents
Fibroblast
Osteoblast
Particle size
(tissue implant comprising collagen and hydrated alginate gel matrix)
IT Collagens, biological studies
Fibers
Fibronectins
Gelatins, biological studies
Glycosaminoglycans, biological studies
Polyanhydrides
Polyoxyalkylenes, biological studies
Proteoglycans, biological studies
Vitronectin
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
IT **Angiogenic factors**
Chemotactic factors
Cytokines
Enzymes, biological studies
Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
IT 1306-06-5, Hydroxyapatite 9000-07-1, Carrageenan 9004-61-9, Hyaluronan 9005-32-7, Alginic acid 9012-36-6, Agarose 24980-41-4, Polycaprolactone 25322-68-3, Polycaprolactone 25248-42-4, Polycaprolactone 26063-00-3, Polyhydroxybutyrate 26124-68-5, Polyethyleneoxide 26161-42-2 26744-04-7 26811-96-1, PolyL-lactic acid PolyL-glycolic acid **99896-85-2**
RL: DEV (Device component use); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
IT **99896-85-2**

RL: DEV (Device component use); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)

RN 99896-85-6 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:133534 HCAPLUS
DN 128:168273
TI Cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy
IN Mixson, Archibald James
PA Mixson, Archibald James, USA
SO Eur. Pat. Appl., 47 pp.
CODEN: EPXXLW
DT **Patent**
LA English
IC ICM C12N015-12
ICS C12N015-14; A61K048-00
CC 1-6 (Pharmacology)
Section cross-reference(s): 9

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 819758	A2	19980121	EP 1997-112154	19970716 <--
	EP 819758	A3	19980204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6080728	A	20000627	US 1997-985526	19971205 <--
	JP 11187886	A2	19990713	JP 1998-201906	19980716 <--
PRAI	US 1996-680845	A	19960716 <--		
	EP 1997-112154	A	19970716 <--		
	US 1997-985526	A	19971205 <--		

AB Cationic vesicles:DNA complexes comprising DNA encoding an anti-**angiogenic** peptide or DNA encoding a tumor suppressor protein and DNA encoding an anti-**angiogenic** peptide, as well as their use in gene therapy, are disclosed. The liposomal components may comprise 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine, 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine, and 2,3-dioleoyloxypropyl-N,N,N-trimethylammonium chloride), optionally in combination with polyethylene glycol and a targeted ligand such as Arg-Gly-Asp, ferritin, or antibodies targeted toward HER2. DNA is prepd. encoding anti-**angiogenic** peptide fragments of thrombospondin 1, fibronectin, laminin, platelet factor 4, angiostatin, and prolactin, as well as concatemers of these fragments. Tumor suppressor protein genes include p53, p21, or Rb. Thus, liposome:DNA vectors encoding p53 in combination with a thrombospondin I fragment reduced tumors more effectively than p53 alone. The cationic polymer allows superior transfection of endothelial cells; Superfect is a better transfection agent than cationic liposomes for many different cell lines.

ST cationic liposome DNA vector gene therapy; **antiangiogenic** peptide liposome vector gene therapy; tumor inhibitor

antiangiogenic peptide DNA liposome
IT Thrombospondins
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Gene, animal
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RE1; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Transcription factors
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Rb; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Gene, animal
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP53; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Peptides, biological studies
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-**angiogenic**; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT **Angiogenesis inhibitors**
Antitumor agents
Gene therapy
Liposomes
Transformation, genetic
(cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Antibodies
Ferritins
Fibronectins
Laminins
Polyoxyalkylenes, biological studies
p53 (protein)
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Synthetic gene
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT DNA sequences
(for synthetic genes encoding anti-**angiogenic** peptides in cationic liposome:DNA complex vehicles for use in gene therapy)
IT Protein sequences
(of anti-**angiogenic** peptides in cationic liposome:DNA complex vehicles for use in gene therapy)
IT Proteins, specific or class
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p21; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
IT Gene, animal
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(p21; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor suppressor; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-31-3, Thrombospondin 1 (human fragment) [illegible]-32-4 [illegible]-40-4, Angiostatin (human fragment) [illegible]-41-5, Angiostatin (human fragment concatemer) [illegible]-44-8, Prolactin, human fragment) [illegible]-46-0, Pertactin (human fragment concatemer) [illegible]-05-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT 4004-05-1, Dioleoylphosphatidylethanolamine [illegible]-62-4, Prolactin, biological studies [illegible]-66-8, Polyethylenimine [illegible]-18-1, Polylysine [illegible]-68-3 [illegible]-48-4, Polyhistidine 26654-81-9, Polynistidine [illegible]-94-3, Bloo platelet factor 4 [illegible]-06-5, Polylysine 51110-01-1, Angiostatin [illegible]-06-0, Angiostatin **99896-85-2** [illegible]-48-3, DOTMA [illegible]-3[illegible]-7 [illegible]-43-5 [illegible]-04-5, APL Polycat57 [illegible]-02-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-56-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibronectin fragment concatemer; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-79-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibronectin fragment-specifying; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-55-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibronectin fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-52-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(laminin fragment concatemer; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-51-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(laminin fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-06-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(laminin peptide fragment-specifying; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT [illegible]-47-1 [illegible]-48-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT 202937-23-5 202937-34-6 202937-35-7 202937-36-8 202937-37-9
202937-38-0 202937-39-1 202937-41-5 202937-42-6 202937-45-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy

IT 202645-53-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platelet factor 4 fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT 203008-99-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(somatostatin fragment concatemer; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT 202936-69-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(somatostatin fragment-specifying; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT 202645-54-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(somatostatin fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

IT **99896-85-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:543532 HCAPLUS
DN 127:134690
TI Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
IN Schwender, Charles F.; Shroff, Hitesh N.
PA Leukosite, Inc., USA; Schwender, Charles F.; Shroff, Hitesh N.
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT **Patent**

LA English
IC ICM C07K014-705
ICS C07K005-06; A61K038-05; A61K038-08
CC 15-2 (Immunochemistry)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 97/[illegible]351	A2	19970717	WO 1997-US[illegible]91	19970103 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6057224	A	20000614	US 1996-59[illegible]740	19960104 <--
	CA 2241169	AA	19970717	CA 1997-2241169	19970103 <--
	AU 9715415	A1	19970801	AU 1997-[illegible]2415	19970103 <--
	AT 7[illegible]1[illegible]	B[illegible]	[illegible]		
	EP 871670	A2	19981021	EP 1997-90[illegible]064	19970103 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000503203	T2	20000321	JP 1997-527181	19970103 <--
	US 6274596	B1	20010814	US 1998-11[illegible]79	19980702 <--
	US 2001[illegible]3111	A1	20020801	US 2001-85[illegible]214	20010516 <--
PRAI	US 1996-[illegible]1747	A[illegible]	19960104 <--		
	WO 1997-US[illegible]91	W	19970103 <--		
	US 1996-[illegible]1747	A1	19960104 <--		

OS MARPAT 127:[illegible]4698
AB The present invention provides novel compds. comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human .alpha.4.beta.7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compd. of the present invention. The MAdCAM-1 inhibitors are useful for treating disease assocd. with leukocyte infiltration of tissue, such as inflammatory bowel disease, with fewer side effects in other tissues where adhesion is mediated by .alpha.4.beta.1 integrin, for example. The inhibitors can also be used for induction of antibodies selectively bind epitopes of MAdCAM-1 and useful for quantitating MAdCAM-1 on cell surface.
ST MAdCAM1 peptide leukocyte infiltration inhibition; inflammatory bowel disease MAdCAM1 inhibitor
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(LPAM-1 (lymphocyte Peyer's patch high endothelial venule adhesion mol. 1); peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration
IT Proteins, specific or class
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(addressins, MAdCAM-1 or mucosal addressing cell adhesion mol.-1; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
IT **Blood vessel**
endothelium, cells; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
IT Leukocyte
infiltration; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
IT Intestine, disease

(inflammatory; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT Diabetes mellitus
(insulin-dependent; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT Cell migration
(leukocyte infiltration; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT Protein sequences
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT 193217-87-5 193217-90-1 193218-01-8 193218-05-2
193218-07-4 193218-08-5 193218-11-0 193218-13-2 193218-15-4
193218-17-6 193218-18-7 193218-23-4 193218-25-6 193218-27-8
193218-28-9 193218-30-3 193218-31-4 193218-32-5 193218-33-6
193218-34-7 193218-35-8 193218-36-9 193218-37-0 193218-38-1
193218-39-2 193218-40-5 193218-41-6 193218-42-7 193218-43-8
193218-44-9 193218-45-0 193218-46-1 193218-47-2 193218-48-3
193218-49-4 193218-50-7 193218-52-9 193218-53-0 193218-54-1
193218-55-2 193218-56-3 193218-57-4 193218-58-5 193218-59-6
193218-60-9 193218-61-0 193218-63-2 193218-64-3 193218-65-4
193218-66-5 193218-67-6 193218-68-7 193218-69-8 193218-70-1
193218-71-2 193218-72-3 193218-73-4 193218-74-5 193218-75-6
193218-76-7 193218-77-8 193218-78-9 193218-80-2 193218-81-3
193218-82-4 193218-83-5 **193218-84-7** **193218-85-8**
193218-86-9 193218-87-0 193219-00-6 193219-01-7 193219-02-8
193219-03-9 193219-04-0 193219-05-1 193219-06-2 193219-07-3
193219-08-4 193219-10-8 193219-11-9 **193219-14-6**
193219-16-8 193219-18-0 **193219-20-4**
PL: PAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT **193218-84-7** **193218-85-8** **193219-14-6**
193219-16-8 **193219-20-4**
PL: PAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

RN 193218-54-7 HCAPLUS
CN L-Threonine, N-benzoyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193218-85-8 HCAPLUS
CN L-Threonine, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193219-14-6 HCAPLUS
CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193219-16-8 HCAPLUS
CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclooctyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193219-23-4 HCAPLUS
CN L-Threoninamide, N-(2-benzofuranylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-(2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 199?:319?16 HCAPLUS
DN 126:272?41
TI Molecules that home to a selected organ or tissue in vivo, and methods of identifying them
IN Ruoslahti, Erkki; Pasqualini, Renata
PA La Jolla Cancer Research Foundation, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-567
ICS G01N033-53; C07K001-04; A61K047-48
CC 1-1 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT ..

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9710?07	A1	1997?310	WO 1996-US14600	19960910	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US ?61?·?9	A	1?97?4??	US 1995-526710	19950911	<--
	CA 2?04?35	AA	1997?31?	CA 1996-2204535	19960910	<--
	AU ?? ?·?39	A1	1?97?4?1	AU 1996-69?39	19960910	<--
	AU ?9?7?3	B2	1?98?7??			
	EP ?71441	A1	1?97?514	EP 1996-?50195	19960?10	<--
	EP ?71441	B1	2??1?1??			
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	JP 1?9?·?674	T2	1?9?1?1?	JP 1996-?12087	19960?10	<--
	EP ?76?11	A1	1?9?1111	EP 1996-?50824	19960?10	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	EP ?97?7?	A1	2??1?311	EP 1999-?50432	19960?10	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	AT 1?51?1	E	2?0?·?17	AT 1996-?50195	19960?10	<--
	AU ?9?·??	A1	1?9?·?1?	AU 1993-?3?40	19980430	<--
	AU 7?9???	B2	2?·1?1?·			
PRAI	US 1995-?26708	A	1?·?0911	<--		
	US 1995-?26710	A	1?·?0911	<--		
	EP 1996-?50195	A3	1?·?0910	<--		
	WO 1996-US14600	W	1?·?0910	<--		

AB The present invention provides an in vivo method for identifying mols. that home to a selected organ or tissue. In addn., the invention provides peptides that home to a selected organ or tissue. For example, the invention provides peptides that selectively home to an organ, e.g. brain or kidney, or to a tissue, e.g. a tumor tissue. The invention further provides methods of using an organ homing mol. e.g. to target an agent such as a drug to a selected organ or to identify the target mol.

expressed by the selected organ. The invention also provides methods for targeting an organ or tissue contg. **angiogenic** vasculature by contacting the organ or tissue with a mol. that specifically binds an .alpha.v-contg. integrin. Methods are demonstrated for prepg. a phage library and screening the library using in vivo panning to identify phage-expressing peptides that home to a selected organ or tissue; peptide sequences are included. The brain-homing peptide CLSSRLDAC directs red blood cells to the brain. Also described is use of in vivo panning to identify peptides homing to a breast tumor or a melanoma.

ST tissue organ targeting mol identification; drug targeting tissue organ homing mol; peptide organ tissue tumor homing; brain kidney tumor homing mol; **angiogenic** vasculature tissue targeting integrin ligand

IT **Blood vessel**
(**angiogenic**; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Erythrocyte
(brain-homing peptide directs red blood cells to brain)

IT Mammary gland
(carcinoma; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Medical goods
(chambered microdevices, targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Animal tissue
Brain
Drug targeting
Immobilization, biochemical
Kidney
Melanoma
Neoplasm
Nucleic acid library
Organ, animal
Phage display library
Protein sequences
Reticuloendothelial system
(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Peptides, biological studies
RGD peptides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Mammary gland
(neoplasm; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Proliferation inhibition
(proliferation inhibitors, targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Liver
Spleen
(reticuloendothelial system; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Cytotoxic agents
(targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.v-contg. integrin-binding; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(.alpha.v; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.3; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT 106781-65-0
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT 106179-97-7 176254-11-8 176254-12-9 176254-13-0 176254-14-1
176254-15-2 176254-16-3 176254-17-4 176254-18-5 176254-19-6
176254-20-9 189023-57-2 189023-58-3 189023-59-4 189023-60-7
189023-61-8 189023-62-9 189023-63-0 189023-64-1 189023-65-2
189023-66-3 189023-67-4 189023-68-5 189023-69-6 189023-70-9
189023-71-0 189023-72-1 189023-73-2 189023-74-3 189023-75-4
189023-76-5 189023-77-6 189023-78-7 189023-79-8 189023-80-1
189023-81-2 189023-82-3 189023-83-4 189023-84-5 189023-85-6
189023-86-7 189023-87-8 189023-88-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT **99896-85-2**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide conjug. sequence of; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT **99896-85-2**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide conjug. sequence of; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

PN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:141047 HCAPLUS
DN 126:133476
TI Anti-metastatic and anti-**angiogenic** thrombin derivatives
IN Bar-Shavit, Rachel
PA Hadassit Medical Research Services and Development Co. Ltd., Israel; Bar-Shavit, Rachel
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K038-10
ICS A01N037-18; G01N033-574; C07K016-00; C12P021-08
CC 1-6 (Pharmacology)
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9700077	A1	19970103	WO 1996-IL12	19960612 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	IL 114140	A1	20000601	IL 1995-114140	19950614 <--
	CA 2224560	AA	19970103	CA 1996-2224560	19960612 <--
	AU 9660146	A1	19970115	AU 1996-60146	19960612 <--
	EP 837694	A1	19980429	EP 1996-91764.	19960612 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT				
	US 6146624	A	20001114	US 1998-98198*	19980127 <--
PRAI	IL 1995-114140	A	19950614 <--		
	WO 1996-IL12	W	19960612 <--		

AB A novel pharmaceutical compn. for the treatment of cancer, either by inhibition of the tumor metastatic tendency or alternatively by inhibiting formation of new blood vessels (**angiogenesis**) and thus depriving the tumor of its blood source, consists of a fragment of the thrombin B-chain comprising the sequence Arg-Gly-Asp in an exposed orientation, or modified thrombin in which the naturally cryptic Arg-Gly-Asp (RGD) sequence has been modified so that it is in an exposed orientation. Thus, RGD-contg. thrombin fragments inhibited lung colonization in mice by metastatic murine melanoma cells with a potency .apprx.20-fold greater than that of prior art RGD-contg. fragments of other proteins such as fibronectin; the fragments bound strongly to these cells in vitro. Such fragments also inhibited microvessel sprouting and induced apoptosis in an exptl. model of **angiogenesis** in rat aorta rings in vitro.

ST thrombin peptide metastasis **angiogenesis** inhibitor; antitumor thrombin peptide

IT **Angiogenesis inhibitors**
Antiarthritics
(anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Adhesion, biological
(by metastatic cells, detn. of; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Eye, disease
(diabetic retinopathy; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Neoplasm
(metastasis, adhesion by cells of, detn. of; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Antitumor agents
Melanoma
(metastasis; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Lung, neoplasm
(metastatic melanoma cell colonization of; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT Antimedius
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(of thrombin RGD domain; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT 9002-04-4D, Thrombin, derivs. and fragments 186684-36-1 186669-87-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT **99896-85-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thrombin derivs. and fragments contg.; anti-metastatic and anti-**angiogenic** thrombin derivs.)

IT **99896-85-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thrombin derivs. and fragments contg.; anti-metastatic and anti-**angiogenic** thrombin derivs.)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:324413 HCAPLUS
DN 125:13376
TI Cyclic peptide analogs that mimic the CS-1 domain of fibronectin for inhibition of interaction of fibronectin and the VLA-4 receptor
IN Arfhenius, Thomas S.; Elices, Marian J.; Tempczyk, Anna; Zheng, Zhong-Li
PA Cytel Corporation, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K005-11
ICS C07K014-78; C07K007-16
CC 1-7 (Pharmacology)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606108	A2	19960229	WO 1995-US10811	19950825 <--
	WO 9606108	A3	19960801		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5811391	A	19980922	US 1995-483077	19950607 <--
	AU 9534995	A1	19960314	AU 1995-34995	19950825 <--
	EP 777681	A2	19970611	EP 1995-931586	19950825 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1994-306241		19940915 <--		
	US 1995-483077		19950607 <--		
	WO 1995-US10811		19950825 <--		

OS MARPAT 125:13376
AB A class of cyclic peptides (Markush structures given) that inhibit the binding of the VLA-4 receptor of inflammatory leukocytes to the CS-1 domain of fibronectin on endothelial cells that are involved in immunoinflammatory disease states are described. Pharmaceutical compns. contg. a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.

ST CS1 fibronectin peptidomimetic inflammation inhibitor

IT Inflammation inhibitors
(cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Leukocyte
(inflammatory, inhibition of binding to endothelium of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Fibronectins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(inhibition of VLA-4 binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Asthma
(non-bronchodilator treatment of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Multiple sclerosis
(treatment of exptl. models of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Inflammation inhibitors
(antirheumatics, cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Encephalomyelitis
(autoimmune, demyelinating, exptl., treatment of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclo-, mimetics; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT **Blood vessel**
(**endothelium**, inhibition of inflammatory leukocyte binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Transplant and Transplantation
(graft-vs.-host reaction, inhibitors of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(.alpha.4.beta.1, inhibition of fibronectin binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT 13453-09-5DP, N- and C-terminal extension and cyclic analogs
38763-90-5P 77292-72-9P 177130-87-4DP, N- and C-terminal extension and cyclic analogs 177130-88-5DP, N- and C-terminal extension and cyclic analogs 177080-89-6DP, N- and C-terminal extension and cyclic analogs 177080-90-9DP, N- and C-terminal extension and cyclic analogs 177080-91-0DP, N- and C-terminal extension and cyclic analogs
177080-92-1DP, N- and C-terminal extension and cyclic analogs
177080-93-2DP, N- and C-terminal extension and cyclic analogs
177080-94-3DP, N- and C-terminal extension and cyclic analogs
177080-95-4DP, N- and C-terminal extension and cyclic analogs
177080-96-5DP, N- and C-terminal extension and cyclic analogs

177080-97-6DP, N- and C-terminal extension and cyclic analogs
177080-98-7DP, N- and C-terminal extension and cyclic analogs
177080-99-8DP, N- and C-terminal extension and cyclic analogs
177081-00-4DP, N- and C-terminal extension and cyclic analogs
177081-01-5DP, N- and C-terminal extension and cyclic analogs
177081-02-6DP, N- and C-terminal extension and cyclic analogs
177081-03-7DP, N- and C-terminal extension and cyclic analogs
177081-04-8DP, N- and C-terminal extension and cyclic analogs
177081-05-9DP, N- and C-terminal extension and cyclic analogs
177081-06-0DP, N- and C-terminal extension and cyclic analogs
177081-07-1DP, N- and C-terminal extension and cyclic analogs
177081-08-2DP, N- and C-terminal extension and cyclic analogs
177081-09-3DP, N- and C-terminal extension and cyclic analogs
177081-10-6DP, N- and C-terminal extension and cyclic analogs
177081-11-7P 177081-12-8P 177081-13-9P 177081-14-0P 177081-15-1DP,
N- and C-terminal extension and cyclic analogs 177081-16-2P
177081-17-3DP, N- and C-terminal extension and cyclic analogs
177081-18-4P 177081-19-5P 177081-20-8P 177081-21-9P 177081-22-0P
177081-23-1P 177081-24-2P 177081-25-3DP, N- and C-terminal extension
and cyclic analogs 177081-26-4DP, N- and C-terminal extension and cyclic
analogs 177081-27-5DP, N- and C-terminal extension and cyclic analogs
177081-28-6P 177081-29-7P 177081-30-0P 177081-31-1P 177081-32-2P
177081-33-3P 177081-34-4P 177081-35-5P 177081-36-6P 177081-37-7P
177081-38-8P 177081-39-9P 177081-40-2P 177081-41-3P 177081-42-4P
177081-43-5P 177081-44-6P 177081-45-7P 177081-46-8P 177081-47-9P
177081-48-0P 177081-49-1P 177081-50-4P 177081-51-5P
177081-52-6P 177081-53-7P 177081-54-8P 177081-55-9P 177081-56-0P
177081-57-1P 177081-58-2P 177081-59-3P 177081-60-6P 177081-61-7P
177081-62-8P 177081-63-9P 177081-64-0P 177081-65-1P 177081-66-2P
177081-67-3P 177081-68-4P 177081-69-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

IT **38763-90-5P 77292-72-9P 177081-48-0P**
177081-49-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)

RN 38763-90-5 HCAPLUS
CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77292-72-9 HCAPLUS
CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177081-43-0 HCAPLUS
CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177081-49-1 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:958291 HCAPLUS
DN 124:787
TI Integrin antagonists for inhibition of **angiogenesis**
IN Brooks, Peter; Cheresh, David A.
PA Scripps Research Inst., USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT **Patent**
LA English

IC ICM A61K038-395
ICS C 7K016-10; C07K016-18; C07K016-28; C07K016-30
CC 1-5 (Pharmacology)
Section cross-reference(s): 15
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9529[illegible]	A1	19951[illegible]	WO 1995-US5035	19950309 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5[illegible]	A	19[illegible]	US 1994-210715	19940318 --
	US 5[illegible]	A	19[illegible]	US 1994-366665	19941230 <--
	AU 9[illegible]	A1	19951009	AU 1995-19952	19950309 <--
	AU 7[illegible]	B2	19[illegible]		
	EP [illegible]	A1	19[illegible]	EP 1995-913644	19950309 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 1[illegible]	T2	19[illegible]	JP 1995-526675	19950309 <--
	RU 2[illegible]	C2	20[illegible]	RU 1996-124[illegible]	19950309 <--
	NO 9[illegible]	A	19[illegible]	NO 1996-3[illegible]	19960917 --
	FI 9[illegible]	A	19[illegible]	FI 1996-3[illegible]	19960916 <--
PRAI	US 1994-210715	A	19940318	<--	
	US 1994-366665	A	19941212	<--	
	WO 1995-US3035	W	19950309	<--	

AB **Angiogenesis** is inhibited in tissues, esp. in inflamed tissues, tumor tissues, and metastases, by application of integrin .alpha.v.beta.3 antagonists to the tissue. The antagonist may be a monoclonal antibody to .alpha.v.beta.3 or a polypeptide contg. the sequence Arg-Gly-Asp. This method may be applied for treatment of inflammation, arthritis, diabetic retinopathy, hemangiomas, and tumors. Thus, basic FGF-induced **angiogenesis** in the chick chorioallantoic membrane was inhibited by the cyclic peptide cyclo(L-Arg-Gly-L-Asp-D-Phe-L-Val); a similar effect was seen when this peptide was injected into melanoma-induced blood vessels.

ST **angiogenesis** inhibitor integrin antagonist peptide; antitumor monoclonal antibody integrin

IT Fibrinogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(binding to integrin .alpha.v.beta.3; integrin antagonists for inhibition of **angiogenesis**

IT **Blood vessel**
(formation of; integrin antagonists for inhibition of **angiogenesis**)

IT Apoptosis
(in neovasculature; integrin antagonists for inhibition of **angiogenesis**)

IT Inflammation inhibitors
Neoplasm inhibitors
(integrin antagonists for inhibition of **angiogenesis**)

IT Granulation tissue
(integrin .alpha.v.beta.3 of blood vessels of; integrin antagonists for inhibition of **angiogenesis**

IT Neoplasm
(integrin .alpha.v.beta.3 of; integrin antagonists for inhibition of **angiogenesis**)

IT Skin
(integrins and laminins of; integrin antagonists for inhibition of **angiogenesis**)

IT Chorioallantois
(integrins of; integrin antagonists for inhibition of **angiogenesis**)
IT Basement membrane
(laminins of, of skin epithelium; integrin antagonists for inhibition of **angiogenesis**)
IT Laminins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of blood vessels and skin epithelium basement membrane; integrin antagonists for inhibition of **angiogenesis**)
IT Diabetes mellitus
(retinopathy in; integrin antagonists for inhibition of **angiogenesis**)
IT Inflammation inhibitors
(antiarthritics, integrin antagonists for inhibition of **angiogenesis**)
IT **Artery, disease**
(coronary, restenosis, integrin antagonists for inhibition of **angiogenesis**)
IT **Blood vessel, neoplasm**
(hemangioma, integrin antagonists for inhibition of **angiogenesis**)
IT Neoplasm inhibitors
(metastasis, integrin antagonists for inhibition of **angiogenesis**)
IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, to integrin .alpha.v.beta.3; integrin antagonists for inhibition of **angiogenesis**)
IT Eye, disease
(retinopathy, in diabetes mellitus; integrin antagonists for inhibition of **angiogenesis**)
IT Lymphokines and Cytokines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(tumor necrosis factor-.alpha., integrin .alpha.v.beta.3 expression in chorioallantois in response to; integrin antagonists for inhibition of **angiogenesis**)
IT Animal growth regulators
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(vitronectins, binding to integrin .alpha.v.beta.3; integrin antagonists for inhibition of **angiogenesis**)
IT Integrins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(.alpha.v.beta.3, integrin antagonists for inhibition of **angiogenesis**)
IT Integrins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(.beta.1, of skin and granulation tissue; integrin antagonists for inhibition of **angiogenesis**)
IT **99896-85-2D**, peptides conte. 133563-70-9 137811-35-5
137813-36-6 137894-01-0 137894-03-2 153127-31-2 153127-32-3
153127-33-4 170931-40-3 170930-41-9 170930-42-4 170930-43-5
170930-44-6 171035-53-3 171035-54-4 171035-55-5 171035-56-6
171035-57-7 171035-58-8 171035-59-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(integrin antagonists for inhibition of **angiogenesis**)
IT 106096-94-9, Basic FGF
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(integrin alpha.v.beta.3 expression in chorioallantois in response to; integrin antagonists for inhibition of **angiogenesis**)
IT **99896-85-2D**, peptides, conjg.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(integrin antagonists for inhibition of **angiogenesis**)
RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:780404 HCAPLUS
DN 123:333264
TI Novel integrin-binding peptides and their analytical and therapeutic uses in the control of cellular adhesion
IN Ruoslahti, Erkki; Koivunen, Erkki
PA La Jolla Cancer Research Foundation, USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07K014-75
ICS C07K014-78; C 7K014-705; A61K038-39; A61K027-00
CC 9-3 (General Biochemistry)
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9514714	A1	19950601	WO 1994-US13542	19941122	<--
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, MD, MG, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, VN					
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	US 5981478	A	19991109	US 1994-266861	19940804	<--
	AU 9512796	A1	19950613	AU 1995-12796	19941122	<--
	AU 682501	B2	19971009			
	EP 736037	A1	19961009	EP 1995-903595	19941122	<--
	EP 736037	B1	2 010530			
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE					
	JP 09505014	T2	19970916	JP 1994-515220	19941122	<--
PRAI	US 1993-158001	A	19931124	<--		
	US 1994-266861	A	19940804	<--		
	WO 1994-US13542	W	19941122	<--		
OS	MARPAT 123:333264					

AB Novel integrin-binding peptides that bind to .alpha.v- or .alpha.5-contg. integrins and can exhibit high binding affinity. They contain one of the following sequence motifs: RX1ETX2WX3 (esp. RRETAWA); RGDGX in which Xn is an amino acid with a hydrophobic, arom. side chain; the double cyclic CX1CRGDCX2C; and RLD. The peptides generally exhibit their highest binding affinity when they assume a conformationally stabilized configuration, e.g. by cyclization through disulfide bonds. These peptides may be used as affinity ligands for purifn. and anal. of integrins, e.g. in the testing of the efficacy of integrin-binding pharmaceuticals such as antithrombotics. These peptides may also be useful as substrates for attachment of integrin-bearing cells to surfaces such as prosthetic devices or in preventing the unwanted binding of cells to a target, such as the binding of osteoclasts to bone in the treatment of of osteoporosis; the inhibition of **angiogenesis**, and as tumor inhibitors. Integrin-binding peptides were obtained by affinity purifn. of a phage display library contg. random sequences in the display cassette by panning with integrins. Peptides specific for several different classes of integrin were obtained.

ST integrin binding peptide cellular adhesion control

IT Transplant and Transplantation
(controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Fibronectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(integrin binding of, inhibition of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT bone
(integrin binding peptides for prevention of binding of osteoclasts to; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Osteoclast
(integrin binding peptides for prevention of binding to bone of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Peptides, biological studies
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(integrin-binding; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT **Blood vessel**
(integrin-binding peptides for inhibition of formation of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Wound healing promoters
(patch grafts contg. integrin-binding peptides for use as; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Collagens, biological studies
Glycosaminoglycans, biological studies
Proteoglycans, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prosthetic matrixes contg., controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Antibodies
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(to cytoplasmic tails of integrins; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins

PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(.alpha.v- or .alpha.b-subunit-contg.; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Adhesion
(bio-, control of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Prosthetic materials and Prosthetics
(implants, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT **Prosthetic materials and Prosthetics**
(implants, **vascular**, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Neoplasm inhibitors
(metastasis, integrin-binding peptides as; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Muscle
(smooth, integrin-binding peptides for inhibition of migration of cells of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Skin
(transplant, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT **Prosthetic materials and Prosthetics**
(**vascular**, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins
PL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.IIb.beta.3, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins
PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(.alpha.v.beta.3, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins
PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(.alpha.5.beta.1, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168179-04-2 168179-05-3 168179-06-4 168179-07-5 168179-08-6
168179-09-7 168179-10-8 168179-11-1 168179-12-2 168179-13-3
168179-14-4 168179-15-5 168179-16-6 168179-17-7 168179-18-8
168179-19-9 168179-21-1 168179-21-2 168179-22-4 168179-23-5
168179-24-6 168179-25-7 168179-26-8 168179-27-9 168179-28-0
168179-29-1 168179-30-4 168179-31-5 168179-32-6 168179-33-7
168179-34-8 168179-35-9 168179-36-0 168179-37-1 168179-38-2
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding to .alpha.IIb.beta.3 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168178-56-1 168178-57-2 168178-58-3 168178-59-4 168178-60-7

168178-61-8 168178-62-9 168178-63-0 168178-64-1 168178-65-2
168178-66-3 168178-67-4 168178-68-5 168178-69-6 168178-70-9
168178-71-0 168178-72-1 168178-73-2 168178-74-3 168178-75-4
168178-76-5 168178-77-6 168178-78-7 168178-79-8 168178-80-1
168178-81-2 168178-82-3 168178-83-4 168178-84-5 168178-85-6
168178-86-7 168178-87-8 168178-88-9 168178-89-0 168178-90-3
168178-91-4 168178-92-5 168178-93-6 168178-94-7 168178-95-8
168178-96-9 168178-97-0 168178-98-1 168178-99-2 168179-01-8
168179-01-9 168179-02-0 168179-03-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding to .alpha.v.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168179-39-3 168179-40-6 168179-41-7 168179-42-8 168179-43-9
168179-44-0 168179-45-1 168179-46-2 168179-47-3 168179-48-4
168179-49-5 168179-50-8 168179-51-9 168179-52-0 168179-53-1
168179-54-2 168179-55-3 168179-56-4 168179-57-5D, internal disulfide bond-containing 168179-58-6D, internal disulfide bond-containing 168179-59-7D, internal disulfide bond-containing 168179-60-0D, internal disulfide bond-containing 168179-61-1 168179-62-2 168179-63-3 168179-64-4
168179-65-5 168179-66-6 168179-67-7 168179-68-8 168179-69-9
168179-70-2 168179-71-3 168179-72-4 168179-73-5 168179-74-6
168179-75-7 168179-76-8 168179-77-9 168179-78-0 168179-79-1
168179-80-4 168179-81-5 168179-82-6 168179-83-7 168179-84-8
168179-85-9 168179-86-0 168179-87-1 168179-88-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding to .alpha.v.beta.5 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168178-46-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding to .alpha.5.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168177-80-4 168177-81-5 168177-82-6 168177-83-7 168177-84-8
168177-85-1 168177-86-2 168177-87-3 168177-88-4 168177-89-5
168177-90-8 168177-91-9 168177-92-0 168177-93-1 168178-00-8
168178-01-9 168178-02-0 168178-03-1 168178-04-2 168178-05-3
168178-06-4 168178-07-5 168178-08-6 168178-09-7 168178-10-0
168178-11-1 168178-12-2 168178-13-3 168178-14-4 168178-15-5
168178-16-6 168178-17-7 168178-18-8 168178-19-9 168178-20-2
168178-21-3 168178-22-4 168178-23-5 168178-24-6 168178-25-7
168178-26-8 168178-27-9 168178-28-0 168178-29-1 168178-30-4
168178-31-5 168178-32-6 168178-33-7 168178-34-8 168178-35-9
168178-36-0 168178-37-1 168178-38-2 168178-39-3 168178-40-6
168178-41-7 168178-42-8 168178-43-9 168178-44-0 168178-45-1
168178-47-3 168178-48-4 168178-49-5 168178-50-8 168178-51-9
168178-52-0 168178-53-1 168178-54-2 168178-55-3 168178-56-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding to .alpha.5.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 99696-33-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(control peptide, lack of integrin binding by; novel integrin-binding

peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 91037-79-1 **99896-85-2D**, N- and C-terminal extension analogs
111119-28-9 129136-79-0D, N- and C-terminal extension analogs
135701-81-7 149635-24-0D, analogs 149635-34-7 152889-66-5
162901-66-9 167820-96-4D, analogs 167820-97-5D, analogs
167820-98-6D, analogs 167820-99-7D, analogs 167821-01-4D, analogs
167821-02-5D, analogs 168174-96-6D, N- and C-terminal extension analogs
168178-92-8 168178-93-9 168178-94-0 168178-95-1 168178-96-2
168178-97-3 168178-98-4 168178-99-5 168180-00-5D, analogs
168180-01-6D, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(integrin binding properties of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168178-89-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT **99896-85-2D**, N- and C-terminal extension analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(integrin binding properties of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L 3 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:578743 HCAPLUS
DN 123:322364
TI Local polymeric gel cellular therapy
IN Slepian, Marvin; Massia, Stephen P.
PA USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61L027-00
ICS A61L031-00; A61L025-00
CC 63-5 (Pharmaceuticals)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509659	A1	19950413	WO 1994-US11304	19941006 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5575811	A	19961119	US 1993-132745	19931006 <--
	AU 9479671	A1	19950501	AU 1994-79671	19941006 <--

AU 703003 B2 19990211
EP 723465 A1 19960731 EP 1994-930606 19941006 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 09506011 T2 19970617 JP 1994-511004 19941006 <--
PRAI US 1994-132745 A 19941006 --
US 1994-338031 A 19941110 --
US 1988-235998 B1 19880824 --
US 1990-493112 B1 19900312 --
US 1992-857700 A1 19920325 --
US 1993-987357 B2 19931207 --
US 1994-211878 B2 19940329 --
WO 1994-US11304 W 19941006 --

AB A synthetic barrier made of biocompatible polymeric materials is applied in vivo to a tissue or cellular surface such as the interior surface of a blood vessel, tissue lumen or other hollow space. The material may also be applied to tissue-contacting surfaces of implantable medical devices. The polymeric materials are characterized by a fluid state which allows application to, and preferably adhesion to, tissue lumen surfaces, which can be increased or altered to a gel less fluid state in situ; controlled permeability and degradability; and, in the preferred embodiments, incorporation of bioactive materials (e.g. peptides) for release in vivo, either to the tissue lumen surface or to the interior of the lumen, which alter cell-to-cell interactions. The materials may be used to prevent proliferation or migration of smooth muscle or endothelial cells and thereby prevent intimal thickening, restenosis, adhesions, etc. Tenascin is a mediator of smooth muscle cell migration through interaction with specific integrin components of the cells; the polymeric material may be used to inhibit this interaction. Thus, application of a thermoreversible, biodegradable, -rodible polyether gel film to the injured intimal surface of rat aorta reduced the thrombogenicity of the intimal surface and the eventual development of neointimal hyperplasia.

ST polymer gel film tissue barrier; blood vessel film barrier polymer; cell migration proliferation polymer gel

IT Chemotaxis
(agents; local polymeric gel cellular therapy)

IT Chelating agents
(for calcium; local polymeric gel cellular therapy)

IT Laminins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments; local polymeric gel cellular therapy)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gel films; local polymeric gel cellular therapy)

IT Cell proliferation
(inhibitors; local polymeric gel cellular therapy)

IT Animal cell
(interactions and migration and proliferation; local polymeric gel cellular therapy)

IT Adhesion, anatomical
Animal tissue
Anticoagulants and Antithrombotics
Cation exchangers
Inflammation inhibitors
Organ
Prosthetic materials and Prosthetics
Surgery
Transplant and Transplantation
(local polymeric gel cellular therapy)

IT Animal growth regulators
Peptides, biological studies
Polyethers, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(local polymeric gel cellular therapy)

IT Lipids, processes
RL: REM (Removal or disposal); PROC (Process)
(local polymeric gel cellular therapy)

IT Proteins, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of extracellular matrix; local polymeric gel cellular therapy)

IT Integrins
RL: PPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(of smooth muscle cells; local polymeric gel cellular therapy)

IT Biodegradable materials
Pharmaceutical dosage forms
(polymer gel films; local polymeric gel cellular therapy)

IT Films
(polymer gel; local polymeric gel cellular therapy)

IT Extracellular matrix
(proteins of; local polymeric gel cellular therapy)

IT Heart, disease
(angina pectoris, local polymeric gel cellular therapy)

IT **Animal growth regulators**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**angiogenic factors**, antagonists; local polymeric gel cellular therapy)

IT Antiarteriosclerotics
(antiatherosclerotics, local polymeric gel cellular therapy)

IT Animal growth regulators
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(blood platelet-derived growth factors, local polymeric gel cellular therapy)

IT Medical goods
(catheters, local polymeric gel cellular therapy)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclo-, local polymeric gel cellular therapy)

IT **Blood vessel**
(**endothelium**, local polymeric gel cellular therapy)

IT Gels
(hydro-, polymeric, films; local polymeric gel cellular therapy)

IT Prosthetic materials and Prosthetics
(implants, local polymeric gel cellular therapy)

IT Heart, disease
(infarction, local polymeric gel cellular therapy)

IT **Artery, disease**
(injury, local polymeric gel cellular therapy)

IT Lymphokines and Cytokines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrophage chemotactic factor, local polymeric gel cellular therapy)

IT Biological transport
(secretion, inhibitors; local polymeric gel cellular therapy)

IT Muscle
(smooth, local polymeric gel cellular therapy)
IT Medical goods
(stents, local polymeric gel cellular therapy)
IT Glyc proteins, specific or class
PL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tenascins, local polymeric gel cellular therapy)
IT Integrins
PL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.3, of smooth muscle cells; local polymeric gel cellular therapy)
IT 7440-70-2, Calcium, processes
PL: REM (Removal or disposal); PROC (Process)
(chelators; local polymeric gel cellular therapy)
IT 117503-96-3
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogel film; local polymeric gel cellular therapy)
IT 9005-49-6, Heparin, biological studies 62229-50-9, EGF 71812-41-4, Tumor-**angiogenesis** factor 106096-93-9, Basic fibroblast growth factor 106392-12-5, Pluronic F127 110590-61-9 126716-28-7
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(local polymeric gel cellular therapy)
IT **99896-85-2** 110590-64-2 122192-97-6 131167-89-0
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptides and proteins contg.; local polymeric gel cellular therapy)
IT **99896-85-2**
PL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptides and proteins contg.; local polymeric gel cellular therapy)
RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg
FILE 'REGISTRY' ENTERED AT 10:39:33 ON 16 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-1
DICTIONARY FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l71

L71 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **302578-05-8** REGISTRY
CN L-Valine, L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 16: PN: WO0063236 PAGE: 37 claimed sequence
FS STEREOSEARCH
MF C11 H21 N3 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:308023

L71 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **255052-65-4** REGISTRY
CN L-Proline, L-isoleucyl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H26 N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:106963

L71 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **243647-63-4** REGISTRY
CN L-Alanine, L-leucylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4: PN: WO0028996 SEQID: 13 unclaimed sequence
FS STEREOSEARCH
MF C11 H21 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:111 1

REFERENCE 2: 133:22140

REFERENCE 3: 131:219027

L71 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **222169-81-5** REGISTRY
CN L-Threonine, L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 12: PN: WO0173956 PAGE: 92 claimed sequence
FS STEREOSEARCH
MF C16 H22 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:300243

REFERENCE 2: 134:266373

L71 ANSWER 5 OF 26 REGISTRY COPYRIGHT 2002 ACS
RN **222169-80-4** REGISTRY
CN L-Serine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: WO0173956 PAGE: 92 claimed sequence
FS STEREOSEARCH
MF C15 H21 N3 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:300243

REFERENCE 2: 134:266373

L71 ANSWER 6 OF 26 REGISTRY COPYRIGHT 2002 ACS
RN **222169-79-1** REGISTRY

CN L-Threonine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: WO0172956 PAGE: 92 claimed sequence
FS STEREOSEARCH
MF C16 H23 N3 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



HO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303243

REFERENCE 2: 130:266873

L71 ANSWER 7 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **193219-20-4** REGISTRY
CN L-Threoninamide, N-(2-benzofuranylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-(2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H38 N4 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:154699

L71 ANSWER 8 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **193219-16-8** REGISTRY
CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclooctyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C32 H45 N5 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 9 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **193219-14-6** REGISTRY
CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclopropyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H35 N5 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 10 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **193218-85-8** REGISTRY
CN L-Threonine, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H30 N4 O8

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:177422

REFERENCE 2: 127:134690

L71 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **193218-84-7** REGISTRY
CN L-Threonine, N-benzoyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H29 N3 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **177081-49-1** REGISTRY
CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 N4 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:103312

REFERENCE 2: 131:139436

REFERENCE 3: 130:163130

REFERENCE 4: 129:291438

REFERENCE 5: 129:245438

REFERENCE 6: 129:95722

REFERENCE 7: 126:1376

L71 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **177081-48-0** REGISTRY
CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H30 N4 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 142:108312

REFERENCE 2: 141:139436

REFERENCE 3: 140:161260

REFERENCE 4: 139:290411

REFERENCE 5: 139:243493

REFERENCE 6: 139:95702

REFERENCE 7: 135:1376

L71 ANSWER 14 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **175177-02-3** REGISTRY
CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Lysine, N2-(N-L-.alpha.-aspartyl-L-.alpha.-aspartyl)-
FS STEREOSEARCH
MF C14 H24 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:98141

REFERENCE 2: 134:307689

REFERENCE 3: 133:16774

REFERENCE 4: 131:97601

REFERENCE 5: 130:160628

REFERENCE 6: 124:337696

L71 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2002 ACS
RN **172684-39-8** REGISTRY
CN L-Arginine, L-lysylglycyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Arginine, N2-(N-L-lysylglycyl)-
FS STEREOSEARCH
MF C14 H29 N7 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

. REFERENCES IN FILE CA (1962 TO DATE)
. REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:195763

REFERENCE 2: 124:106631

L71 ANSWER 16 OF 15 REGISTRY COPYRIGHT 2002 ACS
RN **157535-09-6** REGISTRY
CN L-Lysine, L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Lysine, N2-(N-L-asparaginyl-L-glutaminyl)-
OTHER NAMES:
CN 4: PN: WO0172956 PAGE: 92 claimed sequence
FS STEREOSEARCH
MF C15 H28 N6 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441

REFERENCE 2: 136:360243

REFERENCE 3: 132:187174

REFERENCE 4: 131:97601

REFERENCE 5: 131:149077

L71 ANSWER 17 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **143113-41-1** REGISTRY
CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Valine, N-(N-L-histidyl-L-alanyl)-
FS STEREOSEARCH
MF C14 H23 N5 O4
SR CA
IC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1962 TO DATE)
15 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441

REFERENCE 2: 137:73269

REFERENCE 3: 136:161398

REFERENCE 4: 136:4a463

REFERENCE 5: 13[illegible]:147-98

REFERENCE 6: 13[illegible]:261L63

REFERENCE 7: 134:90B-4

REFERENCE 8: 13[illegible]:286723

REFERENCE 9: 13[illegible]:109695

REFERENCE 10: 131:97621

L71 ANSWER 18 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **132151-24-7** REGISTRY
CN L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Glutamine, N2-(N-L-.alpha.-glutamyl-L-alanyl)-
OTHER NAMES:
CN 1159: PN: WO0106861 TABLE: 17 claimed sequence
FS STEREOSEARCH
MF C13 H22 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:22[illegible]99

REFERENCE 2: 137:88441

REFERENCE 3: 13[illegible]:18774

REFERENCE 4: 131:97621

REFERENCE 5: 114:116372

L71 ANSWER 19 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **117058-06-7** REGISTRY
CN L-Leucine, L-arginyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Leucine, N-(N-L-arginyl-L-alanyl)-
OTHER NAMES:
CN 9: PN: WO0172256 PAGE: 92 claimed sequence

FS STEREOSEARCH
MF C15 H30 N6 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:300243

REFERENCE 2: 130:266673

REFERENCE 3: 110:171424

L71 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **99896-85-2** REGISTRY
CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Aspartic acid, N-(N-L-arginylglycyl)-
OTHER NAMES:
CN 13: PN: WO0147185 SEQID: 1 claimed protein
CN 1: PN: US6340666 SEQID: 1 claimed protein
CN 1: PN: WO0304941 PAGE: 31 claimed protein
CN 1: PN: WO0343659 PAGE: 199 claimed protein
CN 1: PN: WO0147555 PAGE: 13 claimed sequence
CN 4: PN: WO0147549 PAGE: 19 claimed sequence
CN 503: PN: WO0183525 TABLE: 9 claimed sequence
CN 81: PN: US6001965 SEQID: 81 claimed protein
CN Arginylglycylaspartic acid
FS STEREOSEARCH
DR 122106-47-2
MF C12 H22 N6 O6
CI COM
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE, MEDLINE, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

634 REFERENCES IN FILE CA (1962 TO DATE)
117 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
634 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:237626

REFERENCE 2: 137:186136

REFERENCE 3: 137:181241

REFERENCE 4: 137:175009

REFERENCE 5: 137:174738

REFERENCE 6: 137:166872

REFERENCE 7: 137:150814

REFERENCE 8: 137:145645

REFERENCE 9: 137:140769

REFERENCE 10: 137:133625

L71 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **77292-72-9** REGISTRY
CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 27: PN: WO9004941 PAGE: 32 claimed sequence
FS STEREOSEARCH
MF C15 H28 N4 O5
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1962 TO DATE)
9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:142003

REFERENCE 2: 136:10[illegible]402

REFERENCE 3: 131:[illegible]94[illegible]6

REFERENCE 4: 130:[illegible]

REFERENCE 5: 129:[illegible]

REFERENCE 6: 124:[illegible]

REFERENCE 7: 123:[illegible]

REFERENCE 8: 122:[illegible]

REFERENCE 9: 94:[illegible]

L71 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **68293-03-8** REGISTRY
CN Glycine, L-isoleucylglycyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycine, N-(N-L-isoleucylglycyl)-
OTHER NAMES:
CN 34: PN: WO[illegible] PROID: 3 unclaimed sequence
CN L-Isoleucylglycylglycine
FS STEREOSEARCH
MF C10 H19 N3 O4
CI COM
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1962 TO DATE)
12 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 1[illegible]:[illegible]

REFERENCE 2: 1[illegible]:[illegible]

REFERENCE 3: 1[illegible]:[illegible]

REFERENCE 4: 1[illegible]:[illegible]

REFERENCE 5: 123:[illegible]

REFERENCE 6: 11[illegible]:[illegible]

REFERENCE 7: 113:168289

REFERENCE 8: 111:1[illegible]55

REFERENCE 9: 107:7[illegible]41

REFERENCE 10: 101:2[illegible]408

L71 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **60961-76-4** REGISTRY
CN L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Tyrosine, N-(N-L-.alpha.-glutamyl-L-.alpha.-glutamyl)-
FS STEREOSEARCH
MF C19 H25 N3 O9
CI COM
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441

REFERENCE 2: 131:1[illegible]774

REFERENCE 3: 131:9[illegible]621

REFERENCE 4: 114:1[illegible]1070

REFERENCE 5: 111:2[illegible]7767

L71 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **38763-90-5** REGISTRY
CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN L-Leucyl-L-aspartyl-L-phenylalaninamide
FS STEREOSEARCH
MF C19 H28 N4 O5
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1962 TO DATE)
13 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:108302

REFERENCE 2: 131:179496

REFERENCE 3: 130:103160

REFERENCE 4: 114:204488

REFERENCE 5: 113:248488

REFERENCE 6: 113:6722

REFERENCE 7: 113:1376

REFERENCE 8: 112:56959

REFERENCE 9: 111:50304

REFERENCE 10: 111:147041

L71 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2002 ACS
RN **1187-50-4** REGISTRY
CN Glycine, L-leucylglycyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycine, N-(N-L-leucylglycyl)- (7CI, 8CI)
CN Glycine, N-(N-leucylglycyl)- (6CI)
OTHER NAMES:
CN 37: PN: WO 0.8906 SEQID: 6 unclaimed sequence
CN L-Leucylglycylglycine
CN Leu-Gly-Gly
CN Leucylglycylglycine
FS STEREOSEARCH
MF C10 H19 N3 O4
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, GMELIN*, MEDLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

246 REFERENCES IN FILE CA (1962 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
246 REFERENCES IN FILE CAPLUS (1962 TO DATE)
45 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:[illegible]495

REFERENCE 2: 136:[illegible]

REFERENCE 3: 136:[illegible]

REFERENCE 4: 136:11191

REFERENCE 5: 135:1[illegible]

REFERENCE 6: 135:1[illegible]

REFERENCE 7: 135:[illegible]

REFERENCE 8: 134:[illegible]

REFERENCE 9: 134:[illegible]

REFERENCE 10: 134:[illegible]

=> d his

(FILE 'HOME' ENTERED AT 09:53:31 ON 16 OCT 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:53:48 ON 16 OCT 2002
L1 STR
L2 22 S L1 CSS
L3 SCR [illegible]943 OR 2127
L4 7 S L1 NOT L3 CSS
L5 STR L1
L6 6 S L5 CSS
L7 SCR [illegible] OR 2127 OR 2030 OR 2049 OR 2048 OR 2053 OR 2052 OR 205
L8 3 S L7 NOT L6 CSS
L10 SCR [illegible]16 OR 2126 OR 1929
L11 1 S L7 NOT (L8 OR L10) CSS SAM
L12 SCR [illegible]
L13 4 S L7 NOT (L8 OR L10 OR L12) CSS SAM
L14 SCR 2044
L15 6 S L7 NOT (L8 OR L10 OR L12 OR L14) CSS SAM
L16 7 S L13 NOT L11
L17 SCR 2[illegible] OR 2130 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
L18 7 S L7 NOT L17 CSS
L19 SCR 20[illegible] OR 2130 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204

```
L29             4 S L7 NOT L19 CSS
L21               SCR 2059 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 254
L22             7 S L7 NOT L21 CSS
L23               STR L7
L24            19 S L23 NOT L1 CSS
L25           284 S L23 NOT L1 CSS FUL
                  SAV L27 GAB10 47A
L26               STR L23
L27               S L26 CSS SAM SUB=L25
L28            16 S L26 CSS FUL SUB=L25
                  SAV L29 GAB10 48A/A
L29            17 S L27 NOT SQL FA
L30          1831 S L27 NOT L28
L31          1674 S L30 NOT SQL FA

     FILE 'HCAPLUS' ENTERED AT 10:30:07 ON 16 OCT 2002
L32             6 S L29
                E SCIALLONE M AU
L33            17 S E4,E5
                E MOUSA S/AU
L34           194 S E3,E4,E12-E13
                E SHUEY S/AU
L35            1 S E6-E9
L36        54249 S (IMPONT OR DU PONT OR NEMOUR?)/PA,CS
L37             1 S L32 AND L35-L36
                SEL RN

     FILE 'REGISTRY' ENTERED AT 10:32:47 ON 16 OCT 2002
L38            1 S E1-E11
L39           12 S L38 AND L19
L40           11 S L39 NOT L19
L41           10 S L40 NOT PMS/CI
L42            7 S L41 NOT SQL FA
L43           12 S L38,L42
L44            9 S L38 NOT L43
                SAV L44 GAB10048B/A

     FILE 'HCAPLUS' ENTERED AT 10:35:08 ON 16 OCT 2002
L45             6 S L43
L46             1 S L45 AND L35-L36
L47             6 S L45,L46

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:35:26 ON 16 OCT 2002
L48             6 S L45

     FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002

     FILE 'HCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002
L49          6144 S L31
L50          1065 S L49 AND (PD<=20010216 OR PRD<=20010216 OR AD<=20010216)
L51            51 S L50 AND PANGIOGEN?
                E ANGIOGENESIS/CT
                E E7+ALL
L52          7139 S E6+NT
                E E10+ALL
L53          2607 S E4+NT
                E E5+ALL
L54          1511 S E3,E4,E2+NT
                E E5+ALL
L55          1755 S E6,E1+NT
                E ANGIOGENESIS/CT
                E E3+ALL
                E E12+ALL
```

```
L56       127085 S E5,E4+NT
                 E ANGIOGENESIS/CT
                 E E7+ALL
L57         2605 S E4+NT
L58           45 S L50 AND L52-L55,L57
L59          138 S L5? AND L56
L60         2279 S L56 (L) ANGIOGEN?
L61        36951 S L56 (L) ENDOTHEL?
L62           47 S L59 AND L60,L61
L63          112 S L51,L58,L62
L64          111 S L63 NOT L47
L65           39 S L61 AND P/DT
L66           41 S L65 AND US/PC
L67          414 S L31 (L) (PAC OR THU)/RL
L68           45 S L67 AND L64
L69           22 S L68 AND L66
                 SEL HIT FN

     FILE 'REGISTRY' ENTERED AT 10:45:54 ON 16 OCT 2002
L70           26 S E1-E26
L71           25 S L70 NOT NCSC2/ES

     FILE 'HCAPLUS' ENTERED AT 10:51:54 ON 16 OCT 2002
L72          924 S L71
L73           21 S L72 AND L69

     FILE 'REGISTRY' ENTERED AT 10:59:33 ON 16 OCT 2002
```